Return to Arthritis & Rheumatism Table of Contents Page
Volume 40, Numbers 1-12, 1997
|
|
|
Abdominal pain
acute intermittent porphyria and, 586
in Henoch-Schonlein purpura, 859
Abdominal surgery, in fibromyalgia, 1553, 1560, 1571
Abortion
maternal MTX, congenital anomalies and, 971
in relapsing polychondritis, 1245
spontaneous, 209, 1245
Accessory cells, anti-CD2 in SLE and, 822
Accessory soleus muscle, chronic calf pain and, 783
Acetylcholine, l-arginine in Raynaud's phenomenon and,
352
N-acetylprocainamide in drug-induced lupus, 1436
Acetylsalicylic acid, human synovial mast cells and, 469
Acinar epithelial cells, in Sjogren's syndrome, 87, 875
Acquired factor VIII inhibitor, intravenous immunoglobulin in, in
SLE, 775
Actinomycin D, collagenase 1 gene in synoviocytes and, 1772
Acute arthritis, peptidoglycan, kinins and, in rats, 1327
Acute calcific tendinitis, of the hip, 974
Acute intermittent porphyria, presenting as acute muscle pain,
fever, and weakness, 586
Acute-phase protein
kinins in peptidoglycan arthritis in rats and, 1327
in OA, 723, 1940, 1944
in RA, 1096, 1940, 1944
Acute-phase response, in JRA, 332
Adenosine
human synovial mast cells and, 469
monocytes, MTX and, 1308
receptor, collagenase 1 gene in synoviocytes and, 1772
Adenovirus, collagen arthritis, TNFα receptor gene and, 1662
Adherent cells
anti-CD2 in SLE and, 822
AP-1 in RA synovium and, 912
Adhesion molecules
cell, anti-TNFα monoclonal antibody and, 789
endothelial cells, β2-glycoprotein I and, 551
ICAM-1, 80, 397
oxicams, leukocytes and, 143
in RA, 397, 598
in rheumatology, 991
vascular cell, 991, 1420
Adjuvant arthritis
inflammatory cachexia and, 534
mononuclear phagocytes, rheumatoid synovitis and, 5
mycobacterial heat shock protein 65 in, 277
Adolescent medicine
azathioprine-induced pancytopenia in HLA-B27 spondylarthritis,
1896
hip pain, 583
Adrenal cortex, neuroscience and endocrinology of fibromyalgia and,
1928
Adult respiratory distress syndrome, heterotopic ossification,
neuromuscular blockade and, 1619
Adverse reactions
to antiinflammatory drugs in polymyalgia rheumatica, 1873
to MTX, rheumatoid nodules in JRA and, 175
in RA, 62, 849, 1843
in SLE, 27, 797
to steroids and cyclophosphamide in Wegener's granulomatosis,
2099, 2187
2-methoxyestradiol in collagen arthritis and, 154
African-American studies, TNFα in SLE, 2207
Age
AS in twins and, 1746, 1823
autologous stem cell transplantation and, 1005
bacterial arthritis and, 884
in JRA, 1962, 2235
in OA, 723, 1037, 2260
polymyalgia rheumatica and, 1817, 1873
in RA, 237, 718, 1580, 1955, 2248
in SLE, 47, 804, 1429
in SSc, 441, 734
thrombosis in primary antiphospholipid syndrome and, 834
Aggrecan, in OA, 562, 1037, 1046
Aging
chondrocytes and, 966, 1275
neuroscience and endocrinology of fibromyalgia and, 1928
OA and, 2075
Alanine aminotransferase, MTX, liver and, in JRA, 2226
Alcohol consumption, MTX, liver and, in JRA, 2226
Alkaline phosphatase
heterotopic ossification, neuromuscular blockade and, 1619
in Paget's disease, 461
Alleles
anticardiolipin IgG subclasses and, 1998
in idiopathic inflammatory myopathy, 1257
in RA, 1383, 1387, 2241
in SLE, 1138, 1383, 2207
TAP2*Bky2 (VAL577), in
Sjogren's syndrome, 1685
vitamin D receptor gene in knee OA and, 1444
Allergic encephalomyelitis, experimental, CD40-CD40L in, 1735
Allergies, Th1/Th2 cytokine balance and, 2105
Allogeneic bone marrow transplantation, autologous stem cell
transplantation and, 1005
Alloimmune neonatal neutropenia, reproductive immunology and, 209
α-chain
adhesion molecules and, 991
T cell receptors in Felty's syndrome and, 615
α1-antitrypsin
in ANCA-related vasculitis, 1680
in arthritis and pancreatitis, 1732
α/β T cells, self-antigens, epitopes and, 1374
Aluminum-modified renal osteopathy, 1724
Alveolitis, in SSc, 743, 1129
Ambulatory care
cost of, in managed care, 1475
rheumatologists and, 610
Amenorrhea, glucocorticoid-induced osteoporosis and, 1548
American College of Rheumatology (ACR)
care for children with rheumatic diseases and, 2273
challenges and opportunities for, 610
guidelines for management of hip OA, 1914
recommendations for the prevention and treatment of
glucocorticoid-induced osteoporosis, 1547, 1548, 1549, 1550, 1551
slide competition and osteoporosis slide collection, 2116
Amino acids
adhesion molecules and, 991
IgG antibodies and, in SLE, 1364
in RA, 341, 598, 1316, 1387
T cell receptors in Felty's syndrome and, 615
Aminotransferase, alanine, MTX, liver and, in JRA, 2226
Amputation, bacterial arthritis and, 884
Amyloid arthropathy, 1903
Anabolic steroids, SLE, membranous glomerulonephritis, transverse
myelitis and, 1899
Anabolism, cartilage matrix gene in OA chondrocytes and, 562
Anaerobic pathways, P-31 MRS in polymyalgia rheumatica and, 1817
Analgesia, in neuroscience and endocrinology of fibromyalgia, 1928
Analgesic drugs, in Henoch-Schonlein purpura, 859
Androgens, oral contraceptives, SLE and, 797
Anemia
autoantibodies to human recombinant erythropoietin in SLE and,
2212
pernicious, in new-onset juvenile DM, 1526
Angiitis, primary, in the CNS, 1189
Angiogenesis
adhesion molecules and, 991
autologous stem cell transplantation and, 1005
2-methoxyestradiol in collagen arthritis and, 154
TNFα in SLE in African-Americans and, 2207
Angiography, CNS vasculitis and, 1189
Animal studies
See also Bovine; Canine; Guinea pig; Mouse; Pig; Rat
adhesion molecules and, 991
autologous stem cell transplantation and, 1005
CD40-CD40L in autoimmune diseases and, 1735
of degenerative joint diseases, 1420
Ankle, tenosynovial nodulosis in HTLV-I and, 578
Ankylosing spondylitis (AS)
cervical cord compression in fracture of the posterior
longitudinal ligament in, 2277
genetics of, 1746, 1823
sulfasalazine in, 1911
Anorexia, adjuvant arthritis, inflammatory cachexia and, 534
Anterior cruciate ligament, in OA, 284, 1012, 1756
Anti-α4, anti-α5, anti-αV integrins, rheumatoid synovial
fibroblasts, articular cartilage and, 1298
Anti-B27, chlamydial antigen in HLA-B27 transgenic mice and, 945
Anti-β1
integrin, 270, 1298
oxicams, leukocytes and, 143
Anti-β2 glycoprotein I
antibodies, endothelial cells and, 551
heat inactivation in assays for, 2095
in SLE, 1366
Anti-Bh autoantibodies, C1, C2 core proteins and, in SSc and
psoriatic arthritis, 2172
Antibiotics
in Henoch-Schonlein purpura, 859
in RA, 794, 842
Antibodies
anti-β1 integrin, 270
anti-β2-glycoprotein I, 551
anticardiolipin, 797, 834
anticardiolipin IgG subclasses and, 1998
anti-CD40, 1735
anticytokine, 69, 955
anti-DNA, 683, 1054, 1334, 1703
anti-dsDNA, 1262
anti-Fas, 919
anti-48-kd SS-B/La, 936
anti-52-kd, 936
antihistone, 1374
anti-IL-1, 1298
anti-IL-4, 249
anti-IL-10, 249, 1788
anti-Jo-1, 394
anti-Ku, 1257, 1344
anti-La, 381
anti-native chromatin, 1374
anti-native DNA, 1374
antineutrophil cytoplasmic, 135, 710, 986, 1250, 1680, 2030
antinuclear, 175, 209, 295, 410, 413, 1085, 1374, 1803
antinucleolar, 1487
antinucleosome, 2217
anti-proteinase 3, 2030
anti-p70, anti-p80, 1344
antiphospholipid, 103, 196, 209, 551, 797, 1720, 1907
anti-PM-Scl, 1257
antipneumococcal, 1716
anti-Ro, 381
anti-TF, 2030
apoptosis in the rheumatic diseases and, 1917
dsDNA, 2162
high mobility group proteins in JRA and, 1803
IgG, 1364
maternal, 655
monoclonal, 109, 125, 135, 143, 237, 306, 527, 551, 598, 648, 723,
789, 822, 849, 865, 945, 955, 1130, 1344, 1644, 1653, 1810, 1998, 2172
mycobacterial heat shock protein 65 in adjuvant arthritis and, 277
in new-onset juvenile DM, 1526
polyclonal, 551
in proliferative lupus glomerulonephritis, 1504
reproductive immunology and, 209
rheumatoid synovial fibroblasts, articular cartilage and, 1298
SS-A, 1685
T cells, B cells, U snRNP and, in SLE and mixed connective tissue
disease, 1493
Anticardiolipin
heat inactivation in assays for, 2095
IgG subclasses, 1998
oral contraceptives, SLE and, 797
in parvovirus B19 and SLE, 103
reproductive immunology and, 209
thrombosis in primary antiphospholipid syndrome and, 834
Anti-CD2, in SLE, 822
Anti-CD3, in SLE, 822, 1130
Anti-CD4, in RA, 397
Anti-CD5 monoclonal antibody, in RA, 397
Anti-CD11b, oxicams, leukocytes and, 143
Anti-CD25, biologic agents in RA and, 397
Anti-CD28, anti-CD2 in SLE and, 822
Anti-CD40, CD40-CD40L and, 124, 1735
Anti-CD44, fibroblast-macrophage interaction in cartilage
degradation and, 490
Anti-CD95, Fas ligand and, in RA, 1644
Anticentromere antibodies, clinical significance of, 1612
Anticoagulants, in catastrophic antiphospholipid syndrome, 1534
Anti-collagen, T cell responses to collagen in RA and, 1210
Anti-Crithidia, anti-F(ab`)2 reactivity and,
109
Anticytokine antibodies, endothelial activtion in monosodium urate
monohydrate crystal inflammation and, 955
Anticytokines
in collagen arthritis, 249
IL-10, IL-12 and, in reactive arthritis, 1788
T cell cytokines in Lyme arthritis and, 69
Anti-DNA
antibodies, 683, 1054, 1334, 1703
anti-F(ab`)2 reactivity and, 109
clinical significance of, 1612
Id human myeloma protein, intravenous gamma globulin and, 683
self-antigens, epitopes and, 1374
in SLE, 2092
Anti-dsDNA
antibodies, circulating plasma nucleosomes in SLE and, 2217
anti-F(ab`)2 reactivity and, 109
in SLE, 1703, 1810, 2162
transcriptional activator Sp1 and, 1085
Anti-erythropoietin, autoantibodies to human recombinant
erythropoietin in SLE and, 2212
Anti-E-selectin monoclonal antibody 1.2B6, monosodium urate
monohydrate crystal inflammation and, 955
Anti-F(ab`)2
anti-DNA Id, intravenous gamma globulin and, 683
reactivity, with nuclear antigens, 109
Anti-Fas
antibody, 919, 1130
Fas/Fas ligand, apoptosis, chondrocytes and, 1749
rheumatic diseases in MRL/gld mice and, 1054
Antifibroproliferative effect of tenidap, in antigen-induced
arthritis, 2147
Antifolate effect of MTX, 1545
Antigen-induced arthritis
mononuclear phagocytes, rheumatoid synovitis and, 5
tenidap in, 2147
Antigen-presenting cells, in RA, 595, 598
Antigens
apoptosis-related Fas, in primary Sjogren's syndrome, 1912
in autoimmune diseases, 661, 1735
C1, C2 core proteins, autoantibodies and, in SSc and psoriatic
arthritis, 2172
cartilage and, 901, 1282
chlamydial, in HLA-B27 transgenic mice, 945
in chronic fatigue syndrome, 295
congenital heart block, 52β and, 655
52-kd protein, immune response and, 936
foreign, 1409, 1735
Ku, human autoantibodies and, 1344
leukocyte function-associated 1, in drug-induced lupus, 1436
leukocyte function-associated 3, adhesion molecules and, 991
nuclear, 109, 1085, 2162
oncostatin M in human synovial fibroblasts and, 2139
phospholipid, reproductive immunology and, 209
in pneumatosis cystoides intestinal and anti-proliferating cell
nuclear antigen, 2279
PR3-ANCA antiidiotype antibody and, 135
in RA, 5, 237, 598, 794, 842, 854, 1115, 1210, 1292, 1409
reference sera for antinuclear antibodies and, 410, 413
rheumatic diseases and, 1054, 1917
self, epitopes and, 1374
in SLE, 103, 672, 1493, 2162
T cell receptors in Felty's syndrome and, 615
TAP2*Bky2 (VAL577) allele in
Sjogren's syndrome and, 1685
Th1/Th2 cytokine balance and, 2105
Anti-Golgi antibodies, in Sjogren's syndrome, 1693
Anti-Gu antibodies, anti-RNA helicase antibodies and, in connective
tissue disease, 1487
Anti-H2, chlamydial antigen in HLA-B27 transgenic mice and, 945
Antihistone antibodies, circulating plasma nucleosomes in SLE and,
2217
Anti-ICAM-1
fibroblast-macrophage interaction in cartilage degradation and,
490
monoclonal antibody, murine, in RA, 849
Antiidiotypes, anti-F(ab`)2 reactivity and, 109
Anti-IgE, human synovial mast cells and, 469
Anti-IL-1 antibodies, rheumatoid synovial fibroblasts, articular
cartilage and, 1298
Anti-IL-4, in collagen arthritis, 249
Anti-IL-10
antibodies, IL-10, IL-12 and, in reactive arthritis, 1788
anti-CD2 in SLE and, 822
in collagen arthritis, 249
Anti-IL-12
IL-10, IL-12 and, in reactive arthritis, 1788
T cell cytokines in Lyme arthritis and, 69
Antiinflammatory cytokines, mononuclear phagocytes, rheumatoid
synovitis and, 5
Antiinflammatory drugs
adverse reactions to, in polymyalgia rheumatica, 1873
human synovial mast cells and, 469
Anti-Jo-1
antibodies, in DM, hepatocarcinoma, and hepatitis C, 394
reference sera for antinuclear antibodies and, 410, 413
Anti-Ku antibodies
human autoantibodies and, 1344
in idiopathic inflammatory myopathy, 1257
Anti-L7 autoantibodies, in systemic autoimmune diseases, 661
Anti-La antibodies, complete congenital heart block in twins and,
381
Anti-Mi-2, in idiopathic inflammatory myopathy, 1257
Anti-MMP-1, anti-MMP-13 (collagenase 3) in rheumatoid synovium and,
1391
Anti-native chromatin antibodies, self-antigens, epitopes and, 1374
Antineutrophil cytoplasmic antibodies (ANCA)
classic, anti-proteinase 3 antibodies in human umbilical vein
endothelial cells and, 2030
perinuclear, in RA, 710
Antineutrophil cytoplasmic antibody (ANCA)-positive pauci-immune
glomerulonephritis, renal CD40 and CD40L in, 124
Antineutrophil cytoplasmic antibody (ANCA)-related vasculitis, 986,
1250, 1680
Antinuclear antibodies
antibodies against high mobility group proteins in JRA and, 1803
in chronic fatigue syndrome, 295
clinical significance of, 1612
in ``healthy'' individuals, 1601
MTX, rheumatoid nodules and, in JRA, 175
in reproductive immunology, 209
reference sera for, 410, 413
self-antigens, epitopes and, 1374
standards of care and, 410, 413
transcriptional activator Sp1 and, 1085
Antinuclear autoantibodies, CD40-CD40L in autoimmune diseases and,
1735
Antinucleolar antibodies, anti-RNA helicase antibodies and, in
connective tissue disease, 1487
Antinucleosome antibodies, circulating plasma nucleosomes in SLE
and, 2217
Anti-p53, in SLE and rheumatic diseases, 980
Anti-p70, anti-p80, Ku antigen, human autoantibodies and, 1344
Antiphospholipid antibodies
endothelial cells and, 551
HLA-DRB genes and, in familial antiphospholipid syndrome, 1907
immunogenesis, T cells and, 196
reproductive immunology and, 209
SLE and, 103, 797, 1720
Antiphospholipid syndrome
anticardiolipin IgG subclasses and, 1998
β2-glycoprotein I, endothelial cells and, 551
catastrophic, 1534
familial, HLA-DRB genes and, 1907
primary, thrombosis in, 834
Anti-PM-Scl antibodies, in idiopathic inflammatory myopathy, 1257
Antipneumococcal antibodies, in Streptococcus pneumoniae
infection in SLE, 1716
Anti-proliferating cell nuclear antigen, in pneumatosis cystoides
intestinalis, 2279
Anti-proteinase 3 antibodies, in human umbilical vein endothelial
cells, 2030
Antirheumatic drugs
autologous stem cell transplantation and, 1005
CD4 cells in RA and, 1106
mononuclear phagocytes, rheumatoid synovitis and, 5
in OA, 284
Anti-RNP, clinical significance of, 1612
Anti-Ro antibody, complete congenital heart block in monozygotic
twins and, 381
Anti-Scl-70, reference sera for antinuclear antibodies and, 410,
413
Antisense oligonucleotides, RA synovial fibroblasts and, 1292
Antisera, congenital heart block, 52β and, 655
Anti-Sm
anti-F(ab`)2 reactivity and, 109
clinical significance of, 1612
Sm snRNP in SLE and, 672
Anti-snRNP autoantibodies, self-antigens, epitopes and, 1374
Anti-Sp1, transcriptional activator Sp1 and, 1085
Anti-SRP, in idiopathic inflammatory myopathy, 1257
Anti-SS-A, clinical significance of, 1612
Anti-SS-A/Ro
52β, congenital heart block and, 655
reference sera for antinuclear antibodies and, 410, 413
Anti-SS-B/La
congenital heart block, 52β and, 655
reference sera for antinuclear antibodies and, 410, 413
Antisynthetase syndrome, in Poland, 1257
Anti-TF antibodies, anti-proteinase 3 antibodies in human umbilical
vein endothelial cells and, 2030
Anti-TNFα
endothelial activation in monosodium urate monohydrate crystal
inflammation and, 955
fibroblast-macrophage interaction in cartilage degradation and,
490
monoclonal antibody, cell adhesion molecules and, 789
in RA, 397
Anti-U1 small nuclear RNP, reference sera for antinuclear
antibodies and, 410, 413
Antiviral drugs, hepatitis C virus in type II cryoglobulinemia and,
2007
Antroduodenal manometry, in esophageal dysfunction in scleroderma,
2252
Anxiety, in fibromyalgia, 1553, 1560, 1571
AP-1
collagenase 1 gene in synoviocytes and, 1772
in RA, 5, 912, 919
Apatite, in spinal calcinosis in SSc, 1892
Aplastic anemia, autologous stem cell transplantation and, 1005
APO1, CD95, in rheumatic diseases, 1126
Apoptosis
in autoimmune diseases, 306, 1735
C1, C2 core proteins, autoantibodies and, in SSc and psoriatic
arthritis, 2172
Fas and, 80, 87, 919, 1749
Fas antigen and, in primary Sjogren's syndrome, 1912
Fas ligand and, 1644, 1749
Fas-mediated, of RA synoviocytes, 919
after hydroxychloroquine, 927
in the rheumatic diseases, 1054, 1917
ribozyme-based gene cleavage, HTLV-I and, in chronic arthritis,
2118
soluble oligonucleosomal complexes in SF and, 648
synoviocytes, paclitaxel and, 1073
TNFα in SLE in African-Americans and, 2207
Appendectomy, in fibromyalgia, 1553, 1560, 1571
Arginine vasopressin, neuroscience and endocrinology of
fibromyalgia and, 1928
Arm, tenosynovial nodulosis in HTLV-I and, 578
Arterial thrombosis
anticardiolipin IgG subclasses and, 1998
reproductive immunology and, 209
Arteries, cortical, CNS vasculitis and, 1189
Arterioles
cytokines in muscle tissue in inflammatory myopathy and, 865
pulse methylprednisolone, osteonecrosis and, in rabbits, 2055
Arteritis
diffuse cerebral, CNS vasculitis and, 1189
giant cell, 19, 1873
granulomatous, rheumatic diseases in MRL/gld mice and,
1054
Takayasu, apoptosis in, 306
Arthralgia, in SLE and anabolic steroid use, 1899
Arthritides
inflammatory, human synovial mast cells and, 469
venereal diseases and, 592
Arthritis
adjuvant, 5, 277, 534
antigen-induced, 5
chronic, 534, 1371, 2118
collagen, 5, 154, 249, 893, 907, 1064
erosive, 183
experimental, 5, 277
human cartilage glycoprotein-39-induced, 1115
inflammatory, 261, 534
juvenile, 1202
peptidoglycan-induced, 1327
psoriatic, 1868
reactive, 592, 945, 1788, 1911, 2084
rheumatic diseases in MRL/gld mice and, 1054
septic, 592, 2084
Th1/Th2 cytokine balance in, 2105
transcriptional activator Sp1 and, 1085
Arthritis & Rheumatism
guidelines for rheumatic diseases in, 2
references in, 199, 793
status of, in 1997, 1
Arthritis and Rheumatoid Conditions: Their Nature and
Treatment, review of, 1723
Arthritis Foundation
ACR and, 610
patient education in chronic arthritis and, 1371, 1466
Arthritis Impact Measurement Scales 2 (AIMS2), short form of, 1267
Arthrodesis, bacterial arthritis and, 884
Arthropathy
amyloid, 1903
β2-microglobulin, hemodialysis and, 709
in fibroblastic rheumatism, 183
H-ras mutations in arthritic synovium and, 1636
neuropathic, periosteal new bone formation in canine OA and, 1756
in polyarthritis and chromosome 22q11.2 deletion, 430
ribozyme-based gene cleavage, HTLV-I and, in chronic arthritis,
2118
tenosynovial nodulosis in HTLV-I and, 578
Arthroplasty, AP-1 in RA synovium and, 912
Arthroscopy
in OA, 1856
in RA, 1400, 1856
Arthrotomy, MRI-determined synovial membrane volumes in RA and OA
and, 1856
Articular cartilage
bone morphogenetic protein 2 and, 1020
chondrocytes and, 270, 1275, 1455
collagen and, 164, 249, 1046
in degenerative joint diseases, 1420
gene transfer into, 901
human, membrane type I matrix metalloproteinase in, 704
in OA, 1756, 1766, 2075
rheumatoid synovial fibroblasts and, 1298
transglutaminase in, 966
Articular chondrocytes
aging, transglutaminase in, 966
cartilage matrix protein in, 1029
Fas/Fas ligand, apoptosis and, 1749
growth-arrest-specific gene 6, tyrosine kinase receptors axl and,
1455
nitric oxide and, 261
recombinant human osteogenic protein 1 and, 2157
Articular disease
active, bone mineral density in JRA and, 1967
autologous stem cell transplantation and, 1005
Articular lesions, in mono-iodoacetate-induced experimental OA,
1670
Aspartate, MTX, liver and, in JRA, 2226
Aspirin, reproductive immunology and, 209
Association of Rheumatology Health Professionals, challenges and
opportunities for, 610
Atrophy
acinar cell, nitric oxide in Sjogren's syndrome and, 875
MRI and MRS of brain in SLE and, 36
of steroid-induced subcutaneous tissue, 294
Autoantibodies
anticardiolipin IgG subclasses and, 1998
anti-proliferating cell nuclear antigen in pneumatosis cystoides
intestinalis and, 2279
anti-RNA helicase, in connective tissue disease, 1487
apoptosis in the rheumatic diseases and, 1917
C1, C2 core proteins in SSc and psoriatic arthritis and, 2172
CD40-CD40L in autoimmune diseases and, 1735
in chronic fatigue syndrome, 295
clinical rheumatology, reproductive immunology and, 209
in collagen arthritis, 907, 1064
complete congenital heart block in monozygotic twins and, 381
in drug-induced lupus in mice, 1334
eukaryotic ribosomal protein L7 and, 661
in idiopathic inflammatory myopathy, 1257
Ku antigen and, 1344
self-antigens, epitopes and, 1374
in Sjogren's syndrome, 1685, 1693
in SLE, 672, 1168, 1493, 2162, 2212
standards of care and, 410, 413
transcriptional activator Sp1 and, 1085
Autoantigens
C1, C2 core proteins, autoantibodies and, in SSc and psoriatic
arthritis, 2172
52-kd SS-A/Ro, 52β, congenital heart block and, 655
HLA-B27, in AS, 2047
97-kd Golgi complex, in Sjogren's syndrome, 1693
in RA, 5, 397, 1115
transcriptional activator Sp1, 1085
Autoimmune diseases
antiphospholipid antibodies in parvovirus B19 and, 103
apoptosis in, 306, 927
autologous stem cell transplantation and, 1005, 1712
azathioprine-induced pancytopenia in juvenile HLA-B27
spondylarthritis, 1896
CD40-CD40L in, 1735
familial, new-onset juvenile DM and, 1526
human herpesvirus 8 and, 1906
insoluble cellular antigens in chronic fatigue syndrome, 295
liver, in drug-induced lupus in mice, 1334
mononuclear phagocytes, rheumatoid synovitis and, 5
mycobacterial heat shock protein 65 in adjuvant arthritis and, 277
procalcitonin and infection in, 1250
self-antigens, epitopes and, 1374
systemic, 661, 1344
Autoimmune IgG anticardiolipin antibodies, anticardiolipin IgG
subclasses and, 1998
Autoimmune lesions, T cells in RA and, 598
Autoimmune lymphoproliferative syndrome, apoptosis in the rheumatic
diseases and, 1917
Autoimmune oophoritis, self-antigens, epitopes and, 1374
Autoimmune response
CD40-CD40L in autoimmune diseases and, 1735
cytokines, MHC class II and, in SSc, 540
self-antigens, epitopes and, 1374
Autoimmune vasculitides, apoptosis in, 306
Autoimmunity
in drug-induced lupus, 1436
histones, dsDNA antibodies and, in SLE, 2162
Ku antigen, human autoantibodies and, 1344
mononuclear phagocytes, rheumatoid synovitis and, 5
rheumatic diseases and, 1054, 1917
systemic, self-antigens and epitopes in, 1374
Autologous stem cell transplantation, RA and, 1005, 1712
Autoreactive T cells, self-antigens, epitopes and, 1374
Autoreactivity, in drug-induced lupus, 1436
AV genes, mycobacterial heat shock protein 65, T cells and, in RA,
510
Azathioprine
acquired factor VIII inhibitor in SLE and, 775
in Behcet's syndrome, 769
MTX, rheumatoid nodules and, in JRA, 175
pancytopenia induced by, in juvenile HLA-B27 spondylarthritis,
1896
B
B cells
antibodies against high mobility group proteins in JRA and, 1803
anti-F(ab`)2 reactivity with nuclear antigens and, 109
in autoimmune diseases, 661, 1735
autologous stem cell transplantation and, 1005
lymphoproliferation of, in Sjogren's syndrome, 318
mononuclear phagocytes, rheumatoid synovitis and, 5
in RA, 397, 426, 598, 1210, 1409
reproductive immunology and, 209
rheumatic diseases and, 1054, 7
self-antigens, epitopes and, 1374
in SLE, 822, 1429, 1493, 1703, 2162
Th1/Th2 cytokine balance and, 2105
B7 molecules, biologic agents in RA and, 397
B7/CD28, adhesion molecules and, 991
B7-1, B7-2 pathway, Th1/Th2 cytokine balance and, 2105
B220, rheumatic diseases in MRL/gld mice and, 1054
Back surgery, in fibromyalgia, 1553, 1560, 1571
Bacteria
CNS vasculitis and, 1189
HLA-B27 and, 694
reactive arthritis and, 592, 1788
septic arthritis and, 592
Bacterial antigens, chlamydial antigen in HLA-B27 transgenic mice,
945
Bacterial arthritis, outcome of, 884
Bacterial infections
mononuclear phagocytes, rheumatoid synovitis and, 5
procalcitonin in autoimmune diseases and, 1250
Bacterial lipopolysaccharide, nitric oxide, articular chondrocytes
and, 261
Baculovirus, Ku antigen, human autoantibodies and, 1344
bak, apoptosis in autoimmune diseases and, 306
BALB/c mice
52-kd protein and immune response in, 936
human cartilage glycoprotein-39 in RA in, 115
Basement membrane, C1q and collagen-like region antibodies in
proliferative lupus glomerulonephritis and, 1504
bax, apoptosis in autoimmune diseases and, 306
BB87, BB3003, collagen degradation in cartilage and, 164
bcl-2
apoptosis and, 306, 1917
Fas in Sjogren's syndrome and, 87
bcl-XL, apoptosis in autoimmune diseases
and, 306
Behcet's disease
azathioprine in, 769
penicillin in, 1728
T cells and tacrolimus in, 1157
uveitis and, 358
vasculopathy of, 1915
β-chain
adhesion molecules and, 991
T cell receptors in Felty's syndrome and, 615
β-galactosidase
collagen arthritis, TNFα receptor gene and, 1662
IL-1 receptor antagonist gene therapy in OA and, 1012
β-thromboglobulin, phosphate in SLE and, 2178
β2-glycoprotein I
antiphospholipid antibodies and, in parvovirus B19 infection, 103
endothelial cells and, 551
in SLE, 103, 1366
β2-microglobulin
arthropathy, after hemodialysis, 709
chlamydial antigen in HLA-B27 transgenic mice and, 945
Biglycan, proteoglycans, link proteins and, in OA cartilage, 1037
Bioactivity, tenidap in OA and, 284
Biochemistry
apoptosis in the rheumatic diseases and, 1917
C1, C2 core proteins, autoantibodies and, in SSc and psoriatic
arthritis, 2172
MTX, liver and, in JRA, 2226
neuroscience and endocrinology of fibromyalgia and, 1928
NSAID and, 1940, 1944
OA and, 1670, 2075
in Paget's disease, 461
P-31 MRS in polymyalgia rheumatica and, 1817
Biologic agents
adhesion molecules and, 991
in RA, 397
Biologic markers, serum, knee OA and, 590
Biomineralization, transglutaminase in articular chondrocytes and,
966
Biopsy
bone, cartilage metabolism and, in OA, 1282
brain, CNS vasculitis and, 1189
leptomeningial, in chronic meningitis in Wegener's granulomatosis,
573
lung, collagen biosynthesis in scleroderma lung fibroblasts and,
1237
needle, 1886, 2226
renal CD40, CD40L and, 124
in Sjogren's syndrome, 87, 318, 2016
skin, 1450, 1810, 2116, 2266
synovial, 217, 1400, 1856, 1903, 2266
temporal artery, cytokines in giant cell arteritis and, 19
Biosynthesis, collagen, in scleroderma lung fibroblasts, 1237
Biphosphonate clodronate, mononuclear phagocytes, rheumatoid
synovitis and, 5
Birmingham Vasculitis Activity Score, procalcitonin, infection and,
in autoimmune diseases, 1250
Bky2 allele, in Sjogren's syndrome, 1685
Blindness, azathioprine in Behcet's syndrome and, 769
Blood
adhesion molecules and, 991
peripheral, 5, 306, 510, 540, 578, 598, 615, 624, 639, 822, 912,
927, 1005, 1115, 1126, 1210, 1257, 1703, 1838, 1917, 2039, 2047, 2162
in RA, 510, 718, 1955
vessels, 865, 1780, 1856, 2007
Body cell mass, adjuvant arthritis, inflammatory cachexia and, 534
Body mass index, knee OA and, 728, 1518
Bone
apoptosis and, 1073, 1917
cartilage and, 1020, 1282
degradation, collagen crosslinks in fibromyalgia and, 1450
effect of pulse methylprednisolone on, 2055
formation, in canine OA, 1756
heterotopic ossification and neuromuscular blockade, 1619
loss, 1547, 1549, 1559, 2022
marrow, 490, 1005, 1374, 1712, 1917
mass, 797, 2022
mineral density, 797, 1551, 1967, 2022
pain, in a transplant patient, 1361
in Paget's disease, 461
in polymyalgia rheumatica, 2022
in RA, 341, 499, 2241
subchondral, in spontaneous femoral neck fracture in multicentric
reticulohistiocytosis, 2266
Book Reviews
Connective Tissue Diseases (Belch and Zurier, eds), 198
Rheumatology Guidebook: A Step-by-Step Guide to Diagnosis
and Treatment (Ferrari et al), 1734
Rheumatology Secrets (West, ed), 1188
Therapeutic Immunology (Austen et al, eds), 1733
Borrelia burgdorferi, T cell cytokines in Lyme arthritis
and, 69
Bovine studies
chondrocytes and, 261, 270, 2157
collagen degradation in cartilage, 164
Bowel motility, small, esophageal dysfunction in scleroderma and,
2252
Bradykinin, in peptidoglycan arthritis, 1327
Brain
biopsy, CNS vasculitis and, 1189
injury, heterotopic ossification, neuromuscular blockade and, 1619
MRI and MRS of, in SLE, 36
in neuroscience and endocrinology of fibromyalgia, 1928
Breast implants
cervical traction and, 2097
in connective tissue disease, 437
silicone, clinical experience with, 1545
Bronchoalveolar lavage fluid, cytokines in, in SSc, 743
Burns, heterotopic ossification, neuromuscular blockade and, 1619
BV genes, mycobacterial heat shock protein 65, T cells and, in RA,
C1 and C2 core protein, autoantibodies and, in SSc and psoriatic
arthritis, 2172
C1q, and collagen-like region antibodies in proliferative lupus
glomerulonephritis, 1504
C2
HOX4C gene in RA and, 1628
in SLE, 1138, 2042
C3, in SLE, 2092, 2178
C4, autoantibodies to human recombinant erythropoeitin in SLE and,
2212
Cachexia, inflammatory, adjuvant arthritis and, 534
Caenorhabditis elegans, apoptosis in the rheumatic
diseases and, 1917
Calcific tendinitis, acute, of the hip, 974
Calcineurin, T cells, tacrolimus and, in Behcet's disease,
1157
Calcinosis, spinal, in SSc, 1892
Calcinosis cutus universalis, surgery of, in SLE, 570
Calcitonin, glucocorticoid-induced osteoporosis and, 1549
Calcium
chelation, cytolytic activity in SLE and, 1130
ionophore A23187, oxicams, leukocytes and, 143
Calcium pyrophosphate dihydrate (CPPD) crystals, transglutaminase
in articular chondrocytes and, 966
Calf pain, chronic, accessory soleus muscle and, 783
cAMP, collagenase 1 gene in synoviocytes and, 1772
Canale-Smith syndrome, apoptosis in the rheumatic diseases and,
1917
Cancer
autologous stem cell transplantation and, 1005
carcinoma polyarthritis and vasculitis, 779
DM, hepatocarcinoma, and hepatitis C, 394
mortality in psoriatic arthritis and, 1868
in RA, 426, 1580
in SLE, 761
Canine studies, of OA, 284, 1012, 1756
Capillaries, cytokines in muscle tissue in inflammatory myopathy
and, 865
Carcinoma polyarthritis, vasculitis and, 779
Cardiac involvement, 52β and congenital heart block, 655
Cardiolipin, in parvovirus B19 and SLE, 103
Cardiovascular involvement, in RA, 62, 718
Carpal tunnel syndrome, in fibromyalgia, 1553, 1560, 1571
Cartilage
apoptosis in the rheumatic diseases and, 1917
articular, 164, 249, 270, 704, 901, 966, 1020, 1046, 1275, 1298,
1420, 1756, 1766, 2075
collagen degradation in, 164
collagenase 3 in, 1653
degradation, 249, 261, 490, 893, 1210, 1282, 1749, 2076
diseases of, 1275
Fas/Fas ligand, apoptosis, chondrocytes and, 1749
link protein gene, 1760
matrix gene, 562, 1760
matrix protein synthesis, 1029
metabolism, 589, 1282
nasal, 164
nitric oxide, articular chondrocytes and, 261
in OA, 284, 562, 1012, 1037, 1046, 1050, 1670, 1756, 1760
paclitaxel, synoviocyte apoptosis and, 1073
in RA, 1115, 1210
Cartilage-pannus junction
collagenase 3 in arthritic cartilage and, 1653
in degenerative joint diseases, 1420
mononuclear phagocytes, rheumatoid synovitis and, 5
recombinant human osteogenic protein 1, articular chondrocytes
and, 2157
Caspases, apoptosis in the rheumatic diseases and, 1917
Catastrophic antiphospholipid syndrome, 1534
Catastrophic occlusion syndrome, reproductive immunology and, 209
Cathepsin B pre-messenger RNA, in rheumatoid synovial tissue, 1540
Cathepsin G, thrombospondin 1 in rheumatoid synovium and, 1780
Cathepsin L, in RA, 499
Cationic IgG myeloma proteins, intravenous gamma globulin and, 683
CD2, adhesion molecules and, 991
CD3
adhesion molecules and, 991
cells, in Felty's syndrome, 615
CD4
adhesion molecules and, 991
cells, 217, 822, 1054, 1106, 1374, 1735, 1917, 2105
in RA, 397, 598, 1106, 1186
CD5, in RA, 397
CD6, in RA, T cells and, 598
CD7, in RA, 397
CD8
adhesion molecules and, 991
cells, 251, 598, 615, 822, 945, 1054
CD25, in RA, 397
CD27
ligand, T cells in RA and, 1186
Th1/Th2 cytokine balance and, 2105
CD28
anti-CD2 in SLE and, 822
monoclonal antibody, apoptosis in autoimmune diseases and, 306
in RA, 397, 598, 1106
CD30, Th1/Th2 cytokine balance and, 2105
CD31
adhesion molecules and, 991
nitric oxide in Sjogren's syndrome and, 875
CD34
granulocyte colony-stimulating factor in RA and, 1838
stem cells, mononuclear phagocytes, rheumatoid synovitis and, 5
CD35, in inflammatory joint diseases, 520
CD40
in kidney, 124
self-antigens, epitopes and, 1374
CD40-CD40L, in autoimmune diseases, 1735
CD40L, in kidney, 124
CD44, fibroblast-macrophage interaction in cartilage degradation
and, 490
CD45RO, adhesion molecules and, 991
CD52, in RA, 397
CD54, in RA, 849
CD57, in RA, 237
CD60, in RA, T cells and, 598
CD68, glycoprotein, cathepsin L in RA and, 499
CD70, T cells in RA and, 1186
CD95, Fas ligand and, 1126, 1644
CDR1β D30, CDR2β N51, T cells and, in RA, 1316
CDR3, mycobacterial heat shock protein 65, T cells and, in RA, 510
CDR3β Q97, T cells and, in RA, 1316
CED-3 protein, apoptosis in the rheumatic diseases and, 1917
Cell adhesion molecules, anti-TNFα monoclonal antibody and, 789
Cell cultures, cytokine induction by JRA SF immune complexes and,
2039
Cell cycle, paclitaxel, synoviocyte apoptosis and, 1073
Cell death, apoptosis in the rheumatic diseases and, 1917
Cell lysates
aging, chondrocytes, TGFβ and, 1275
thrombosis in primary antiphospholipid syndrome and, 834
Cell membrane, cytokines in muscle tissue in inflammatory myopathy
and, 865
Cell proliferation, chondrocytes and, 1275, 1455
Cell surface
adhesion molecules and, 991
cathepsin L in RA and, 499
growth factors, chondrocytes and, 270
rheumatic diseases in MRL/gld mice and, 1054
T cells, B cells, U snRNP and, in SLE and mixed connective tissue
disease, 1493
thrombosis in primary antiphospholipid syndrome and, 834
Cellular antigen autoantibodies, insoluble, in chronic fatigue
syndrome, 295
Cellular DNA, transcriptional activator Sp1 and, 1085
Cellular immunity, Th1/Th2 cytokine balance and, 2105
Cellular infiltration
IL-4, IL-10 and, in collagen arthritis, 249
tenidap in antigen-induced arthritis and, 2147
Cellular matrix protein, adhesion molecules and, 991
Cellular pathway, biologic agents in RA and, 397
Cellulitis, Streptococcus pneumoniae infection in SLE
and, 1716
Centers for Disease Control and Prevention, reference sera for
antinuclear antibodies and, 410, 413
Central nervous system (CNS)
CD40-CD40L in autoimmune diseases and, 1735
in fibromyalgia, 1544, 1928
in SLE, 1544
vasculitis in the, 1189
Cerebral blood flow, in neuroscience and endocrinology of
fibromyalgia, 1928
Cerebral proton spectroscopy, in SLE, 36
Cerebrospinal fluid, CNS vasculitis and, 1189
Cervical spine
calcinosis of, in SSc, 1892
in fracture of the posterior longitudinal ligament, 2277
injury, fibromyalgia after, 446
traction, breast implants and, 2097
c-fos
AP-1 in RA synovium and, 912
collagenase 1 gene in synoviocytes and, 1772
Chelation, calcium, cytolytic activity in SLE and, 1130
Chemokines
adhesion molecules and, 991
oncostatin M in human synovial fibroblasts and, 2139
Chemotaxis
adhesion molecules and, 991
mononuclear phagocytes, rheumatoid synovitis and, 5
Chest radiography, breast implants in connective tissue disease
and, 437
Childhood-onset scleroderma, 1183
Chimeras, bone marrow, self-antigens, epitopes and, 1374
Chinese studies, MHC genes in SLE and, 1138
Chlamydia antigen, in HLA-B27 transgenic mice, 945
Chlamydia trachomatis, IL-10, IL-12 and, in reactive
arthritis, 1788
Chlorambucil, low-dose, in Clostridium difficile
diarrhea in RA, 2090
Chondrocalcinosis, knee OA in the elderly and, 728
Chondrocytes
aging, TGFβ and, 1275
articular, 261, 966, 1029, 1455, 2157
cartilage and, 562, 704, 901, 1029, 1037
collagen mRNA in experimental OA and, 1046
in degenerative joint diseases, 1420
Fas/Fas ligand, apoptosis and, 1749
growth-arrest-specific gene 6, tyrosine kinase receptors axl and,
1455
human IL-1 receptor antagonist in murine collagen arthritis and,
893
integrins, growth factors and, 270
in OA lesions, 2065
paclitaxel, synoviocyte apoptosis and, 1073
Chondrophytes, cartilage proteoglycan synthesis by bone
morphogenetic protein and, 1020
Chondroprotective drugs
in mono-iodoacetate experimental OA, 1670
paclitaxel, synoviocyte apoptosis and, 1073
Chondrosarcoma cells, membrane type I matrix metalloproteinase in
cartilage and, 704
Chromatin, self-antigens, epitopes and, 1374
Chromosomal protein, antibodies against high mobility group
proteins in JRA and, 1803
Chromosome 22q11.2 deletion syndrome, polyarthritis in, 430
Chronic arthritis
antigen-induced, tenidap in, 2147
inflammatory, adjuvant arthritis, inflammatory cachexia and, 534
patient education and, 1371, 1466
ribozyme-base gene cleavage, HTLV-I and, 2118
Chronic fatigue syndrome
insoluble cellular antigen autoantibodies in, 295
neuroscience and endocrinology of fibromyalgia and, 1928
Chronic inflammation
autologous stem cell transplantation and, 1005
human cartilage glycoprotein-39 in RA and, 1115
Chronic intestinal pseudo-obstruction, anti-proliferating cell
nuclear antigen and, 2279
Chronic meningitis
CNS vasculitis and, 1189
in Wegener's granulomatosis, 573
Chronic pain
calf, accessory soleus muscle and, 783
fibromyalgia and, 752, 1184, 1928
Chronic pain syndrome, fibromyalgia after spinal injury and, 446
Chronic tenosynovitis, tenosynovial nodulosis in HTLV-I and, 578
Chymase, in rheumatoid synovium, 479, 1780
Circadian rhythm, neuroscience and endocrinology of fibromyalgia
and, 1928
Circulating monocytes, mononuclear phagocytes, rheumatoid synovitis
and, 5
Circulating plasma nucleosome, in SLE, 2217
Circulation
fetal, congenital heart block, 52β and, 655
mortality in psoriatic arthritis and, 1868
T cells in RA and, 598
c-jun
AP-1 in RA synovium and, 912
collagenase 1 in synoviocytes and, 1772
Claudication, jaw, cytokines in giant cell arteritis and, 19
Clinical Images
aluminum-modified renal osteopathy, 1724
β2-microglobulin arthropathy and hemodialysis, 709
skin hyperpigmentation and minocycline, 1353
steroid-induced subcutaneous tissue atrophy, 294
Clodronate, collagenase 3 in rheumatoid synovium and, 1391
Cloning, B cell proliferation in Sjogren's syndrome and, 318
Clostridium difficile, diarrhea, low-dose chlorambucil
and, in RA, 2090
cM-T412 monoclonal antibody, in RA, 397
c-myc, apoptosis in autoimmune diseases and, 306
Coagulation
anti-proteinase 3 antibodies in human umbilical vein endothelial
cells and, 2030
oral contraceptives, SLE and, 797
Codon 13 mutations, codon 14 mutations, H-ras mutations
in arthritic synovium and, 1636
Codon 57, TAP2*Bky2 (VAL577)
allele in Sjogren's syndrome and, 1685
Cognitive function
in neuroscience and endocrinology of fibromyalgia, 1928
in SLE, 1542, 1544
Colitis, Th1/Th2 cytokine balance and, 2105
Collagen
apoptosis in the rheumatic diseases and, 1917
in arthropathy of fibroblastic rheumatism, 183
biosynthesis, in scleroderma lung fibroblasts, 1237
in fibromyalgia, 1450
in OA, 2075
in RA, 397, 1210, 1391
type I, in Paget's disease, 461
type II, 164, 270, 392, 562, 1046, 1064, 1210, 1409, 1735, 2105
type VI, growth factors, chondrocytes and, 270
Collagen arthritis
CD40-CD40L in, 1735
dehydroepiandrosterone in, in DBA/1 mice, 907
mononuclear phagocytes, rheumatoid synovitis and, 5
murine, human IL-1 receptor antagonist in, 893
silicone and, 1064
TNFα receptor gene and, 1662
2-methoxyestradiol and, 154
Collagenase
collagen degradation in cartilage and, 164
in degenerative joint diseases, 1420
in OA, 284, 2065
in RA, 912, 2128
Collagenase 1 gene, in synoviocytes, 1772
Collagenase 3
in arthritic cartilage, 1653
in OA lesions, 2065
in rheumatoid synovium, 1391
Collagen-like region antibodies, C1q and, in proliferative lupus
glomerulonephritis, 1504
Colorectal malignancy, in RA, 1580
Comorbidity
bacterial arthritis and, 884
fibromyalgia and, 1553, 1560, 1571
Complement
adhesion molecules and, 991
anti-proteinase 3 antibodies in human umbilical vein endothelial
cells and, 2030
apoptosis in the rheumatic diseases and, 1917
C1q and collagen-like region antibodies in proliferative lupus
glomerulonephritis, 1504
cytokine induction by JRA SF immune complexes and, 2039
regulatory protein, CD59, in synovial tissue in rats, 527
Complement C2
HOX4C gene in RA and, 1628
in SLE, 1138, 2092
Complement C3, in SLE, 2092, 2178
Complement C4, autoantibodies to human recombinant erythropoietin
in SLE and, 2212
Complementary DNA
97-kd Golgi complex autoantigen in Sjogren's syndrome and,
1693
in RA, 598, 615, 2128
Complete heart block, congenital, in monozygotic twins, 381
Compliance, risk and outcome in SLE and, 47
Computed tomography
CNS vasculitis and, 1189
in mediastinal mass and hilar adenopathy in Wegener's
granulomatosis, 1992
in SSc, 1129, 1892
Condylar cartilage, cartilage matrix protein synthesis and, 1029
Congenital anomalies, maternal low-dose MTX and, 971
Congenital heart block
complete, in monozygotic twins, 381
52β and, 655
Connective tissue disease
anti-RNA helicase in, 1487
breast implants in, 437
calcinosis cutis in SLE and, 570
CNS vasculitis and, 1189
collagen crosslinks in fibromyalgia and, 1450
mixed, 306, 1126, 1493
registries, 1556
undifferentiated, 1085, 1487
Connective tissue matrix, apoptosis in the rheumatic diseases and,
1917
Contraceptives, oral, SLE and, 797, 804
Coping, in primary juvenile fibromyalgia, 752
Core proteins C1 and C2, autoantibodies and, in SSc and psoriatic
arthritis, 2172
Cortical vasculitis disease, CNS vasculitis and, 1189
Corticosteroid drugs
acquired factor VIII inhibitor in SLE and, 775
bone mineral density in JRA and, 1967
in catastrophic antiphospholipid syndrome, 1534
in Henoch-Schonlein purpura, 859
HLA-DRB1 genotype in early RA and, 2241
inflammation, bone loss and, in polymyalgia rheumatica, 2022
injections of, in hip OA, 1914
in mediastinal mass and hilar adenopathy in Wegener's
granulomatosis, 1992
mononuclear phagocytes, rheumatoid synovitis and, 5
in osteonecrosis in rabbits, 2055
periodontal disease in RA and, 2248
in polymyalgia rheumatica, 1873, 2022
in pregnancy in relapsing chondritis, 1245
in reproductive immunology, 209
in SLE, 27, 1899
soluble Fas and soluble Fas ligand in rheumatic diseases and, 1126
subcutaneous tissue atrophy induced by, 294
in systemic vasculitis and myelodysplastic syndromes, 179
in Wegener's granulomatosis, 1354, 2099, 2187
Corticotropin-releasing hormone, neuroscience and endocrinology of
fibromyalgia and, 1928
Cost studies
of fibromyalgia, 1553, 1560, 1571
of RA and OA, in managed care, 1475
Cough, in MTX lung injury in RA, 1829
Counseling, risk and outcome in SLE and, 47
Coxsackievirus B, in new-onset juvenile DM, 1526
CR1, in inflammatory joint diseases, 520
Cranial neuropathy, chronic meningitis in Wegener's granulomatosis
and, 573
C-reactive protein
in ANCA-related vasculitis, 1680
in JRA, 332
NSAID and, 1940, 1944
in OA of the knee, 723
procalcitonin, infection and, in autoimmune diseases, 1250
in RA, 80, 1096
Creatine, in brain MRI and MRS in SLE, 36
Creatinine
collagen crosslinks in fibromyalgia and, 1450
in inflammation and bone loss in polymyalgia rheumatica, 2022
serum, 27, 1250, 1843
c-rel, nuclear factor [gk]B, cyclooxygenase 2 and, 226
Cross-reactivity
autoantibodies to human recombinant erythropoietin in SLE and,
2212
of anti-F(ab`)2 antibody and nuclear antigens, 109
Cruciate ligament, in OA, 284, 1012, 1046, 1756
Cryoglobulinemia, type II, hepatitis C virus in, 2007
Crystals
CPPD, transglutaminase in articular chondrocytes and, 966
monosodium urate monohydrate, inflammation, endothelial activation
and, 955
C-terminal telopeptide, in Paget's disease, 461
C3H/HeJ-gld/gld mice, rheumatic diseases in
MRL/gld mice and, 1054
Cutaneous lesions
in Henoch-Schonlein purpura, 859
vasculitic, hepatitis C virus in type II cryoglobulinemia and,
2007
Cutaneous nodules, in fibroblastic rheumatism, 183
Cutaneous SSc, 1146, 1892, 2252
Cutaneous vascular involvement, l-arginine in Raynaud's
phenomenon and, 352
Cyanogen bromide 11, T cells, collagen and, in RA, 1210
Cycloheximide
anti-proteinase 3 antibodies in human umbilical vein endothelial
cells and, 2030
IL-17, nitric oxide and, in OA cartilage, 1050
Cyclooxygenase 1, NSAID and, 1940, 1944
Cyclooxygenase 2
inhibitors, 595
NSAID and, 1940, 1944
nuclear factor [gk]B and, 226
in RA, 595, 639
Cyclophosphamide
in catastrophic antiphospholipid syndrome, 1534
intravenous pulse, methylprednisolone and, in systemic JRA, 1852
in pregnancy in rheumatic diseases, 1245, 1354
in SLE, 775, 797, 1186
in Wegener's granulomatosis, 2099, 2187
Cyclosporine
human synovial mast cells and, 469
in RA, 791, 1721
in SLE, 27
Cytokines
adhesion molecules and, 991
adjuvant arthritis, inflammatory cachexia and, 534
apoptosis in the rheumatic diseases and, 1917
in catastrophic antiphospholipid syndrome, 1534
CD40-CD40L in autoimmune diseases and, 1735
in collagen arthritis, 249, 1064
IL-10, IL-12 and, in reactive arthritis, 1788
induction of, by JRA SF immune complexes, 2039
in mixed connective tissue disease, 1493
in muscle tissue in inflammatory myopathies, 865
neuroscience and endocrinology of fibromyalgia and, 1928
nitric oxide, articular chondrocytes and, 261
in OA, bone, cartilage metabolism and, 1282
oxicams, leukocytes and, 143
in RA, 5, 80, 217, 397, 595, 598, 639, 1400, 2128
in salivary glands in Sjogren's syndrome, 987
in SLE, 1493, 1703, 2162, 2207
in spontaneous femoral neck fracture in multicentric
reticulohistiocytosis, 2266
in SSc lung disease, 743
T cell, in Lyme arthritis, 69
Th1/Th2 balance, 2104
thrombosis in primary antiphospholipid syndrome and, 834
tissue, in giant cell arteritis, 19
Cytolytic activity, in SLE, 1130
Cytoplasmic antibodies, antineutrophil, 710, 986, 1250, 1680, 2030
Cytoplasmic antigens, in chronic fatigue syndrome, 295
Cytoplasmic protein, apoptosis in the rheumatic diseases and, 1917
Cytoplasmic vacuoles, cathepsin L in RA and, 499
Cytosol, transglutaminase in articular chondrocytes and, 966
Cytotoxic drugs
autologous stem cell transplantation and, 1005
cyclosporine in SLE and, 27
in Henoch-Schonlein purpura, 859
in mediastinal mass and hilar adenopathy in Wegener's
granulomatosis, 1992
Cytotoxic T cells, chlamydial antigen in HLA-B27 transgenic mice
and, 945
Cytotoxic T lymphocyte antigen 4, in RA, 397
Cytotoxicity
chlamydial antigen in HLA-B27 transgenic mice and, 945
cytolytic activity in SLE and, 1130
Th1/Th2 cytokine balance and, 2105
D
Danish Hospital Discharge Register, Danish Cancer Registry, cancer
in SLE and, 761
Dapsone, pregnancy in relapsing polychondritis and, 1245
DBA/1 mice, collagen arthritis in, 154, 249, 893, 907, 1064
Decorboxylase, glutamatic acid, self-antigens, epitopes and, 1374
Decorin, proteoglycans, link protein and, in OA cartilage, 1037
Deep vein thrombosis, reproductive immunology and, 209
Degenerative joint diseases, in vitro model for, 1420
Dehydroepiandrosterone, exogenous, in DBA/1 mice, 907
Delayed-type hypersensitivity, Th1/Th2 cytokine balance and, 2105
Demographic studies
of adverse reactions to antiinflammatory drugs in polymyalgia
rheumatica, 1873
of blood transfusion, smoking, and obesity in RA, 1955
of fibromyalgia, 1553, 1560, 1571
of JRA, 1962, 2235
of SSc, 734, 1146, 1229
Dendritic cells
autologous stem cell transplantation and, 1005
CD40-CD40L in autoimmune diseases and, 1735
in RA, 595
self-antigens, epitopes and, 1374
Th1/Th2 cytokine balance and, 2105
Deoxypyridinoline
collagen crosslinks in fibromyalgia and, 1450
in inflammation and bone loss in polymyalgia rheumatica, 2022
in Paget's disease, 461
Depression, in fibromyalgia, 1553, 1560, 1571
Dermal fibroblasts
collagenase 1 gene in synoviocytes and, 1772
in SSc, 540, 1237
Dermal nodules, in fibroblastic rheumatism, 183
Dermatologic Vignette, tuberculosis cutis colliquative,
immunosuppressive drugs and, in RA, 188
Dermatology and dermatologists, childhood-onset scleroderma and,
1183
Dermatomyositis (DM)
cytokines in muscle tissue in, 865
EBV strain type and lymphoma in, 1152
hepatocarcinoma, hepatitis C and, 394
new-onset juvenile, 1526, 1533
soluble Fas and Fas ligand in, 1126
des-Arg9-Bk, in peptidoglycan arthritis in rats, 1327
Destructive reactive polyarthritis, Ureaplasma
urealyticum in, 2084
Dexamethasone, IL-17, nitric oxide and, in OA cartilage, 1050
Diabetes mellitus, adverse reactions to antiinflammatory drugs in
polymyalgia rheumatica and, 1873
Diarrhea, Clostridium difficile, low-dose chlorambucil
and, in RA, 2090
Diclofenac
hepatic injury and, 201
human synovial mast cells and, 469
tenidap in antigen-induced arthritis and, 2147
Diet, bone mineral density in JRA and, 1967
Differentiated connective tissue disease, breast implants in, 437
Diffuse cerebral arteritis, CNS vasculitis and, 1189
Diffuse glomerulonephritis, rheumatic diseases in
MRL/gld mice and, 1054
Diffuse musculoskeletal pain, neuroscience and endocrinology of
fibromyalgia and, 1928
Diffuse SSc
cutaneous, spinal calcinosis in, 1892
palpable tendon friction rub in, 1146
racial factors in, 734
DiGeorge anomalad/velocardiofacial syndrome/conotruncal anomaly
face syndrome, polyarthritis and chromosome 22q11.2 deletion syndrome
in, 430
Digital ulcers, Health Assessment Questionnaire in SSc and, 1984
Digoxigenin-dUTP, Fas in Sjogren's syndrome and, 87
Disability
fibromyalgia and, 453, 752, 1184
Health Assessment Questionnaire in SSc and, 198
in OA, 1371, 1466, 1940, 1944
psychosocial outcome and health status of adults who had JRA and,
2235
in RA, 1940, 1944
work, in SLE, 2199
Discoid lupus, 2116
Discs, cartilage matrix protein in, 1029
Disease activity
in ANCA-related vasculitis, 1680
eukaryotic ribosomal protein L7 in, 661
Health Assessment Questionnaire in SSc and, 1984
heterotopic ossification, neuromuscular blockade and, 1619
in inflammation and bone loss in polymyalgia rheumatica, 2022
in JRA, 332
in juvenile arthritis, 1202
in juvenile idiopathic inflammatory myopathy, 1976
in OA, 1856, 1940, 1944
in Paget's disease, 461
procalcitonin, infection and, in autoimmune diseases, 1250
in RA, 5, 217, 479, 639, 912, 1096, 1838, 1856, 1940, 1944
in SLE, 27, 47, 57, 797, 809, 822, 1810, 2092, 2199, 2212, 2217
Disease duration
in fibromyalgia, 1553, 1560, 1571
in inflammation and bone loss in polymyalgia rheumatica, 2022
in RA, 217, 794, 842, 1106, 2241
in SLE, 47, 2199
Disease flares
adhesion molecules and, 991
pregnancy in relapsing polychondritis and, 1245
in RA, 1400, 1512, 1838
in SLE, 393, 797, 2092, 2093, 2178, 2217
Disease-modifying antirheumatic drugs (DMARD)
autologous stem cell transplantation and, 1005
in RA, 5, 397, 791, 2241, 2248
Disease onset
in AS in twins, 1746, 1823
dehydroepiandrosterone and, in collagen arthritis in DBA/1 mice,
907
in Henoch-Schonlein purpura, 859
IL-4, IL-10 and, in collagen arthritis, 249
in JRA in affected sibpairs, 1962
in knee OA in the elderly, 728
neuroscience and endocrinology of fibromyalgia and, 1928
in new-onset juvenile DM, 1526
racial factors in SSc and, 734
Disease progression
HLA-DRB1 genotypes in early RA and, 2241
in OA of the knee, 590, 723
Disease remission
in carcinoma polyarthritis and vasculitis, 779
after intravenous pulse cyclophosphamide and methylprednisolone in
systemic JRA, 1852
in Wegener's granulomatosis, 2099, 2187
Disease severity
in AS in twins, 1746, 1823
in collagen arthritis, 249, 907, 1064, 1662
in drug-induced lupus in mice, 1334
in fibromyalgia, 1553, 1560, 1571
HLA and, in RA, 341
in OA, 284, 1012
in SSc, 1129, 1984, 2252
Diskectomy, in spinal calcinosis in SSc, 1892
Distal extremity swelling with pitting edema, in polymyalgia
rheumatica, 1551
Distal femur, periosteal new bone formation in canine neuropathic
OA and, 1756
Distal tubules, renal CD40, CD40L and, 124
Disulfides, thrombospondin 1 in rheumatoid synovium and, 1780
Dithiocarbamate, IL-17, nitric oxide and, in OA cartilage, 1050
Dizygotic twins, AS in, 1746, 1823
DNA
anti-DNA Id, intravenous gamma globulin and, 683
anti-F(ab`)2 reactivity with, 109
apoptosis after hydroxychloroquine and, 927
binding, 912, 919, 1085
cellular, transcriptional activator Sp1 and, 1085
complementary, 598, 615, 1693, 2128
complete congenital heart block in monozygotic twins and, 381
in drug-induced lupus, 1436
genomic, 1257, 1998
naked, mycobacterial heat shock protein 65 in adjuvant arthritis
and, 277
in RA, 510, 613, 1219, 1383, 1798
recombinant human osteogenic protein 1, articular chondrocytes
and, 2157
in Sjogren's syndrome, 87, 2016
in SLE, 1383, 2162
soluble oligonucleosomal, in SF, 648
tenosynovial nodulosis in HTLV-I and, 578
Ureaplasma urealyticum in destructive reactive
polyarthritis and, 2084
DNase
anti-DNA Id, intravenous gamma globulin and, 683
C1q and collagen-like region antibodies in proliferative lupus
glomerulonephritis and, 1504
Dorsal root ganglionectomy, periosteal new bone formation in canine
neuropathic OA and, 1756
Double-stranded DNA (dsDNA) antibodies, histones in SLE and, 2162
Doxycycline
collagenase 3 in rheumatoid synovium and, 1391
minocycline in RA and, 794, 842
DQB1 alleles
in RA, 341
in SLE, 1138
DR
alleles, TNFα in SLE in African-Americans and, 2207
in RA, 598, 854, 1316
DR2, DR3, MHC genes in SLE and, 1138
DR4, in RA, 341, 624, 1115
DRB1
autologous stem cell transplantation and, 1005
MHC genes in SLE and, 1138
prolactin and, in SLE, 1383
in RA, 598, 1368, 1383, 2241
DRB5, MHC genes in SLE and, 1138
Drug-induced lupus, 1334
Drugs
acetylsalicylic acid, 469
analgesic, 859
antibiotic, 794, 842, 859
anticoagulant, 1534
antiinflammatory, 469, 1873
antirheumatic, 5, 284, 1106
antiviral, 2007
aspirin, 209
azathioprine, 175, 769, 775, 1896
biologic agents, 397
calcitonin, 1548
chlorambucil, 2090
chondroprotective, 1073, 1670
clodronate, 5, 1391
contraceptive, 797
corticosteroid, 5, 27, 179, 209, 775, 859, 1245, 1354, 1534, 1852,
1873, 1914, 1967, 1992, 2022, 2055, 2099, 2187, 2241, 2248
cost of, in managed care, 1475
cyclooxygenase 2 inhibitors, 595
cyclophosphamide, 775, 797, 1186, 1245, 1354, 1534, 1852, 2099,
2187
cyclosporine, 27, 469, 791, 1721, 1843
cytotoxic, 27, 859, 1992
dapsone, 1245
dexamethasone, 1050
diclofenac, 201, 469, 2147
DMARD, 5, 397, 791, 1005, 2241, 2248
doxycycline, 794, 842, 1391
estrogen, 1548
Filgrastim, 1838
FK-506, 469
glucocorticoid, 1547, 1548, 1549, 1550, 1551
gold sodium thiomalate, 197
granulocyte colony-stimulating factor, 1838
heparin, 209
hydralazine, 1436
hydroxychloroquine, 927, 1482, 1852
immunosuppressive, 188, 426, 469, 775, 884, 1680, 1992
immunotoxin, 598
intravenous gamma globulin, 1534
intravenous immunoglobulin, 775, 1732
ionomycin, 1644
ketoprofen, 1940, 1944
l-arginine, 352
leukotriene inhibitors, 595
meloxicam, 143
metalloproteinase inhibitors, 595
methotrexate, 5, 175, 193, 195, 391, 469, 718, 791, 971, 984,
1308, 1545, 1721, 1829, 1843, 1852, 2099, 2187, 2226
methylprednisolone, 1400, 1512, 1852, 2022, 2055, 2187
minocycline, 419, 794, 842, 1353
myeloablative, 1712
nimesulide, 469
NSAID, 143, 201, 469, 595, 1245, 1580, 1852, 1873, 1940, 1944,
2248
oxicam, 143
paclitaxel, 1073
pamidronate, 1391
penicillamine, 183, 1391, 1984
penicillin, 1728
piroxicam, 143, 469, 1940, 1944
prednisolone, 2022
prednisone, 183, 209, 1852, 1873, 2187
procainamide, 1436
progestagens, 797
rapamycin, 469
SAARD, 1005
second-line, 175
sulfasalazine, 1852, 1911
sulindac, 201
tacrolimus (FK-506), 1157
Taxol, 1073
tenidap, 284, 2147
tetracycline, 794, 842
``Drummer's finger,'' finger exostosis and, 1185
Ductal epithelial cells, nitric oxide in, in Sjogren's
syndrome, 875
Ductal epithelium, hepatitis C virus in type II cryoglobulinemia
Early OA
experimental, 1012, 1046
vitamin D receptor gene in, 1444
Early RA
HLA in, 341, 2241
joint damage in, after cyclosporine or MTX, 791
minocycline in, 794, 842
synovial tissue in, 217
Economic evaluations, in rheumatology, 1587
Economic factors
psychosocial outcome and health status of adults who had JRA and,
2235
in work disability in SLE, 2199
Ectasia, gastric antral vascular, anti-RNA helicase antibodies, in
connective tissue diseases, 1487
Ectopic calcification, surgery of calcinosis cutis in SLE and, 570
Ectopic nidation, pregnancy in relapsing polychondritis and, 1245
Edema
after IFNγ in RA, 62
kinins in peptidoglycan arthritis in rats and, 1327
MRI-determined synovial membrane volumes in RA and OA and, 1856
peripheral, in SLE and anabolic steroid use, 1899
pitting, distal extremity swelling with, in polymyalgia
rheumatica, 1551
Education
psychosocial outcome and health status of adults who had JRA and,
2235
work disability in SLE and, 2199
Effusions, joint, MRI-determined, in RA and OA, 1856
8-cyclopentyl-dipropylxanthine, adenosine A1,
monocytes, MTX and, 1308
EJ, in idiopathic inflammatory myopathy, 1257
Elastase
leukocyte, thrombospondin 1 in rheumatoid synovium and, 1780
plasma, in ANCA-related vasculitis, 1680
Elbow, tenosynovial nodulosis in HTLV-I and, 578
Elderly, knee OA in, 728, 1518, 2260
Embolism, pulse methylprednisolone, osteonecrosis and, in rabbits,
2055
Embryogenesis, apoptosis in the rheumatic diseases and, 1917
Embryopathy, low-dose maternal MTX and, 971
Emotional trauma, fibromyalgia and, 453, 1553, 1560, 1571
Employment, fibromyalgia after spinal injury and, 446
Encephalomyelitis
experimental allergic, CD40-CD40L in, 1735
Th1/Th2 cytokine balance and, 2105
Endocrinology
of fibromyalgia, 1928
somatostatin in RA and, 2128
Endocytosis, hepatitis C virus in type II cryoglobulinemia and,
2007
Endogenous estrogen, 2-methoxyestradiol and collagen arthritis, 154
Endogenous IL-4, in collagen arthritis, 249
Endogenous kinins, in peptidoglycan arthritis in rats, 1327
Endogenous protective cytokines, Th1/Th2 cytokine balance and, 2105
Endogenous synovial retroviruses, in RA, 627
Endometriosis, reproductive immunology and, 209
Endomysium, cytokines in muscle tissue in inflammatory myopathy
and, 865
Endothelial activation
β2-glycoprotein I, endothelial cells and, 551
in monosodium urate monohydrate crystal inflammation, 955
Endothelial cells
adhesion molecules and, 991
anticardiolipin IgG subclasses and, 1998
β2-glycoprotein I and, 551
in catastrophic antiphospholipid syndrome, 1534
collagenase 3 in rheumatoid synovium and, 1391
cytokines and, 540, 865
human umbilical cord, anti-proteinase 3 antibodies in, 2030
nitric oxide in, 875, 1810
in RA, T cells and, 598
renal CD40, CD40L and, 124
2-methoxyestradiol in collagen arthritis and, 154
Endothelium
cutaneous vascular response in Raynaud's phenomenon and, 352
vascular, nitric oxide and, in SLE, 1810
Endotoxin lipopolysaccharide, anti-proteinase 3 antibodies in human
umbilical vein endothelial cells and, 2030
Enterotoxin B, staphylococcal, apoptosis in autoimmune diseases
and, 306
Enterovirus, in new-onset juvenile DM, 1526
Environmental factors
in AS, 1746, 1823
in complete congenital heart block in monozygotic twins, 381
in neuroscience and endocrinology of fibromyalgia, 1928
in new-onset juvenile DM, 1526
Enzyme-linked immunosorbent assay, antinuclear antibodies and, 1612
Enzymes
C1, C2 core proteins, autoantibodies and, in SSc and psoriatic
arthritis, 2172
in catastrophic antiphospholipid syndrome, 1534
in degenerative joint diseases, 1420
Fas in Sjogren's syndrome and, 87
in OA, 1012, 1444
oxicams, leukocytes and, 143
Th1/Th2 cytokine balance and, 2105
Epidemiologic studies
of HLA in RA, 341
of JRA in affected sibpairs, 1962
Epidermal growth factor, adhesion molecules and, 991
Epithelial cells
adhesion molecules and, 991
apoptosis in the rheumatic diseases and, 1917
renal CD40, CD40L and, 124
in Sjogren's syndrome, 87, 875
Epitopes
antibodies against high mobility group proteins in JRA and, 1803
anti-eukaryotic ribosomal protein L7 and, 661
chlamydial antigen in HLA-B27 transgenic mice and, 945
in RA, 341, 598, 1210, 2241
self-antigens and, 1374
Sm snRNP in SLE and, 672
Epstein-Barr virus (EBV)
anti-F(ab`)2 reactivity with nuclear antigens and, 109
lymphoma in rheumatic diseases and, 1152
transcriptional activator Sp1 and, 1085
Erosions
cartilage, tenidap in OA and, 284
in RA, 499, 1387
Erosive arthritis, in fibroblastic rheumatism, 183
Erythrocyte sedimentation rate
in arteritis temporalis, 191
in juvenile arthritis, 1202
in polymyalgia rheumatica, 191, 1725, 1726
Erythropoietin, human recombinant, autoantibodies to, in SLE, 2212
Escherichia coli, IL-1 receptor antagonist gene therapy
in OA and, 1012
E-selectin, endothelial activation in monosodium urate monohydrate
crystal inflammation and, 955
Esophageal dysfunction, in scleroderma, 2252
Estrogen
glucocorticoid-induced osteoporosis and, 1548
oral contraceptives, SLE and, 797
2-methoxyestradiol and collagen arthritis, 154
Etiology
antibodies against high mobility group proteins in JRA and, 1803
of RA, T cells and, 598
of SLE, Sm snRNP proteins and, 672
Eukaryotic ribosomal protein L7, in systemic autoimmune diseases,
661
European Consensus Lupus Activity Measurement Scale, autoantibodies
to human recombinant erythropoietin in SLE and, 2212
Exercise
in fibrosing alveolitis in SSc, 1129
psychosocial outcome and health status of adults who had JRA and,
2235
P-31 MRS in polymyalgia rheumatica and, 1817
Exogenous cytokines, Th1/Th2 cytokine balance and, 2105
Exogenous dehydroepiandrosterone, in collagen arthritis in DBA/1
mice, 907
Exogenous estrogen, glucocorticoid-induced osteoporosis and, 1548
Exogenous human β2-glycoprotein I, endothelial cells
and, 551
Exogenous IL-10, exogenous IL-12, in reactive arthritis, 1788
Exostosis, finger, ``drummer's finger'' and, 1185
Experimental allergic encephalomyelitis, CD40-CD40L in, 1735
Experimental arthritis
mononuclear phagocytes, rheumatoid synovitis and, 5
mycobacterial heat shock protein 65 in, 277
Experimental autoimmune diseases, CD40-CD40L in, 1735
Experimental OA
collagen mRNA in, 1046
IL-1 receptor antagonist gene therapy in, 1012
mono-iodoacetate induced, 1670
Extraarticular features of RA, CD4 cells and, 1106
Extracellular ATP, extracellular calcium, in SLE, 1130
Extracellular matrix
collagen crosslinks in fibromyalgia and, 1450
protein, 270, 991
tenidap in antigen-induced arthritis and, 2147
Extracellular phosphorylation, phosphate in SLE and, 2178
Extractable nuclear antigens, transcriptional activator Sp1 and,
1085
Extremities, distal, swelling of, with pitting edema, in
polymyalgia rheumatica, 1551
Eye
azathioprine in Behcet's disease and, 769
hydroxychloroquine and, 1482
uveitis and, 358
F
F(ab`)2, CD59 in synovial tissue in rats and, 527
Factors
granulocyte colony-stimulating, 1838
granulocyte-macrophage colony-stimulating, 5, 143, 865, 1005, 2039
growth, 5, 270, 306, 332, 598, 786, 865, 966, 991, 1005, 1628,
1653, 2105, 2147
leukemia inhibitory, 1096
nuclear, 5, 226, 1157
tissue, 834, 2030
transcription, 226, 912
tumor necrosis, 5, 69, 143, 217, 249, 261, 397, 534, 549, 595,
598, 743, 834, 865, 875, 955, 1096, 1130, 1400, 1662, 1735, 1788, 2039,
2065, 2207, 2266
V Leiden, protein C, antiphospholipid antibodies in SLE and, 1720
Familial antiphospholipid syndrome, HLA-DRB genes and, 1907
Familial Mediterranean fever, diagnosis of, 1879
Family involvement, in primary juvenile fibromyalgia, 752
Family practice, fibromyalgia and, 1553, 1560, 1571
Fas
apoptosis and, 1749, 1912, 1917
cytotoxicity in SLE and, 1130
ligand, 1054, 1126, 1644, 1749, 1917
in rheumatic diseases, 1126
in Sjogren's syndrome, 87
soluble, in RA, 80
Fas/APO-1, apoptosis in autoimmune diseases and, 306
Fas-mediated apoptosis, of RA synoviocytes, 919
Fat necrosis, subcutaneous, 1732, 2116
Fatigue
in adults who had JRA, 2235
chronic, insoluble cellular antigens in, 295
in fibromyalgia, 453, 752, 1928
transcriptional activator Sp1 and, 1085
Fatty liver, pulse methylprednisolone, osteonecrosis and, in
rabbits, 2055
Fc fragments, B cells in RA and, 1409
Fc receptors, anticardiolipin IgG subclasses and, 1998
FcγRIIA polymorphism, in SLE, 1180
Feet
HLA-DRB1 genotype in early RA and, 2241
neuropathic joint of, 2116
Felty's syndrome, immunogenetics and, 624
Femoral condyle, in OA, 284, 1012
Femoral head, OA articular cartilage and, 1766
Femoral neck
antiinflammatory drugs in polymyalgia rheumatica and, 1873
spontaneous fracture of, in multicentric reticulohistiocytosis,
2266
Femur
distal, periosteal new bone formation in canine neuropathic OA
and, 1756
pulse methylprednisolone, osteonecrosis and, in rabbits, 2055
Fertility, oral contraceptives, SLE and, 797
Fertility immunology, clinical rheumatology and, 209
Fetus
congenital heart block, 52β and, 655
loss of, 209, 834
pregnancy in relapsing polychondritis and, 1245
Fever
in acute intermittent porphyria, 586
cytokines in giant cell arteritis and, 19
in Henoch-Schonlein purpura, 859
MTX lung injury in RA and, 1829
Fiber neuropathy, small, vasculitis and, 1173
Fibrin, MRI in RA and OA and, 1856
Fibrinogen, phosphate in SLE and, 2178
Fibroblast collagenase, in OA, 2065
Fibroblast-like mononuclear cells, collagenase 3 in rheumatoid
synovium and, 1391
Fibroblast-like synovial cells, somatostatin in RA and, 2128
Fibroblast-like synoviocytes
collagenase 1 gene and, 1772
in RA, 595, 1292
Fibroblastic rheumatism, arthropathy of, 183
Fibroblasts
apoptosis in the rheumatic diseases and, 1917
Fas ligand, RA synovial lymphocytes and, 1644
HOX4C gene on rheumatoid synovial fibroblasts and, 1628
HS68 dermal, collagenase 1 gene and, 1772
IL-6-type cytokines in RA and, 1096
mononuclear phagocytes, rheumatoid synovitis and, 5
NIH/3T3, human IL-1 receptor antagonist in collagen arthritis and,
893
skin, tenosynovial nodulosis in HTLV-I and, 578
in SSc, 540, 1237
synovial, 490, 1012, 1292, 1298
Fibromodulin, proteoglycans, link protein and, in OA cartilage,
1037
Fibromyalgia
cervical traction, breast implants and, 2097
disability in, 1184
health status and disease severity in, 1571
Medicare Part B, rheumatology and, 1594
neuroscience and endocrinology of, 1928
nociception in, 98
pain in, 2275
primary juvenile, 752
rheumatologists and, 1553
service utilization and costs in, 1560
in SLE, 1544
spinal injury and, 446
trauma in, 453
Fibronectin
growth factors, chondrocytes and, 270
tenidap in antigen-induced arthritis and, 2147
Fibrosing alveolitis, in SSc, 1229
Fibrosis
liver, MTX and, in JRA, 2226
MRI in RA and OA and, 1856
pulmonary, in SSc, 743, 1219, 1237
Fibrous tissue, mast cells in rheumatoid synovium and, 479
52β, congenital heart block and, 655
52-kd protein, Ro/La immune response and, 936
52-kd SS-A/Ro autoantigen, 52β, congenital heart block and, 655
55-kd TNFα receptor, in collagen arthritis, 1662
57-kd heat shock protein, chlamydial antigen in HLA-B27 transgenic
mice and, 945
Filament antigens, intermediate, in chronic fatigue syndrome, 295
Filgrastim, in RA, 1838
Fingers
cutaneous vascular response in Raynaud's phenomenon and, 352
``drummer's finger,'' 1185
5` region, of cathepsin B pre-messenger RNA, in rheumatoid synovial
tissue, 1540
5`-N-ethylcarboxamidoadenosine, collagenase 1 gene and,
1772
FK-506
human synovial mast cells and, 469
T cells and, 1157
Focal lesions, in CNS vasculitis, 1189
Focal segmental glomerulosclerosis, renal CD40 and CD40L in, 124
Folate, MTX in RA and, 391
Followup studies
of fibromyalgia, 1553, 1560, 1571
of mediastinal mass and hilar adenopathy in Wegener's
granulomatosis, 1992
of RA, 426, 984, 1712
Food intake, adjuvant arthritis, inflammatory cachexia and, 534
Forced vital capacity, in SSc, 1984
Foreign antigens
B cells in RA and, 1409
CD40-CD40L in autoimmune disease and, 1735
4F4 monoclonal antibodies, C1, C2 core proteins and, in SSc and
psoriatic arthritis, 2172
48-kd SS-B/La, 52-kd protein, immune response and, 936
Fractures
antiinflammatory drugs in polymyalgia rheumatica and, 1873
leg, fibromyalgia after spinal injury and, 446
posterior longitudinal ligament, cervical cord compression in,
2277
stress, longitudinal, of tibia, 385
Framinginham OA Study, knee OA in the elderly, 728
Free radicals, S-nitrosoproteins in RA and, 1512
Freund's adjuvant
complete, in adjuvant arthritis model of inflammatory cachexia,
534
incomplete, biologic agents and, in RA, 397
Friction rub, palpable tendon, in SSc, 1146
Functional ability
in adults who had JRA, 2235
bacterial arthritis and, 884
bone mineral density in JRA and, 1967
cyclosporine, MTX and, in RA, 1843
fibromyalgia and, 446, 453, 752, 1553, 1560, 1571, 1928
fibrosing alveolitis in SSc and, 1219
in juvenile arthritis, 1202
in knee OA and, 1371, 1466, 2260
risk and outcome in SLE and, 47
Fungi, in CNS vasculitis, 1189
Fusion protein, recombinant, 1364, 1493
G
γ/δ T cell receptor, HLA-B27 autoantigens in AS and, 2047
Ganglionectomy, dorsal root, periosteal new bone formation in
canine neuropathic OA and, 1756
Gastric antral vascular ectasia, anti-RNA helicase antibodies in,
1487
Gastric lesions, B cell proliferation in Sjogren's syndrome
and, 318
Gastric motility, in esophageal dysfunction in scleroderma, 2252
Gastrointestinal involvement
cyclosporine in SLE and, 27
in SSc, 1984
Gelatinase
collagen degradation in cartilage and, 164
oxicams, leukocytes and, 143
tenidap in OA and, 284
Gender
antiinflammatory drugs in polymyalgia rheumatica and, 1873
azathioprine in Behcet's syndrome and, 769
in drug-induced lupus, 1334
in fibromyalgia, 1928
in JRA, 1962, 2235
in OA, 728, 1444, 1760
in RA, 1383, 1580, 1955, 2248
in SLE, 1383, 1429, 1542, 2199
in SSc, 441, 734
thrombosis in primary antiphospholipid syndrome and, 834
transcriptional activator Sp1 and, 1085
Generalized Wegener's granulomatosis, cyclophosphamide and steroids
in, 2187
Genes
apoptosis in autoimmune diseases and, 306
AS and, 1746, 1823
collagenase 1, 1772
HLA-DRB, in familial antiphospholipid syndrome, 1907
IL-1 receptor antagonist and, 893, 1012
membrane protein 1, EBV, lymphoma and, in rheumatic diseases, 1152
mycobacterial heat shock protein 65 in adjuvant arthritis and, 277
in OA, 562, 1037, 1444, 1760
in RA, 5, 237, 397, 598, 627, 854, 1383, 1628
ribozyme-based cleavage, in HTLV-I, 2118
scleroderma lung fibroblast collagen synthesis and, 1237
in SLE, 389, 1138, 1383, 2207
TAP2*Bky2 (VAL577), in
Sjogren's syndrome, 1685
Th1/Th2 cytokine balance and, 2105
transfer of, into articular cartilage, 901
Genetics
anticardiolipin IgG subclasses and, 1998
of AS, 1746, 1823
complete congenital heart block in monozygotic twins and, 381
fibromyalgia and, 1928
in JRA in affected sibpairs, 1962
new-onset juvenile DM and, 1526
in RA, 1005, 1106, 1316, 1798
self-antigens, epitopes and, 1374
in SLE, 1130, 1429, 1720
TAP2*Bky2 (VAL577) in
Sjogren's syndrome and, 1685
vitamin D receptor in knee OA and, 1444
Genomes, anticardiolipin IgG subclasses and, 1998
Genomic DNA, in idiopathic inflammatory myopathy, 1257
Genotypes
anticardiolipin IgG subclasses and, 1998
in OA, 1444, 1760
in RA, 1387, 1798, 2241
Genotyping, HLA, in RA, 341, 624
Giant cell arteritis
antiinflammatory drugs in polymyalgia rheumatica and, 1873
tissue cytokines in, 19
Giant cells
adenosine A1, human monocytes, MTX and, 1308
spontaneous femoral neck fracture in multicentric
reticulohistiocytosis and, 2266
Gingival attachment loss, in RA, 2248
Gingival hyperplasia, cyclosporine in SLE and, 27
Glands
lacrimal, 1917
salivary, 87, 987, 1917, 2271
gld gene, rheumatic diseases in MRL/gld mice
and, 1054
Global assessment
physician, in juvenile arthritis, 1202
in juvenile idiopathic inflammatory myopathy, 1976
NSAID and, in OA, 1940, 1944
in RA, 419, 1843, 1940, 1944
Glomeruli, C1q-collagen-like region antibodies in, in SLE, 1504
Glomerulonephritides, renal CD40 and CD40L in, 124
Glomerulonephritis
in MRL/gld mice, 1054
in SLE, 1504, 1899
Glucocorticoid-induced osteoporosis
bone density in, 1550
exogenous estrogen in premenopausal women with oligo- or
amennorrhea and, 1548
guidelines on, 1547
management of, 1548, 1549
prevention of, 1549
Glutamatic acid decarboxylase, self-antigens, epitopes and, 1374
Gluteus medius muscle, pulse methylprednisolone, osteonecrosis and,
in rabbits, 2055
Glycine, anti-DNA Id, intravenous gamma globulin and, 683
Glycogenolytic and glycolytic pathways, P-31 MRS in polymyalgia
rheumatica and, 1817
Glycoprotein
in RA, 397, 499, 598, 1115
thrombosis in primary antiphospholipid syndrome and, 834
Glycosaminoglycans, OA and, 1262, 2075
Gold sodium thiomalate, recall of, 197
Golgi complex, 97-kd, in Sjogren's syndrome, 1693
Gout, of the hand, 2116
Graft-versus-host disease
autologous hemopoietic stem cell transplantation, RA and, 1005
CD40-CD40L in autoimmune diseases and, 1735
Graft-versus-host disease-like reactions, in reproductive
immunology, 209
Granulation tissue
formation, MRI in RA and OA and, 1856
pulse methylprednisolone, osteonecrosis and, in rabbits, 2055
Granulocyte colony-stimulating factor, in RA, 1838
Granulocyte-macrophage colony-stimulating factor
autologous hemopoietic stem cell transplantation, RA and, 1005
JRA SF immune complexes and, 2039
mononuclear phagocytes, rheumatoid synovitis and, 5
in muscle tissue in inflammatory myopathy, 865
oxicams, leukocytes and, 143
Granulocytes, plasma elastase in ANCA-related vasculitis and, 1680
Granulomatosis, Wegener's, 135, 306, 371, 573, 1183, 1354, 2030,
2099, 2187
Granulomatous angiitis, primary, of the CNS, 1189
Granulomatous arteritis, in MRL/gld mice and, 1054
Granulomatous infiltrates, cytokines in giant cell arteritis and,
19
Growth and development, in JRA, 332, 1852
Growth-arrest-specific gene 6, chondrocytes and, 1455
Growth factors
apoptosis in autoimmune diseases and, 306
chondrocyte integrins and, 270
epidermal, adhesion molecules and, 991
insulin-like, 332, 966
in POEMS syndrome, 786
RA and, 598, 1005, 1628
transforming β, 966, 1653, 2105
Growth hormones
fibromyalgia and, 1928
recombinant human, in JRA, 332
Growth plate cartilage, transglutaminase in articular chondrocytes
and, 966
Guidelines, status of, 1
Guinea pig studies, spontaneous OA in, 2075
Gut
esophageal dysfunction in scleroderma and, 2252
T cells in RA and, 598
Gynecologic surgery, in fibromyalgia, 1553, 1560, 1571
H
Hand
arthritis and subcutaneous fat necrosis with pancreatitis in, 2116
gout in the, 2116
HLA-DRB1 genotype in early RA and, 2241
OA, 728, 1760
in SSc, 1984
Haplotypes
in idiopathic inflammatory myopathy, 1257
in neonatal lupus, 982
prolactin, DRB1 and, in women with RA, 1383
in SLE, 1138, 1383
Head trauma, heterotopic ossification and, 1619
Headache, in CNS vasculitis, 1189
Health Assessment Questionnaire
Disability and Discomfort Scales, self-care education in knee OA
and, 1371, 1466
in fibromyalgia, 1553, 1560, 1571
in JRA, 2235
in RA, 419, 1843
in SSc, 1984
Health care seeking, in fibromyalgia, 453
Health insurance
and adults who had JRA, 2235
work disability in SLE and, 2199
Health maintenance organizations, cost of care for RA and OA in,
1475
Health status
disease severity and, in fibromyalgia, 1553, 1560, 1571
questionnaire, in JRA, 2235
in self-care education for knee OA, 1371, 1466
Heart
complete congenital heart block in monozygotic twins, 381
disease, in SSc, 1984
Heat inactivation, in assays for antibodies to
β2-glycoprotein and anticardiolipin, 2095
Heat shock protein 60, B cells in RA and, 1409
Heat shock protein 65, mycobacterial, 277, 510
Heavy chain, IgG, TNFα receptor gene in collagen arthritis and,
1662
Height
in JRA, 332
in OA of the knee, C-reactive protein and, 723
HeLa cells, C1, C2 core proteins and, in SSc and psoriatic
arthritis, 2172
Helicase protein, nucleolar RNA, autoantibodies to, in connective
tissue disease, 1487
HELLP syndrome, catastrophic antiphospholipid syndrome and, 1534
Helper cells, T cells, B cells, snRNP and, in mixed connective
tissue disease, 1493
Hematology
pulse methylprednisolone, osteonecrosis and, in rabbits, 2055
systemic vasculitis, myelodysplastic syndromes and, 179
Hematopoietic organs, 2-methoxyestradiol in collagen arthritis and,
154
Hemilaminectomy, in spinal calcinosis in SSc, 1892
Hemodialysis, β2-microglobulin arthropathy after, 709
Hemoglobin, in SLE, 27, 2212
Hemolysis, catastrophic antiphospholipid syndrome and, 1534
Hemopoietic stem cell transplantation, autologous, RA and, 1005
Hemorrhage
in CNS vasculitis, 1189
gingival, in periodontal disease in RA, 2248
in SLE, 36, 775
Henoch-Schonlein purpura, in adults and children, 859
HEp-2 cells
antinuclear antibodies and, 1601, 1612
substrate, anti-RNA helicase antibodies in connective tissue
disease and, 1487
Heparin, in reproductive immunology, 209
Hepatitis
C, 394, 2007
self-antigens, epitopes and, 1374
Hepatocarcinoma, DM, hepatitis C and, 394
Hepatosplenomegaly, apoptosis in the rheumatic diseases and, 1917
Hepatotoxicity, MTX in JRA and, 2226
Herpes
simplex virus, in new-onset juvenile DM, 1526
uveitis in, 358
Heterogeneity
cytokines in giant cell arteritis and, 19
eukaryotic ribosomal protein L7 in autoimmune diseases and, 661
Heterogenous nuclear RNP C1 and C2 core proteins, in SSc and
psoriatic arthritis, 2172
Heterotopic ossification, neuromuscular blockade and, 1619
High-dose myeloablative drugs, autologous stem cell tranplantation
in RA and psoriasis and, 1712
High mobility group proteins, in JRA, 1803
Hilar adenopathy, in Wegener's granulomatosis, 1992
Hip
idiopathic transient osteoporosis of the, 1179
Medicare Part B, rheumatology and, 1594
OA, 1262, 1760, 1914
pain, in an adolescent, 583
in polymyalgia rheumatica, 1873
spontaneous femoral neck fracture in multicentric
reticulohistiocytosis and, 2266
surgery of calcinosis cutis in SLE and, 570
Histamine, human synovial mast cells and, 469
Histiocytic multinucleated giant cells, spontaneous femoral neck
fracture in multicentric reticulohistiocytosis and, 2266
Histochemistry, OA articular cartilage and, 1766
Histology
in arthropathy of fibroblastic rheumatism, 183
bone morphogenetic protein 2, cartilage proteoglycan synthesis
and, 1020
CD59 in synovial tissue in rats and, 527
in CNS vasculitis, 1189
liver, MTX and, in JRA, 2226
mycobacterial heat shock protein 65 in adjuvant arthritis and, 277
in OA, 284, 1012, 1756, 1766, 1856, 2075
P-31 MRS in polymyalgia and, 1817
pulse methylprednisolone, osteonecrosis and, in rabbits, 2055
in RA, 5, 479, 710, 1856
scleroderma lung fibroblast collagen synthesis and, 1237
Ureaplasma urealyticum in destructive reactive
polyarthritis and, 2084
Histones
dsDNA antibodies in SLE and, 2162
self-antigens, epitopes and, 1374
soluble oligonucleosomal complexes in SF and, 648
Histopathology
B cell lymphoproliferation in Sjogren's syndrome and, 318
in CNS vasculitis, 1189
MTX lung injury in RA and, 1829
OA articular cartilage and, 1766
percutaneous needle muscle biopsy in inflammatory myopathy and,
1886
pulse methylprednisolone, osteonecrosis and, in rabbits, 2055
rheumatic diseases in MRL/gld mice and, 1054
tenidap in antigen-induced arthritis and, 2147
tenosynovial nodulosis in HTLV-I and, 578
HLA
alleles, class II, in neonatal lupus, 982
AS and, 1746, 1823
in RA, 341, 1368
reproductive immunology and, 209
typing, in twins, 381, 1746, 1823
HLA-B27
AS and, 1746, 1823, 2047
bacteria and, 694
in RA, 341
spondylarthropathy and, 388
HLA-B27*2705 transgenic CBA (H-2k) mice, chlamydial
antigen in, 945
HLA-B60, in AS, 1746, 1823
HLA-DMA, HLA-DMB genes, in RA, 854
HLA-DQ1 alleles, in idiopathic inflammatory myopathy, 1257
HLA-DQB alleles, in SLE, 1130
HLA-DR, cytokines and, in SSc, 540
HLA-DR1, in AS, 1746, 1823
HLA-DR4/1, alleles, in RA, 595
HLA-DRB genes, in familial antiphospholipid syndrome, 1907
HLA-DRB1
alleles, 1130, 1383
in RA, 341, 598, 854, 1005, 2241
HLA-DRB1*04 molecular modeling, T cell receptors and, in RA, 1316
Hodgkin's disease, in RA, 1580
Hodgkin's lymphoma, in CNS vasculitis, 1189
Hoe 140, endogenous kinins in peptidoglycan arthritis and, 1327
Homeostasis, tissue, apoptosis in the rheumatic diseases and, 1917
Homocysteine metabolism, in RA, 718
Hopkins Lupus Cohort, oral contraceptives and SLE in, 797
Hormones
fibromyalgia and, 1928
oral contraceptives, SLE and, 797, 804
in RA, 598, 1096
recombinant human growth, in JRA, 332
Hospitalization
in fibromyalgia, 1553, 1560, 1571
in Wegener's granulomatosis, 2099, 2187
Hospitals
incidence of SSc in, 441
visits to, cost of care for RA and OA in managed care setting and,
1475
HOX4C gene, in rheumatoid synovial fibroblasts, 1628
H-ras oncogene point mutation, in arthritic synovium,
1636
HS68 dermal fibrolasts, collagenase 1 gene and, 1772
3H-thymidine, in RA, 510, 1292
Human cartilage glycoprotein-39, in RA, 1115
Human growth hormone, recombinant, in JRA, 332
Human herpesvirus 8, in autoimmune diseases, 1906
Human immunodeficiency virus (HIV) infection
in SLE, 1168
sulfasalazine and, in reactive arthritis, 1911
Human lymphoproliferative syndrome, apoptosis in the rheumatic
diseases and, 1917
Human recombinant erythropoietin, autoantibodies to, in SLE, 2212
Human retrovirus-5 proviral DNA, in Sjogren's syndrome, 2016
Human studies
adenosine A1, monocytes, MTX and, 1308
anti-DNA Id and intravenous gamma globulin, 683
anti-F(ab`)2 reactivity with nuclear antigens, 109
autoantibodies and Ku antigen, 1344
of cartilage, 164, 704, 1029, 1653
of chondrocytes, 261, 1275, 1455, 2157
endothelial cells and β2 glycoprotein I, 551
fibroblast-macrophage interaction in cartilage degradation, 490
52-kd protein and immune response, 936
human IL-1 receptor antagonist in murine collagen arthritis, 893
synovial mast cells, 469
Human T cell leukemia virus (HTLV-I), ribozyme-based gene cleavage
in, 2118
Human T cell lymphotropic virus I (HTLV-I), tenosynovial nodulosis
in, 578
Humerus, pulse methylprednisolone, osteonecrosis and, in rabbits,
2055
Humoral immune response
in chronic fatigue syndrome, 295
Ku antigen and, 1344
Humoral pathway, biologic agents in RA and, 397
HUTS-21 monoclonal antibody, oxicams, leukocytes and, 143
HVR3, in RA, 341
Hyaluronan, proteoglycans, link protein and, in OA cartilage, 1037
Hydralazine, in drug-induced lupus, 1436
Hydrogen bone, T cell receptors, MHC and, in RA, 1316
Hydroxychloroquine
apoptosis after, 927
intravenous pulse cyclophosphamide, methylprednisolone and, in
systemic JRA, 1852
retinopathy, 1482
Hydroxyproline
in Paget's disease, 461
in spontaneous OA in guinea pigs, 2075
Hydroxyurea, in drug-induced lupus, 1436
Hyperalgesia, fibromyalgia and, 1928
Hypercoagulability, oral contraceptives, SLE and, 797
Hypercreatinemia, cyclosporine in SLE and, 27
Hyperhomocysteinemia, homocysteine metabolism in RA and, 718
Hyperlipemia, pulse methylprednisolone, osteonecrosis and, in
rabbits, 2055
Hyperpigmentation, skin, minocycline and, 1353
Hyperplasia
gingival, cyclosporine in SLE and, 27
in RA, 912, 1005
synovial, HOX4C gene on rheumatoid synovial fibroblasts and, 1628
tenidap in antigen-induced arthritis and, 2147
Hyperprolactinemia, in SLE after anabolic steroids, 1899
Hypersensitivity, delayed-type, Th1/Th2 cytokine balance and, 2105
Hypertension
cyclosporine in SLE and, 27
pulmonary, in SSc, 734, 1219
Hypertrichosis, cyclosporine in SLE and, 27
Hypertrophy, villous, paclitaxel, synoviocytes, apoptosis and, 1073
Hypocomplementemia in Streptococcus pneumoniae infection
in SLE, 1716
Hypofibrinogenemia, pulse methylprednisolone, osteonecrosis and, in
rabbits, 2055
Hypothalamic-pituitary-adrenal axis, in fibromyalgia, 1928
I
Ichthyosis and related disorders, registry for, 1556
Id human myeloma protein, anti-DNA, intravenous gamma globulin and,
683
Idiopathic inflammatory myopathy
cytokines in muscle tissue in, 865
juvenile, 1976
in Poland, 1257
Idiopathic membranous glomerulonephritis, renal CD40 and CD40
ligand in, 124
Idiopathic transient osteoporosis of the hip, 1178
Idiopathic uveitis, diagnosis of, 358
Idiotypes, anti-DNA Id and intravenous gamma globulin, 683
IgA
B cells in RA and, 1409
nephropathy, renal CD40, CD40 ligand and, 124
in polyarthritis in chromosome 22q11.2 deletion syndrome, 430
IgD, rheumatic diseases in MRL/gld mice and, 1054
IgE, synovial mast cells and, 469
IgG
adhesion molecules and, 991
anticardiolipin subclasses, 1998
anti-dsDNA, testosterone, anti-DNA antibody and, in SLE, 1703
anti-F(ab`)2 reactivity with nuclear antigens and, 109
antibodies, 103, 551, 1364, 1374
autoantibodies, CD40 and CD40 ligand in autoimmune diseases and,
1735
B cells in RA and, 1409
C1q collagen-like region antibodies and, in SLE, 1504
in collagen arthritis, 907, 1662
hepatitis C virus in type II cryoglobulinemia and, 2007
intravenous gamma globulin and, 683
reproductive immunology and, 209
rheumatic diseases in MRL/gld mice and, 1054
thrombosis in primary antiphospholipid syndrome and, 834
IgM
antibodies, 109, 551
hepatitis C virus in type II cryoglobulinemia and, 2007
isotypes, reproductive immunology and, 209
rheumatic diseases in MRL/gld mice and, 1054
thrombosis in primary antiphospholipid syndrome and, 834
Immune complexes
anti-ICAM-1 monoclonal antibody in RA and, 849
hepatitis C virus in type II cryoglobulinemia and, 2007
phosphate in SLE and, 2178
SF, cytokine induction by, in JRA, 2039
Immune depositis, C1q collagen-like region antibodies and, in SLE,
1504
Immune response
CD40 and CD40 ligand in autoimmune diseases and, 1735
in CNS vasculitis, 1189
humoral, 295, 1344
in RA, 397, 598, 912, 1115, 1512, 1580
reproductive immunology and, 209
rheumatic diseases in MRL/gld mice and, 1054
Ro/La, 52-kd protein and, 936
silicone effects in collagen arthritis and, 1064
silicone implants and, 1630
Immune system
apoptosis in the rheumatic diseases and, 1917
CD40 and CD40 ligand in autoimmune diseases and, 1735
in fibromyalgia, 1928
in RA, 397, 1005, 1409, 2128
self-antigens, epitopes and, 1374
Immunization
mycobacterial heat-shock protein 65 in adjuvant arthritis and, 277
reproductive immunology and, 209
Immunoblotting, Mycoplasma infection in RA and, 1219
Immunodeficiency in polyarthritis and chromosome 22q11.2 deletion
syndrome, 430
Immunofluorescence, antinuclear antibodies and, 410, 413, 1612
Immunogenesis, antiphospholipid antibody, T cells and, 196
Immunogenetics
anti-RNA helicase antibodies in connective tissue disease and,
1487
in Felty's syndrome and RA, 624
in idiopathic inflammatory myopathy, 1257
Immunogenicity, anti-ICAM-1 monoclonal antibody in RA and, 849
Immunoglobulins
adhesion molecules and, 991
antiphospholipid antibodies and, in parvovirus B19 infection and
SLE, 103
anti-proteinase 3 antibodies in human umbilical vein endothelial
cells and, 2030
cytokine induction by JRA SF immune complexes and, 2039
fusion protein, chondrocytes, growth-arrest-specific gene 6,
tyrosine kinase receptor axl and, 1455
intravenous, in reproductive immunology, 209
Immunohistochemistry, cartilage and, 901, 1029, 1653
Immunohistology
renal CD40 and CD40 ligand in, 124
rheumatoid synovial tissue and, 217
Immunology
anti-F(ab`)2 reactivity with nuclear antigens and, 109
human synovial mast cells and, 469
IL-10 in SLE and, 1429
in polyarthritis and chromosome 22q11.2 deletion syndrome, 430
reproductive, clinical rheumatology and, 209, 1910
Immunomodulation
EBV, lymphoma and, in rheumatic diseases, 1152
reproductive immunology and, 209
Immunopathogenesis
in RA, 595, 598, 1005
in SLE, 1130
Immunophenotypes, mast cells in rheumatoid synovium and, 479
Immunoreactivity
collagenase 3 in rheumatoid synovium and, 1391
human IL-1 receptor antagonist in murine collagen arthritis and,
893
Immunoregulation, Th1/Th2 cytokine balance and, 2105
Immunosuppressive drugs
acquired factor VIII inhibitor in SLE and, 775
in bacterial arthritis, 884
human synovial mast cells and, 469
mediastinal mass, hilar adenopathy and, in Wegener's
granulomatosis, 1992
plasma elastase in ANCA-related vasculitis and, 1680
in RA, 188, 426
Immunotherapy, human cartilage glycoprotein-39 in RA and, 1115
Immunotoxins, T cells in RA and, 598
Inclusion body myositis, cytokines in muscle tissue in, 865
Infarction, myocardial, immunoglobulin therapy and, 1732
Infarcts, brain MRI and MRS in SLE and, 36
Infection
bacterial, 5, 1250
in bacterial arthritis, 884
in CNS vasculitis, 1189
EBV, lymphoma and, in rheumatic diseases, 1152
HLA-B27 autoantigens in AS and, 2047
IL-10/IL-12 regulation in reactive arthritis and, 1788
mediastinal mass and hilar adenopathy in Wegener's granulomatosis
and, 1992
parvovirus B19, antiphospholipid antibodies in, 103
in RA, 598, 1219, 1955
reproductive immunology and, 209
in SLE, 1168, 1180, 1186, 1716
upper respiratory tract, in Henoch-Schonlein purpura, 859
Ureaplasma urealyticum in destructive reactive
polyarthritis and, 2084
viral, 5, 1735, 2016
in Wegener's granulomatosis, 2099, 2187
Infectious diseases, biologic agents in RA and, 397
Inflammation
adhesion molecules and, 991
apoptosis in the rheumatic diseases and, 1917
in collagen arthritis, 154, 249, 893, 1662
cytokines and, 19, 540, 743
in destructive joint diseases, 1409
endogenous kinins in peptidoglycan arthritis and, 1327
in fibromyalgia, 1928
hepatitis C virus in type II cryoglobulinemia and, 2007
joint, 80, 520, 648
monosodium urate monohydrate crystal, endothelial activation in,
955
in OA, 723, 2065
oxicams, leukocytes and, 143
in polymyalgia rheumatica, 1726, 2022
in RA, 5, 217, 397, 479, 510, 595, 710, 1115, 1400, 1409, 1512,
1780, 1912
racial factors in SSc and, 734
reproductive immunology and, 209
synovial, 284, 1308, 1856
TNFα in SLE in African-Americans and, 2207
Inflammatory arthritides, human synovial mast cells and, 469
Inflammatory arthritis, nitric oxide, articular chondrocytes and,
261
Inflammatory bowel disease
adhesion molecules and, 991
uveitis in, 358
Inflammatory cachexia, adjuvant arthritis and, 534
Inflammatory cells
apoptosis in the rheumatic diseases and, 1917
CD59 in synovial tissue in rats and, 527
cytokines in muscle tissue in inflammatory myopathy and, 865
nitric oxide in Sjogren's syndrome and, 875
paclitaxel, synoviocytes, apoptosis and, 1073
T cells in RA and, 598
Inflammatory cytokines, mononuclear phagocytes, rheumatoid
synovitis and, 5
Inflammatory diseases
HLA-DRB1 genotype in early RA and, 2241
Th1/Th2 cytokine balance and, 2105
2-methoxyestradiol in collagen arthritis and, 154
Inflammatory joint disease
CR1, CD35 in SF in, 520
mononuclear phagocytes, rheumatoid synovitis and, 5
Inflammatory lesions
CD4 cells in RA and, 1106
Th1/Th2 cytokine balance and, 2105
Inflammatory myopathy
idiopathic, 865, 1257, 1886, 1976
percutaneous needle muscle biopsy in, 1886
Inflammatory polyarthritis, risk factors for RA and, 1955
Inflammatory renal diseases, CD40 and CD40 ligand in, 124
Inorganic phosphate, P-31 MRS in polymyalgia rheumatica and, 1817
Inorganic pyrophosphate, chondrocytes and, 966, 1275
Insoluble cellular antigen autoantibodies, in chronic fatigue
syndrome, 295
Insulin-like growth factor 1
chondrocytes and, 270
in JRA, 332
transglutaminase in articular chondrocytes and, 966
Insulin-like growth factor binding proteins 1 and 3, in JRA, 332
Insurance claims, fibromyalgia after spinal injury and, 446
Insurance coverage, for reproductive immunology, 209
Integrins
adhesion molecules and, 991
chondrocytes, growth factors and, 270
oxicams, leukocytes and, 143
rheumatoid synovial fibroblasts, cartilage and, 1298
Intercellular adhesion molecule 1 (ICAM-1)
in RA, 80, 397
in SSc, 540
Interferon-α, autologous stem cell transplantation in RA and
psoriasis and, 1712
Interferon β-1B, in RA, 1370
Interferon-γ (IFNγ)
adhesion molecules and, 991
dsDNA antibodies in SLE and, 2162
in giant cell arteritis, 19
IL-10/IL-12 regulation in reactive arthritis and, 1788
in Lyme arthritis, 69
MHC class II in SSc and, 540
in muscle tissue in inflammatory myopathy, 865
in RA, 62, 397
T cells, B cells, snRNP and, in mixed connective tissue disease,
1493
Th1/Th2 cytokine balance and, 2105
Interleukin-1 (IL-1)
adhesion molecules and, 991
adjuvant arthritis, inflammatory cachexia and, 534
anti-proteinase 3 antibodies in human umbilical vein endothelial
cells and, 2030
collagenase 1 gene and, 1772
endothelial activation in monosodium urate monohydrate crystal
inflammation and, 955
fibromyalgia and, 1928
IL-4, IL-10 and, in collagen arthritis, 249
nuclear factor [gk]B, cyclooxygenase 2 and, 226
in RA, 397, 595, 1096
receptor, 1050
receptor antagonist, 389, 865, 893, 1012, 1298, 1400, 1940, 1944,
2030, 2039, 2157
tenidap in OA and, 284
Interleukin-1α (IL-1α)
anti-proteinase 3 antibodies in human umbilical vein endothelial
cells and, 2030
biologic agents in RA and, 397
cartilage, 164, 1020
human IL-1 receptor antagonist in murine collagen arthritis and,
893
mononuclear phagocytes, rheumatoid synovitis and, 5
in muscle tissue in inflammatory myopathies, 865
nitric oxide, articular chondrocytes and, 261
oncostatin M, human synovial fibroblasts and, 2139
in SSc lung disease, 743
Interleukin-1β (IL-1β)
cartilage and, 704, 1050, 1653
C1, C2 core proteins and, in SSc and psoriatic arthritis, 2172
in giant cell arteritis, 19
JRA SF immune complexes and, 2039
in muscle tissue in inflammatory myopathy, 865
nuclear factor [gk]B, cyclooxygenase 2 and, 226
in RA, 5, 397, 639, 1292, 1298, 1400
recombinant human osteogenic protein 1, articular chondrocytes
and, 2157
spontaneous femoral neck fracture in multicentric
reticulohistiocytosis and, 2266
thrombosis in primary antiphospholipid syndrome and, 834
Interleukin-2 (IL-2)
adhesion molecules and, 991
apoptosis in autoimmune diseases and, 306
in giant cell arteritis, 19
in mixed connective tissue disease, 1493
in muscle tissue in inflammatory myopathy, 865
receptor, in RA, 80, 397, 598
silicone effects in collagen arthritis and, 1064
in SLE, 1130, 2162
T cells, tacrolimus and, in Behcet's disease, 1157
Interleukin-3 (IL-3), in muscle tissue in inflammatory myopathy,
865
Interleukin-4 (IL-4)
apoptosis in autoimmune diseases and, 306
in collagen arthritis, 249
dsDNA antibodies in SLE and, 2162
IL-10/IL-12 regulation in reactive arthritis and, 1788
in Lyme arthritis, 69
in muscle tissue in inflammatory myopathy, 865
in RA, 5, 397
in SSc lung disease, 743
T cells, B cells, snRNP and, in mixed connective tissue disease,
1493
Th1/Th2 cytokine balance and, 2105
Interleukin-6 (IL-6)
adhesion molecules and, 991
β2-glycoprotein I, endothelial cells and, 551
inflammation, treatment, bone loss and, in polymyalgia rheumatica,
2022
JRA SF immune complexes and, 2039
in muscle tissue in inflammatory myopathy, 865
oncostatin M, human synovial fibroblasts and, 2139
procalcitonin, infection and, in autoimmune diseases, 1250
in RA, 5, 80, 217, 397, 639, 1096, 2128
soluble oligonucleosomal complexes in SF and, 648
spontaneous femoral neck fracture in multicentric
reticulohistiocytosis and, 2266
in SSc lung disease, 743
T cells, B cells, snRNP and, in mixed connective tissue disease,
1493
testosterone, anti-DNA antibodies and, in SLE, 1703
Interleukin-8 (IL-8)
adhesion molecules and, 991
JRA SF immune complexes and, 2039
in muscle tissue in inflammatory myopathy, 865
oncostatin M, human synovial fibroblasts and, 2139
in RA, 5, 639, 1298, 1400, 2128
in SSc lung disease, 743
Interleukin-10 (IL-10)
adhesion molecules and, 991
in collagen arthritis, 249
in giant cell arteritis, 19
in Lyme arthritis, 69
in muscle tissue in inflammatory myopathy, 865
in RA, 5, 397, 598, 639
in reactive arthritis, 1788
in SLE, 1429
Th1/Th2 cytokine balance and, 2105
Interleukin-11 (IL-11) in RA, 1096
Interleukin-12 (IL-12)
in giant cell arteritis, 19
in reactive arthritis, 1788
Th1/Th2 cytokine balance and, 2105
Interleukin-13 (IL-13)
mononuclear phagocytes, rheumatoid synovitis and, 5
in muscle tissue in inflammatory myopathy, 865
Th1/Th2 cytokine balance and, 2105
Interleukin-15 (IL-15)
apoptosis in autoimmune diseases and, 306
T cells in RA and, 598
Interleukin-17 (IL-17), nitric oxide and, in OA cartilage, 1050
Intermediate filament antigens in chronic fatigue syndrome, 295
Intermittent porphyria, acute, presenting as acute muscle pain,
fever, and weakness, 586
International Uveitis Study Group, rheumatologic diagnosis and, 358
Interstitial collagenase, collagen degradation in cartilage and,
164
Interstitial fluid, C1q collagen-like region antibodies and, in
SLE, 1504
Interstitial mononuclear cells, renal CD40 and CD40 ligand in, 124
Interstitium, Fas in Sjogren's syndrome and, 87
Intestinal pseudo-obstruction, chronic, anti-proliferating cell
nuclear antigen and, 2279
Intraarticular antigen, Th1/Th2 cytokine balance and, 2105
Intraarticular gene transfer, TNFα receptor gene in collagen
arthritis and, 1662
Intracellular perforin, cytotoxicity in SLE and, 1130
Intracellular proteins, T cells, tacrolimus and, in Behcet's
disease, 1157
Intracellular status, mononuclear phagocytes, rheumatoid synovitis
and, 5
Intramuscular methylprednisolone, inflammation, bone loss and, in
polymyalgia rheumatica, 2022
Intraosseous fat embolism, pulse methylprednisolone, osteonecrosis
and, in rabbits, 2055
Intraosseous lipoma, 978
Intravenous cyclophosphamide, in catastrophic antiphospholipid
syndrome, 1534
Intravenous gamma globulin
anti-DNA Id human myeloma proteins and, 683
in catastrophic antiphospholipid syndrome, 1534
Intravenous immunoglobulin
acquired factor VIII inhibitor in SLE and, 775
myocardial infarction as a complication of treatment, 1732
in reproductive immunology, 209
Intravenous pulse cyclophosphamide
methylprednisolone and, in systemic JRA, 1852
oral contraceptives, SLE and, 797
Ionomycin, Fas ligand, RA synovial lymphocytes and, 1644
Isoforms
of nitric oxide synthase in Sjogren's syndrome and, 875
of thrombospondin 1 in rheumatoid synovium and, 1780
Isotypes
antiphospholipid antibodies and, in parvovirus B19 and SLE, 103
CD40 and CD40 ligand in autoimmune diseases and, 1735
IgG, dehydroepiandrosterone in collagen arthritis and, 907
IgM, reproductive immunology and, 209
J
Jaw claudication, cytokines in giant cell arteritis and, 19
JNK/AP-1 pathway in Fas-mediated apoptosis of RA synoviocytes, 919
Jo-1 in idiopathic inflammatory myopathy, 1257
Joints
apoptosis in the rheumatic diseases and, 1917
bacterial arthritis and, 884
CD40 and CD40 ligand in autoimmune diseases and, 1735
collagen and, 893, 1046, 1662
counts of, 1967
damage to, 791, 1210, 1262
destruction of, 341, 1106, 1852
diseases of, 5, 520, 884, 1420, 1636
effusions of, MRI in RA and OA and, 1856
gene transfer into articular cartilage and, 901
in Henoch-Schonlein purpura, 859
heterotopic ossification and, 1619
hip, spontaneous femoral neck fracture in multicentric
reticulohistiocytosis and, 2266
IL-10/IL-12 regulation in reactive arthritis and, 1788
inflammation of, 80, 510, 520, 598, 648, 955
in juvenile arthritis, 1202
knee, 217, 527, 966, 1012, 1020, 2260
laxity, proprioception in knee OA and, 1518, 2260
mycobacterial heat shock protein 65 in adjuvant arthritis and, 277
neuropathic, 2116
in OA, 284, 1760, 1766, 2260
oncostatin M, human synovial fibroblasts and, 2139
paclitaxel, synoviocytes, apoptosis and, 1073
pain in, self-care education in knee OA and, 1371, 1466
in RA, 80, 341, 598, 791, 1096, 1409, 1512, 1644
scores of, 397
space of, 723, 1914
swelling of, 5, 419, 527, 1843
T cell cytokines in Lyme arthritis and, 69
tenderness of, 419, 1843
tissue of, mononuclear phagocytes, rheumatoid synovitis and, 5
Ureaplasma urealyticum in destructive reactive
polyarthritis and, 2084
venereal diseases, arthritis and, 592
Juvenile arthritis, definition of improvement in, 1202
Juvenile Arthritis Functional Assessment Report, 1967
Juvenile DM, new-onset, 1526, 1556
Juvenile DM Disease Activity Collaborative Study Group, 1976
Juvenile fibromyalgia, primary, 752
Juvenile idiopathic inflammatory myopathy, disease activity and
damage indices for, 1976
Juvenile rheumatoid arthritis (JRA)
in affected sibpairs, 1962
bone mineral density in, 1967
cytokine induction by SF immune complexes in, 2039
disease activity and human growth hormone in, 332
high mobility group proteins in, 1803
MTX and, 175, 971, 2226
Mycoplasma infection in, 1219
new-onset juvenile DM and, 1526
oral type II collagen in, 392
psychosocial outcomes and health status of adults who had, 2235
registry for affected sib-pairs, 1556
systemic, intravenous pulse cyclophosphamide and
methylprednisolone in, 1852
Juvenile rheumatoid arthritis-like polyarthritis, chromosome
22q11.2 deletion syndrome and, 430
K
Kaiser Permanente Medical Care Program, hydroxychloroquine
retinopathy in, 1482
Kellgren-Lawrence scale, in knee OA, 723, 728, 1444, 1518, 2260
Keratinocytes
hepatitis C virus in type II cryoglobulinemia and, 2007
nitric oxide in SLE and, 1810
Ketoprofen in OA and RA, 1940, 1944
Kidney
congenital heart block, 52β and, 655
tissue, C1q, collagen-like antibodies and, in proliferative lupus
glomerulonephritis, 1504
Kinase
phosphate in plasma proteins in SLE and, 2178
protein tyrosine, in Fas-mediated apoptosis of RA synoviocytes,
919
Kinetics
P-31 MRS in polymyalgia and, 1817
RA and, 1005, 1210
Kinins, endogenous, in peptidoglycan arthritis, 1327
Knee
cartilage, bone and, 1020, 1282
chondrocytes and, 966, 1749
human IL-1 receptor antagonist in collagen arthritis in, 893
Medicare Part B and, 1594
OA, 590, 723, 728, 1012, 1050, 1371, 1444, 1466, 1518, 1670, 1760,
1856, 2260
in RA, 1400, 1856
tenidap in antigen-induced arthritis and, 2147
Ku
antigen, autoantibodies and, 1344
in idiopathic inflammatory myopathy, 1257
L
Labial salivary glands in Sjogren's syndrome, 865, 2271
lac Z gene, IL-1 receptor antagonist gene therapy in RA
and, 1012
Lacrimal glands, apoptosis in the rheumatic diseases and, 1917
Lambda light chain deposition disease presenting as sicca syndrome,
587
Large granular lymphocytes in RA, Felty's syndrome and, 624
l-arginine in Raynaud's phenomenon, 352
Lebanese studies, HLA-B27 in spondylarthropathy, 388
Lectins, adhesion molecules and, 991
Leg
fracture, fibromyalgia after spinal injury and, 446
lesions in vasculitis and multiple myeloma, 395
pain in longitudinal stress fracture of the tibia, 385
Leptomeningial biopsy, in chronic meningitis in Wegener's
granulomatosis, 573
Leptomeningial vasculitis, 1189
Lesions
angioimmunolymphoproliferative, 1189
autoantibodies to nucleolar RNA helicase protein in connective
tissue disease and, 1487
collagenase 3 in cartilage and, 1653
cutaneous, 859, 2007
focal, 1189
gastric, 318
inflammatory, Th1/Th2 balance and, 2105
lymphoepithelial, 987
mediastinal mass, hilar adenopathy and, in Wegener's
granulomatosis, 1992
in OA, 284, 1012, 1670
pulse methylprednisolone and osteonecrosis in rabbits and, 2055
in RA, 499, 598, 1106
rheumatic diseases and, 1054, 1917
in Sjogren's syndrome, 318, 987
in SLE, 36, 570
in SSc, 540
subchondral bone, 499
in vasculitis, 395, 1189
white matter, 36
Leukapheresis
granulocyte colony-stimulating factor in RA and, 1838
mononuclear phagocytes, rheumatoid synovitis and, 5
Leukemia, in RA, 624, 1580
Leukemia inhibitory factor
oncostatin M in human synovial fibroblasts and, 2139
in RA, 1096
Leukocyte function-associated antigen 3, adhesion molecules and,
991
Leukocytes
adhesion molecules and, 991
in ANCA-related vasculitis, 1680
CR1, CD35 in SF in inflammatory joint diseases and, 520
cytokines, oxicams and, 143
in JRA SF immune complexes, 2039
in OA, 1282, 1856
polymorphonuclear, 520
in RA, 598, 624, 1780, 1856
reproductive immunology and, 209
soluble oligonucleosomal complexes in SF and, 648
2-methoxyestradiol in collagen arthritis and, 154
Leukoencephalopathy in catastrophic antiphospholipid syndrome, 1534
Leukotriene inhibitors, in RA, 595
Leukotriene C4, human synovial mast cells and, 469
Lewis rats
adjuvant arthritis and inflammatory cachexia in, 534
endogenous kinins in peptidoglycan arthritis, 1327
gene transfer into articular cartilage and, 901
mycobacterial heat-shock protein 65 in adjuvant arthritis in, 277
Ligaments
cruciate, in OA, 284, 1012, 1046, 1756
posterior longitudinal, fractured ossification of, 2277
Ligands
adhesion molecules and, 991
CD40, in autoimmune diseases, 1735
Fas, 1054, 1126, 1644, 1749
in RA, 598, 1186
Light chain deposition disease presenting as sicca syndrome, 587
Limited scleroderma, palpable tendon friction rub in, 1146
Limited Wegener's granulomatosis in pregnancy, 1354
Linear scleroderma, childhood-onset and, 1183
Link protein, cartilage in OA and, 562, 1037
Lipoma, intraosseous, 978
Lipopolysaccharides
anti-proteinase 3 antibodies in human umbilical vein endothelial
cells and, 2030
bacterial, nitric oxide, articular chondrocytes and, 261
Lipoprotein
low-density, hepatitis C virus in type II cryoglobulinemia and,
2007
oral contraceptives, SLE and, 797
Liposomes
gene transfer into articular cartilage and, 901
mononuclear phagocytes, rheumatoid synovitis and, 5
Liver
cancer in SLE, 761
in catastrophic antiphospholipid syndrome, 1534
congenital heart block, 52β and, 655
disease in drug-induced lupus, 1334
MTX and, in JRA, 2226
NSAIDs and, 201
pulse methylprednisolone in osteonecrosis in rabbits and, 2055
in RA, 1096, 1721
Low-density lipoprotein, hepatitis C virus in type II
cryoglobulinemia and, 2007
Low-dose chlorambucil, Clostridium difficile diarrhea in
RA and, 2090
Low-dose corticosteroids, inflammation, bone and, in polymyalgia
rheumatica, 2022
Low-dose MTX
maternal, congenital anomalies and, 971
pancytopenia in RA and, 193
rheumatoid nodules and, in JRA, 175
Lower extremities, SLE, anabolic steroids and, 1899
Lower respiratory tract, cytokines in, in SSc lung disease, 743
lpr gene, rheumatic diseases in MRL/gld mice
and, 1054
L-selectin
adhesion molecules and, 991
oxicams, leukocytes and, 143
Lumbar spine, calcinosis of, in SSc, 1892
Lumican, proteoglycans, link protein and, in OA cartilage, 1037
Lung
cancer, 761, 779
congenital heart block, 52β and, 655
mediastinal mass, hilar adenopathy and, in Wegener's
granulomatosis, 1992
in SSc, 1229, 1237, 1984
Lupus
CD40 and CD40 ligand in, 1735
discoid, 2116
drug-induced, 1334, 1436
neonatal, 52-kd protein and immune response in, 936
protein C, thromboembolic disease, antiphospholipid antibodies
and, 1720
self antigens, epitopes and, 1374
Lupus anticoagulant
oral contraceptives, SLE and, 797
in reproductive immunology, 209
thrombosis in primary antiphospholipid syndrome and, 834
Lupus glomerulonephritis
C1q and collagen-like region antibodies in, 1504
renal CD40 and CD40 ligand in, 124
Lupus-like disease
apoptosis and, 1917
drug-induced lupus and, 1436
in mice, 1334
reproductive immunology and, 209
Lupus nephritis
MHC genes in SLE and, 1138
renal CD40 and CD40 ligand in, 124
Lyme arthritis, T cell cytokines in, 69
Lymph nodes
mediastinal mass, hilar adenopathy and, in Wegener's
granulomatosis, 1992
mononuclear phagocytes, rheumatoid synovitis and, 5
T cells in RA and, 598
Lymphadenopathy
hilar, in Wegener's granulomatosis, 1992
rheumatic diseases and, 1054, 1917
Lymphocyte function-associated antigen 1 in drug-induced lupus,
1436
Lymphocytes
adhesion molecules and, 991
anti-CD2 in SLE and, 822
apoptosis in the rheumatic diseases and, 1917
in autoimmune diseases, 306, 1735
cytokines, MHC class II and, in SSc, 540
drug-induced lupus and, 1334
Fas and, 87, 1644, 1912
in Felty's syndrome, 615, 624
large granular, 624
in OA, 1940, 1944
oxicams, leukocytes and, 143
peripheral blood, 615
in RA, 1005, 1940, 1944
2-methoxyestradiol in collagen arthritis and, 154
Lymphoepithelial lesions, cytokines in salivary gland in
Sjogren's syndrome and, 987
Lymphoid cells, rheumatic diseases in MRL/gld mice and,
1054
Lymphoid neoplasms, EBV, lymphoma and, in rheumatic diseases, 1152
Lymphoid organs, self antigens, epitopes and, 1374
Lymphoid tissue
adhesion molecules and, 991
T cells in RA and, 598
Lymphoma
Hodgkin's, CNS vasculitis and, 1189
non-Hodgkin's, 761, 1189, 1580
Lymphoproliferation
B cell, in Sjogren's syndrome, 318
soluble oligonucleosomal complexes in SF and, 648
Lymphoproliferative disorders
apoptosis and, 1917
CNS vasculitis and, 1189
EBV, lymphoma and, in rheumatic diseases, 1152
Lysine high mobility group proteins in JRA and, 1803
Lysis
chlamydial antigen in HLA-B27 transgenic mice and, 945
transglutaminase in articular chondrocytes and, 966
Lysosomes
in ANCA-related vasculitis, 1580
cathepsin L in RA and, 499
oxicams, leukocytes and, 143
Lysyl oxidase, collagen crosslinks in fibromyalgia and, 1450
M
Macrophage inflammatory protein 1α, in SSc lung disease, 743
Macrophage-like mononuclear cells, collagenase 3 in rheumatoid
synovium and, 1391
Macrophage-like synoviocytes, T cells in RA and, 598
Macrophages
CD40 and CD40 ligand, in autoimmune diseases, 1735
in RA, 5, 217, 490, 499, 595, 912, 1005, 1096
rheumatic diseases and, 1054, 1917
mad, apoptosis in autoimmune diseases and, 306
Magnesium, bone mineral density in JRA and, 1967
Magnetic resonance imaging (MRI)
in acute calcific tendinitis of the hip, 974
of brain in SLE, 36
in CNS vasculitis, 1189
of synovial membrane volumes in RA and OA, 1856
Magnetic resonance spectroscopy (MRS)
of brain in SLE, 36
P-31, in polymyalgia rheumatica, 1817
Major histocompatibility complex (MHC)
adhesion molecules and, 991
in AS, 1746, 1823, 2047
class I, 694, 945
class II, 540, 598
in RA, 397, 598, 1316
self antigens, epitopes and, 1374
T cell receptors in Felty's syndrome and, 615
TNFα in SLE in African-Americans and, 2207
Malar rash, transcriptional activator Sp1 and, 1085
Malignancy
hematologic, autologous stem cell transplantation in, 1712
mediastinal mass, hilar adenopathy and, in Wegener's
granulomatosis, 1992
RA and, 426, 1005, 1580
Malignant neoplasms
mortality in psoriatic arthritis and, 1868
in SLE, 761
Managed care
cost of RA and OA in, 1475
rheumatologists and, 610
Manometry, in esophageal dysfunction in scleroderma, 2252
Marrow, pulse methylprednisolone in osteonecrosis in rabbits and,
2055
Mast cells
human synovial, 469
in rheumatoid synovium, 479
Maternal antibodies, 52β, congenital heart block and, 655
Matrix
adhesion molecules and, 991
chondrocytes and, 270, 562, 1029
collagen, in arthropathy of fibroblastic rheumatism, 183
connective tissue, apoptosis in the rheumatic diseases and, 1917
in destructive joint diseases, 1420
extracellular, 1450, 2147
metalloproteinase, 164, 397, 704, 794, 842, 1391, 1653, 2065,
2128, 2139
in OA, 1037, 2075
proteoglycans, 1037
rheumatoid synovium and, 479, 1780
tenidap in antigen-induced arthritis and, 2147
max, apoptosis in autoimmune diseases and, 306
McGill Pain Questionnaire, 1940, 1944
Medial tibial plateau, cathepsin L in RA and, 499
Mediastinal mass in Wegener's granulomatosis, 1992
Medicaid, work disability in SLE and, 2199
Medicare
cost of RA and OA in managed care setting and, 1475
Part B, in rheumatology, 1594
Meloxicam, leukocyte adhesion and, 143
Membrane attack complex, CD59 in synovial tissue in rats and, 527
Membrane protein 1 gene, EBV, lymphoma and, in rheumatic diseases,
1152
Membrane type 1 matrix metalloproteinase in human articular
cartilage, 704
Membranous glomerulonephritis, SLE, anabolic steroids and, 1899
Memory lymphocytes, adhesion molecules and, 991
Meningitis, chronic, 573, 1189
Meniscal trauma, thrombospondin 1 in rheumatoid synovium and, 1780
Mental health status, risk and outcome in SLE and, 47
Mesangial cells, renal CD40, CD40 ligand and, 124
Mesenchymal cells, Th1/Th2 balance and, 2105
Messenger RNA
adhesion molecules and, 991
anti-proteinase 3 antibodies in human umbilical vein endothelial
cells and, 2030
apoptosis and, 306, 1917
cartilage and, 562, 704, 1037, 1455
chondrocytes and, 261, 1749
collagenase and, 1772, 2065
congenital heart block, 52β and, 655
cytokines and, 19, 69, 639
HTLV-I and, 578, 2118
IL-4, IL-10 and, in collagen arthritis, 249
in JRA SF immune complexes, 2039
nuclear factor [gk]B, cyclooxygenase 2 and, 226
in OA, 284, 1046
in RA, 80, 598, 639, 912, 1096, 1292, 1628, 2128
in SSc lung fibroblasts and collagen synthesis, 1237
tacrolimus and, in Behcet's disease, 1157
tenidap in antigen-induced arthritis and, 2147
Metabolism
cartilage, OA bone cells and, 1282
homocysteine, in RA, 718
proteoglycan, in mono-iodoacetate-induced experimental OA, 1670
Metalloprotease, tenidap in OA and, 284
Metalloproteinase
matrix, 164, 704, 794, 842, 1391, 1653, 2128, 2139
in OA, 2065
in RA, 397, 595, 2128
Methionine, homocysteine metabolism in RA and, 718
Methotrexate
AIMS2 short form and, 1267
antifolate effect of, 1545
human synovial mast cells and, 469
in JRA, 175, 1852, 2226
low-dose, 193, 971
lung injury, 1829
in RA, 5, 193, 194, 195, 391, 718, 791, 984, 1308, 1721, 1829,
1843
in Wegener's granulomatosis, 2099, 2187
Methylprednisolone
inflammation, bone and, in polymyalgia rheumatica, 2022
pulse, 1400, 1512, 2055
pulse cyclophosphamide and, 1852, 2099, 2187
MFG retrovirus, IL-1 receptor antagonist gene therapy in RA and,
1012
Microbial antigens, minocycline in RA and, 794, 842
Microorganisms, bacterial arthritis and, 884
Microscopic periarteritis, periarteritis nodosa and, 788
Microscopic polyangiitis, polyarteritis nodosa and, 1183
Minimal change disease, renal CD40, CD40 ligand and, 124
Minocycline
skin hyperpigmentation and, 1353
in RA, 419, 794, 842
Mitogens
anti-CD2 in SLE and, 822
chondrocytes, growth-arrest-specific gene 6, tyrosine kinase
receptor axl and, 1455
Th1/Th2 balance and, 2105
Mitotic arrest, paclitaxel and, 1073
Mixed connective tissue disease
apoptosis in, 306
soluble Fas and soluble Fas ligand in, 1126
T cells, B cells, snRNP and, 1493
Mobility in mono-iodoacetate-induced experimental OA, 1670
Modified Health Assessment Questionnaire, in RA, 419
Molecular analysis of MHC genes in SLE, 1138
Molecular diagnosis of Ureaplasma urealyticum in
destructive reactive polyarthritis, 2084
Molecular modeling, T cells, MHC and, in RA, 1316
Monarthritis, monosodium urate monohydrate crystal, endothelial
activation, inflammation and, 955
Monoclonal antibodies
adhesion molecules and, 991
anticardiolipin IgG subclasses and, 1998
anti-CD40, anti-CD40 ligand, renal CD40, CD40 ligand and, 124
anti-F(ab`)2 reactivity and, 109
antihistone, soluble oligonucleosomal complexes in SF and, 648
anti-TNFα, cell adhesion molecules and, 789
apoptosis in autoimmune diseases and, 306
chlamydial antigen in HLA-B27 transgenic mice and, 945
collagenase 3 in cartilage and, 1653
cytokines in muscle tissue in inflammatory myopathies and, 865
4F4, in SSc and psoriatic arthritis, 2172
Ku antigen and, 1344
in OA of the knee, C-reactive protein and, 723
oxicams, leukocytes and, 143
in RA, 237, 397, 598, 849, 1644
6D1, CD59 in synovial tissue in rats and, 527
in SLE, 822, 1130, 1810
Monocytes
in ANCA-related vasculitis, 1580
anticardiolipin IgG subclasses and, 1998
endothelial activation in monosodium urate monohydrate crystal
inflammation and, 955
fibroblast-monocyte interaction, cartilage degradation and, 490
oncostatin M in human synovial fibroblasts and, 2139
in RA, 5, 397, 598, 639, 1308
in SLE, 822, 1429, 1703
Th1/Th2 balance and, 2105
thrombosis in primary antiphospholipid syndrome and, 834
Mono-iodoacetate-induced experimental OA, 1670
Monokines
mononuclear phagocytes, rheumatoid synovitis and, 5
rheumatoid synovial tissue and, 217
Monomeric IgG, monomeric IgM, hepatitis C virus in type II
cryoglobulinemia and, 2007
Mononeuropathy, small fiber neuropathy and vasculitis, 1173
Mononuclear cells
adjuvant arthritis, inflammatory cachexia and, 534
cytokines and, 540, 865
endothelial activation in monosodium urate monohydrate crystal
inflammation and, 955
in idiopathic inflammatory myopathy, 1257
interstitial, renal CD40, CD40 ligand and, 124
IL-10/IL-12 in reactive arthritis and, 1788
in JRA SF immune complexes, 2039
peripheral blood, 306, 639, 822, 912, 1115, 1130, 1257, 2162
in RA, 80, 499, 639, 912, 1115
rheumatic diseases and, 1054, 1917
in SLE, 1130, 1703, 2162
spontaneous femoral neck fracture in multicentric
reticulohistiocytosis and, 2266
Mononuclear leukocytes, in MRI of synovial membrane volumes in RA
and OA, 1856
Mononuclear phagocytes, rheumatoid synovitis and, 5
Monosodium urate monohydrate crystal inflammation, endothelial
activation in, 955
Monozygotic twins
AS in, 1746, 1823
autologous hemopoietic stem cell transplantation, RA and, 1005
congenital complete heart block in, 381
Mood
drugs and, in OA and RA, 1940, 1944
fibromyalgia and, 1928
Morbidity
adverse reactions to antiinflammatory drugs in polymyalgia
rheumatica and, 1873
in Wegener's granulomatosis, 2099, 2187
Morning stiffness, in RA, 419
Morphogenetic protein 2, bone, cartilage proteoglycan synthesis
and, 1020
Morphology
in fibrosing alveolitis in SSc, 1229
in OA, 1670, 2075
uveitis as a diagnostic marker and, 358
Mortality
in bacterial arthritis, 884
in catastrophic antiphospholipid syndrome, 1534
in psoriatic arthritis, 1868
in RA, 426, 718, 984, 1829
in Wegener's granulomatosis, 1992, 2099, 2187
Mouse studies
See also BALB/c mice; CeH/HeJ-gld/gld mice;
DBA/1 mice; HLA-B*2705 transgenic CBA (H-2k) mice;
MRL/gld mice; (NZB X NZW)F1 mice
adhesion molecules, 991
apoptosis in the rheumatic diseases and, 1917
cartilage proteoglycan synthesis by bone morphogenetic protein 2,
1020
CD40 and CD40 ligand in autoimmune diseases, 1735
collagen arthritis, 249, 893, 1064, 1662
drug-induced lupus, 1334, 1436
52-kd protein in immune response, 936
Ku antigen, 1344
self antigens and epitopes, 1374
Th1/Th2 balance and, 2105
MRL/gld mice, rheumatic diseases in, 1054
Mucosal addressin cell adhesion molecule type I, 991
Multicentric reticulohistiocytosis
arthropathy of fibroblastic rheumatism and, 183
spontaneous femoral neck fracture in, 2266
Multiple myeloma, vasculitis and, 395
Multiple sclerosis
CD40 and CD40 ligand in, 1735
interferon β-1B, in RA, 1370
self antigens, epitopes and, 1374
Murine anti-ICAM-1 monoclonal antibody, in RA, 849
Murine lupus, self antigens, epitopes and, 1374
Muscle
accessory soleus, chronic calf pain and, 783
in inflammatory myopathy, 865, 1886
mycobacterial heat-shock protein 65 in adjuvant arthritis and, 277
pain, acute, in acute intermittent porphyria, 586
P-31 MRS in polymyalgia rheumatica and, 1817
pulse methylprednisolone in osteonecrosis in rabbits and, 2055
in SSc, 1984
tenderness, nociception in fibromyalgia and, 98
Musculoskeletal pain, diffuse, fibromyalgia and, 1928
Mutations
azathioprine-induced severe pancytopenia due to, in juvenile
HLA-B27 spondylarthritis, 1896
H-ras, in arthritic synovium, 1636
TAP2*Bky2 (Val577), in
Sjogren's syndrome, 1685
Mycobacterial heat-shock protein 60, B cells in RA and, 1409
Mycobacterial heat-shock protein 65
in adjuvant arthritis, 277
T cells in RA and, 510
Mycoplasma infection, RA and, 1219
Myelin
basic protein, CD40 and CD40 ligand in autoimmune diseases and,
1735
self antigens, epitopes and, 1374
Myelitis, transverse, SLE, anabolic steroids and, 1899
Myeloablation
autologous hemopoietic stem cell transplantation, RA and, 1005
high-dose, autologous stem cell transplantation for hematologic
malignancy and, 1712
Myelodysplastic syndromes, systemic vasculitis and, 179
Myeloid cells, cytokines and, in RA, 639
Myeloma
multiple, vasculitis and, 395
protein, anti-DNA Id human, intravenous gamma globulin and, 683
Myocardial infarction as a complication of immunoglobulin therapy,
1732
Myoepithelial epithelial cells, nitric oxide in, in Sjogren's
syndrome, 875
Myofibroblast-like cells in arthropathy of fibroblastic rheumatism,
183
Myopathic involvement in esophageal dysfunction in scleroderma,
2252
Myopathy, idiopathic inflammatory, 865, 1257, 1886, 1976
Myositis, racial factors in SSc and, 734
Myositis-like disorders, acute intermittent porphyria and, 586
N
N-acetylprocainamide in drug-induced lupus, 1436
Naked DNA, mycobacterial heat-shock protein 65 in adjuvant
arthritis and, 277
Nasal cartilage, collagen degradation and, 164
Native Ku antigen, autoantibodies and, 1344
Neck
cervical traction, breast implants and, 2097
in fibromyalgia, 446, 1553, 1560, 1571
Streptococcus pneumoniae infection in, in SLE, 1716
Necrosis
fibrinoid, in tenosynovial nodulosis in HTLV-I, 578
subcutaneous fat, 1732, 2116
Necrotizing pneumonitis, Wegener's granulomatosis in pregnancy and,
1354
Needle biopsy
of liver, MTX in JRA and, 2226
percutaneous, in inflammatory myopathy, 1886
Neonatal lupus
52-kd protein and immune response in, 936
research registry for, 1556
Neonatal lupus erythematosus, haplotypes in, 982
Neonatal neutropenia, alloimmune, reproductive immunology and, 209
Neoplasms
CNS vasculitis and, 1189
lymphoid, EBV, lymphoma and, in rheumatic diseases, 1152
malignant, 761, 1868
Neopterin, procalcitonin in autoimmune diseases and, 1250
Nephritis
anti-DNA Id, intravenous gamma globulin and, 683
lupus, 124, 1138
self antigens, epitopes and, 1374
Nephritogenic autoantibodies, CD40 and CD40 ligand in autoimmune
diseases and, 1735
Nephropathy, perinuclear ANCA in RA and, 710
Nephrotoxicity, cyclosporine in SLE and, 27
Nerve fibers
collagen crosslinks in fibromyalgia and, 1450
nitric oxide in, in Sjogren's syndrome, 875
Nerve injury, fibromyalgia and, 1928
Neural cell adhesion molecule type 1, 991
Neurologic involvement
in CNS vasculitis, 1189
oral contraceptives and, in SLE, 797
periosteal new bone formation in canine OA and, 1756
somatostatin in RA and, 2128
Neuromuscular blockade, heterotopic ossification and, 1619
Neuromuscular involvement, proprioception in knee OA and, 1518
Neurons, fibromyalgia and, 1928
Neuropathic involvement in esophageal dysfunction in scleroderma,
2252
Neuropathic joint, feet, 2116
Neuropathic OA, canine, periosteal new bone formation in, 1756
Neuropathy
cranial, chronic meningitis in Wegener's granulomatosis and, 573
small fiber, vasculitis and, 1173
Neuropeptides, somatostatin in RA, 2128
Neuropsychiatric SLE, cognitive function in, 1542
Neuroscience of fibromyalgia, 1928
Neurosensory involvement in fibromyalgia, 2275
Neutropenia, large granular lymphocytes in RA and, 624
Neutrophils
apoptosis in the rheumatic diseases and, 1917
autologous hemopoietic stem cell transplantation, RA and, 1005
oxicams, leukocytes and, 143
soluble oligonucleosomal complexes in SF and, 648
Newborn infants, Wegener's granulomatosis in pregnancy and, 1354
New-onset juvenile DM, 1526, 1533, 1556
NIH-3T3 cells
HOX4C gene on rheumatoid synovial fibroblasts and, 1628
human IL-1 receptor antagonist in murine collagen arthritis and,
893
Nimesulide, human synovial mast cells and, 469
97-kd Golgi complex autoantigen, in Sjogren's syndrome, 1693
Nitric oxide
l-arginine in Raynaud's phenomenon and, 352
chondrocytes and, 261, 1749
IL-17 and, in OA cartilage, 1050
in Sjogren's syndrome, 875
in SLE, 1810
as S-nitrosoproteins in RA, 1512
2-methoxyestradiol in collagen arthritis and, 154
Nociception in fibromyalgia, 98, 1928
Nodules
in arthritis and subcutaneous fat necrosis with pancreatitis, 2116
CD4 cells in RA and, 1106
cutaneous, in fibroblastic rheumatism, 183
rheumatoid, MTX and, in JRA, 175
rheumatoid-like, in carcinoma polyarthritis and vasculitis, 779
skin, spontaneous femoral neck fracture in multicentric
reticulohistiocytosis and, 2266
Nodulosis
adenosine A1, monocytes, MTX and, 1308
tenosynovial, in HTLV-I, 578
Non-Hodgkin's lymphoma
in RA, 1580
in SLE, 761
Non-rapid eye movement sleep, fibromyalgia and, 1928
Nonsteroidal antiinflammatory drugs (NSAIDs)
adverse reactions to, in polymyalgia rheumatica, 1873
hepatic injury and, 201
human synovial mast cells and, 469
intravenous pulse cyclophosphamide, methylprednisolone and, in
systemic JRA, 1852
in OA, 1940, 1944
oxicams and leukocyte adhesion, 143
pregnancy in relapsing polychondritis and, 1245
in RA, 595, 1580, 1940, 1944, 2248
N-terminal
adhesion molecules and, 991
telopeptide, in Paget's disease, 461
Nuclear antigens
anti-F(ab`)2 reactivity with, 109
anti-proliferating cells, in pneumatosis cystoides intestinalis,
2279
antisense treatment of RA synovial fibroblasts and, 1292
dsDNA in SLE and, 2162
transcriptional activator Sp1 and, 1085
Nuclear extracts, AP-1 in RA synovium and, 912
Nuclear factor, tacrolimus and, in Behcet's disease, 1157
Nuclear factor [gk]B
cyclooxygenase 2 and, 226
IL-17, nitric oxide and, in OA cartilage, 1050
Nuclear membrane protein in chronic fatigue syndrome, 295
Nuclear RNP C1 and C2 core protein, heterogeneous, in SSc and
psoriatic arthritis, 2172
Nucleolar RNA helicase protein, autoantibodies to, in connective
tissue disease, 1487
Nucleoside triphosphate pyrophosphohydrolase, aging, chondrocytes,
TGFβ and, 1275
Nucleosomal antigens, CD40 and CD40 ligand in autoimmune diseases
and, 1735
Nucleosomes
circulating plasma levels of, in SLE, 2217
self antigens, epitopes and, 1374
Nucleotides
azathioprine-induced pancytopenia in juvenile HLA-B27
spondylarthritis and, 1896
cytokines in giant cell arteritis and, 19
Fas in Sjogren's syndrome and, 87
Nurses, self-care education for knee OA and, 1371, 1466
Nurses' Health Study, oral contraceptives, SLE and, 804
Nutrition, risk and outcome in SLE and, 47
(NZB [times] NZW)F1 mice, oral contraceptives, SLE and, 797
O
Obesity, RA and, 1955
Obituaries
Bergman, Lester, 2097
Clark, William Stratton, 200
Oligomenorrhea, glucocorticoid-induced osteoporosis and, 1548
Oligonucleosomal complexes, soluble, in SF, 648
Oligonucleotides
antisense, RA synovial fibroblasts and, 1292
cytokines in giant cell arteritis and, 19
nuclear factor [gk]B, cyclooxygenase 2 and, 226
Oligopeptides, high mobility group proteins in JRA and, 1803
Omeprazole, oral, tenidap in OA and, 284
Oncogene point mutations, H-ras, in arthritic synovium,
1636
Oncostatin M
in cartilage metabolism, 589
in human synovial fibroblasts, 2139
IL-6-type cytokines in RA and, 1096
1,25-dihydroxyvitamin D, bone mineral density in JRA and, 1967
Oophorectomy in drug-induced lupus, 1334
Oophoritis, self antigens, epitopes and, 1374
Ophthalmology and ophthalmologists
hydroxychloroquine retinopathy and, 1482
uveitis as a diagnostic marker and, 358
Oral l-arginine in primary Raynaud's phenomenon, 352
Oral collagen in RA, 397
Oral contraceptives, SLE and, 797, 804
Oral cyclophosphamide in Wegener's granulomatosis, 2099, 2187
Oral hygiene in periodontal disease in RA, 2248
Oral omeprazole, tenidap in OA and, 284
Oral prednisolone, inflammation, bone and, in polymyalgia
rheumatica, 2022
Oral prednisone, cyclophosphamide in Wegener's granulomatosis and,
2099, 2187
Organ involvement
in RA, 1005, 1106
self antigens, epitopes and, 1374
in SLE, 47, 2199
in SSc, 1984
Orthovanadate in Fas-mediated apoptosis of RA synoviocytes, 919
Ossification
fractured, of the posterior longitudinal ligament, cervical cord
compression complicating, 2277
heterotopic, neuromuscular blockade and, 1619
Osteoarthritis (OA)
cartilage and, 490, 562, 704, 1029, 1037, 1050, 1282, 1760, 1766
chondrocytes and, 1275, 1749
collagenase 3 in, 1391, 1653
economics of, 1587
experimental, 1046, 1670
of the hand, 728
of the hip, ACR guidelines for management of, steroids and, 1914
H-ras mutations in arthritic synovium and, 1636
IL-1 receptor antagonist gene therapy in, 1012
of the knee, 590, 723, 728, 1371, 1444, 1466, 1518, 2260
lesions and tenidap in, 284
in managed care setting, 1475
Medicare Part B and, 1594
mast cells in, 479
NSAIDs in, 1940, 1944
oncostatin M in human synovial fibroblasts and, 2139
RA and, 627, 912, 1096, 1512, 1628, 1780
soluble Fas in, 80
soluble oligonucleosomal complexes in SF and, 648
spontaneous, in guinea pigs, 2075
unilateral, 1518
in vitro model of, 1420
Osteoblasts, pulse methylprednisolone in osteonecrosis in rabbits
and, 2055
Osteocalcin
in JRA, 332
in OA, bone cells, cartilage metabolism and, 1282
in Paget's disease, 461
Osteoclasts, spontaneous femoral neck fracture in multicentric
reticulohistiocytosis and, 2266
Osteogenesis, periosteal new bone formation in canine neuropathic
OA and, 1756
Osteogenic protein 1, recombinant human, in articular chondrocytes,
2157
Osteonecrosis of the hip, idiopathic transient, 1178
Osteopathy, aluminum-modified renal, 1724
Osteopenia, bone mineral density in JRA and, 1967
Osteophytes in OA, 284, 723
Osteoporosis
economics of, 1587
glucocorticoid-induced, 1547, 1548, 1549, 1550, 1551
oral contraceptives, SLE and, 797
supplement to clinical slide collection, 2116
vitamin D receptor in knee OA and, 1444
Outcome measures
in juvenile arthritis, 1202
in RA, 341, 419, 1843
in self-care education for knee OA, 1371, 1466
uveitis as a diagnostic marker and, 358
in work disability in SLE, 2199
Outcome studies
of autologous stem cell transplantation for hematologic
malignancy, 1712
of bacterial arthritis, 884
of fibromyalgia, 1553, 1560, 1571
of SLE and, 47, 2199
of total lymphoid irradiation in RA, 426
Outpatient studies
hydroxychloroquine retinopathy, 1482
large granular lymphocyte leukemia in RA and Felty's syndrome and,
624
Ovaries, reproductive immunology and, 209
Overlap syndromes, idiopathic inflammatory myopathy and, 1257
Oxicams, leukocyte adhesion and, 143
P
p50, nuclear factor [gk]B, cyclooxygenase 2 and, 226
p53, self antigens, epitopes and, 1374
p65, nuclear factor [gk]B, cyclooxygenase 2 and, 226
Pacemakers, in complete congenital heart block in monozygotic
twins, 381
Pachydermoperiostosis, 1361
Paclitaxel, synoviocyte apoptosis and, 1073
Paget's disease, evaluation of, 461
Pain
abdominal, 586, 859
in adults who had JRA, 2235
bone, after transplantation, 1361
chronic, 446, 752, 783, 1184
in familial Mediterranean fever, 1879
in fibromyalgia, 98, 446, 453, 752, 1450, 1553, 1560, 1571, 1928,
2275
hip, in an adolescent, 583
muscle, in acute intermittent porphyria, 586
in OA, 723, 1466, 1518, 1940, 1944
in RA, 217, 397, 419, 1843, 1912, 1940, 1944
in SSc, 1984
in vasculitis and multiple myeloma, 395
Palpable tendon friction rub in SSc, 1146
Pamidronate, collagenase 3 and, in rheumatoid synovium, 1391
Pancreatitis
alpha1-antitrypsin deficiency, arthritis and, 1732
subcutaneous fat necrosis with, 2116
Pancytopenia
azathioprine-induced, in juvenile HLA-B27 spondylarthritis, 1896
MTX in RA and, 193, 194, 195
Pannus
apoptosis and, 1073, 1917
collagenase 3 in human arthritic cartilage and, 1653
destructive joint disease and, 1420
spontaneous femoral neck fracture in multicentric
reticulohistiocytosis and, 2266
Pansinusitis, Wegener's granulomatosis in pregnancy and, 1354
Paralysis
heterotopic ossification, neuromuscular blockade and, 1619
lower extremity, in anabolic steroid use in SLE, 1899
Parenchymal cells
renal CD40, CD40 ligand and, 124
T cells in RA and, 598
Parenchymal lesions, lung, in mediastinal mass and hilar adenopathy
in Wegener's granulomatosis, 1992
Parent assessment in juvenile arthritis, 1202, 1976
Parvovirus B19 infection, antiphospholipid antibodies in, 103
Patellae, in mono-iodoacetate-induced experimental OA, 1670
Paternal leukocyte immunization, reproductive immunology and, 209
Pathobiology, B cell lymphoproliferation in Sjogren's
syndrome and, 318
Pathogenesis
anti-proteinase 3 antibodies in human umbilical vein endothelial
cells and, 2030
CD40 and CD40 ligand in autoimmune diseases and, 1735
chlamydial antigen in HLA-B27 transgenic mice and, 945
C1q collagen-like antibodies in, in proliferative lupus
glomerulonephritis, 1504
cytokines in JRA SF immune complexes and, 2039
dsDNA antibody in SLE and, 2162
of fibromyalgia, 1450, 1928
hepatitis C virus and, in type II cryoglobulinemia, 2007
kinins and, in peptidoglycan arthritis, 1327
of RA, 5, 237, 397, 595, 598, 912, 1391, 1628
reproductive immunology and, 209
self antigens, epitopes and, 1374
soluble Fas and soluble Fas ligand in rheumatic diseases and, 1126
of SSc lung disease, 743, 1237
Th1/Th2 cytokine balance and, 2105
thrombosis in primary antiphospholipid syndrome and, 834
of vasculitis, 1189, 1680
Pathogenetics
AS and, 1746, 1823
biologic agents in RA and, 397
catastrophic antiphospholipid syndrome and, 1534
soluble oligonucleosomal complexes in SF and, 648
Pathogens, Ureaplasma urealyticum in destructive
reactive polyarthritis and, 2084
Pathology
adhesion molecules and, 991
B cell proliferation in Sjogren's syndrome and, 318
of CNS vasculitis, 1189
of destructive joint disease, 1420
esophageal dysfunction in scleroderma and, 2252
gene transfer into articular cartilage and, 901
percutaneous needle muscle biopsy in inflammatory myopathy and,
1886
of RA, 479, 1005, 1856, 2128
reproductive immunology and, 209
silicone effects in collagen arthritis and, 1064
Pathophysiology
adjuvant arthritis, inflammatory cachexia and, 534
of CNS vasculitis, 1189
cytokines in SSc lung disease and, 743
of fibromyalgia, 1928
human synovial mast cells and, 469
kinins in peptidoglycan arthritis and, 1327
in RA, 595
soluble oligonucleosomal complexes in SF and, 648
tenidap in OA and, 284
Patient assessment
global, 419, 1843, 1940, 1944, 1976
in juvenile arthritis, 1202
Patient education
in chronic arthritis, 1371, 1466
risk and outcome in SLE and, 47
Pauciarticular JRA
in affected sibpairs, 1962
high mobility group proteins in, 1803
outcome in adults who had, 2235
Paulus criteria
in juvenile arthritis, 1202
in RA, 419
Pediatric rheumatology
specialty training for, 2273
as a subspecialty, 1182
Penicillamine
in arthropathy of fibroblastic rheumatism, 183
collagenase 3 and, in rheumatoid synovium, 1391
in SSc, 1984
Penicillin in Behcet's disease, 1728
Peptides
bacterial, chlamydial antigen in HLA-B27 transgenic mice and, 945
CD40 and CD40 ligand in autoimmune diseases and, 1735
high mobility group proteins in JRA and, 1803
HLA-B27, in AS, 2047
IgG antibodies in SLE and, 1364
in RA, 397, 595, 598, 627, 1115, 1210, 1316
self antigens, epitopes and, 1374
Peptidoglycan arthritis, kinins in, 1327
Percutaneous needle muscle biopsy in inflammatory myopathy, 1886
Perforin, cytolytic activity in SLE and, 1130
Periarteritis nodosa, microscopic periarteritis and, 788
Pericarditis, racial factors in SSc and, 734
Perimysium, cytokines in muscle tissue in inflammatory myopathy
and, 865
Perinuclear ANCA in RA, 710
Periodontal disease in RA, 2248
Periosteal new bone formation in canine neuropathic OA, 1756
Peripheral blood
apoptosis in the rheumatic diseases and, 1917
cytokines in JRA SF immune complexes and, 2039
HLA-B27 autoantigens in AS and, 2047
lymphocytes, 578, 615, 927, 991
mononuclear cells, 306, 540, 639, 822, 912, 1130, 1257, 1703, 2162
in RA, 5, 510, 598, 624, 639, 912, 1005, 1115, 1210, 1400, 1838
Peripheral edema in anabolic steroid use in SLE, 1899
Peripheral tissue in fibromyalgia, 1928
Peritoneal macrophages
mononuclear phagocytes, rheumatoid synovitis and, 5
rheumatic diseases in MRL/gld mice and, 1054
Perivascular edema, synovial membrane volume in RA and OA and, 1856
Pernicious anemia in new-onset juvenile DM, 1526
Phagocytes, mononuclear, rheumatoid synovitis and, 5
Phagocytosis, apoptosis in the rheumatic diseases and, 1917
Phagosomes, cathepsin L in RA and, 499
Pharmacology
human synovial mast cells and, 469
S-nitrosoproteins in RA and, 1512
Pharynx, Streptococcus pneumoniae infection of soft
tissue in SLE and, 1716
Phenotypes
cytokine, MHC class II and, in SSc, 540
fibromyalgia and, 1928
nitric oxide, articular chondrocytes and, 261
in RA, 1005, 1106
T cells, B cells, U snRNP and, in SLE and mixed connective tissue
disease, 1493
Phorbol ester, Fas ligand in RA and, 1644
Phorbol myristate acetate
apoptosis in autoimmune diseases and, 306
oxicams, leukocytes and, 143
Phosphatase, alkaline, 461, 1275, 1619
Phosphate in SLE, 2178
Phospholipid antigens, reproductive immunology and, 209
Phospholipid-protein complexes in catastrophic antiphospholipid
syndrome, 1534
Phospholipids, antiphospholipid antibodies in parvovirus B19
infection and SLE, 103
Phosphorylation
chondrocytes, growth-arrest-specific gene 6, tyrosine kinase
receptor axl and, 1455
collagenase 1 gene in synoviocytes and, 1772
extracellular, phosphate in plasma proteins in SLE and, 2178
protein tyrosine, in Fas-mediated apoptosis of RA synoviocytes,
919
Photosensitivity, transcriptional activator Sp1 and, 1085
Phthalazine, drug-induced lupus and, 1436
Physical abuse, fibromyalgia and, 453
Physical activity, knee OA in the elderly and, 728
Physical stress, fibromyalgia and, 1928
Physician assessment, global, 419, 1202, 1843, 1940, 1944, 1976
Physician visits, in fibromyalgia, 453
Physiology
apoptosis in the rheumatic diseases and, 1917
cartilage matrix protein synthesis and, 1029
fibrosing alveolitis in SSc and, 1229
somatostatin in RA and, 2128
spontaneous OA in guinea pigs and, 2075
Phytohemagglutinin
anti-CD2 in SLE and, 822
apoptosis in autoimmune diseases and, 306
Pig studies
cartilage matrix protein synthesis, 1029
transglutaminase in articular chondrocytes, 966
Piroxicam
human synovial mast cells and, 469
leukocyte adhesion and, 143
in RA and OA, 1940, 1944
Pitting edema, distal extremity swelling with, in polymyalgia
rheumatica, 1551
PL-12, in idiopathic inflammatory myopathy, 1257
Placenta, reproductive immunology and, 209
Plasma
cells, apoptosis in the rheumatic diseases and, 1917
elastase, in ANCA-related vasculitis, 1680
NSAIDs in RA and OA and, 1940, 1944
in SLE, 2178, 2217
thrombosis in primary antiphospholipid syndrome and, 834
Plasma exchange in pregnancy in relapsing polychondritis, 1245
Plasmapheresis in catastrophic antiphospholipid syndrome, 1534
Platelets
anticardiolipin IgG subclasses and, 1998
apoptosis in the rheumatic diseases and, 1917
autologous hemopoietic stem cell transplantation, RA and, 1005
catastrophic antiphospholipid syndrome and, 1534
in SLE, 27, 2178
Pleural effusions, racial factors in SSc and, 734
PM-Scl, in idiopathic inflammatory myopathy, 1257
Pneumatosis cystoides intestinalis, anti-proliferating cell nuclear
antigen and, 2279
Pneumococcal infection, in SLE, 1180, 1716
Pneumocystis carinii pneumonia in Wegener's
granulomatosis, 2099, 2187
Pneumonitis, necrotizing, Wegener's granulomatosis in pregnancy
and, 1354
POEMS syndrome, growth factors in, 786
Poisoning, in mortality in psoriatic arthritis, 1868
pol genes, endogenous synovial retroviruses in RA and,
627
Polish studies, idiopathic inflammatory myopathy and, 1257
Polyangiitis, microscopic, polyarteritis nodosa and, 1183
Polyarteritis nodosa
apoptosis in, 306
microscopic polyangiitis and, 1183
Polyarthritis
alpha1-antitrypsin deficiency arthritis, pancreatitis
and, 1732
carcinoma, vasculitis and, 779
destructive reactive, Ureaplasma urealyticum in, 2084
in fibroblastic rheumatism, 183
HLA-DRB1 genotype in early RA and, 2241
JRA-like, chromosome 22q11.2 deletion syndrome and, 430
tenosynovial nodulosis in HTLV-I and, 578
Polyarticular JRA
in affected sibpairs, 1962
high mobility group proteins in, 1803
MTX, rheumatoid nodules and, in systemic JRA, 175
outcome in adults who had, 2235
polyarthritis in chromosome 22q11.2 deletion syndrome and, 430
Polyclonal antibodies, β2-glycoprotein I, endothelial
cells and, 551
Polydimethylsiloxane silicone oil, collagen arthritis and, 1064
Polymerase chain reaction
to detect Mycoplasma infection in RA, 1219
in molecular diagnosis of Ureaplasma urealyticum in
destructive reactive polyarthritis, 2084
Polymorphisms
anticardiolipin IgG subclasses and, 1998
in RA, 854, 1316, 1368, 1387
in SLE, 389, 1180, 2207
TAP2 gene in Sjogren's syndrome and, 1685
Polymorphonuclear cells
adhesion molecules and, 991
endothelial activation in monosodium urate monohydrate crystal
inflammation and, 955
Polymorphonuclear leukocytes
CR1, CD35 in SF in inflammatory joint diseases and, 520
synovial membrane volume in RA and OA and, 1856
Polymyalgia rheumatica
antiinflammatory drugs in, 1873
arteritis temporalis, erythrocyte sedimentation rate and, 191
cytokines in giant cell arteritis and, 19
definition of, 191
distal extremity swelling with pitting edema in, 1551
erythrocyte sedimentation rate in, 1725, 1726
inflammation and bone loss in, 2022
P-31 MRS in, 1817
Polymyositis (PM)
cytokines in muscle tissue in, 865
idiopathic inflammatory myopathy and, 1257
soluble Fas and soluble Fas ligand in, 1126
Polyneuropathy, sensorimotor, small fiber neuropathy, vasculitis
and, 1173
Polypeptides
biologic agents in RA and, 397
52-kd protein, immune response and, 936
lamina-associated, in chronic fatigue syndrome, 295
Sm snRNP and, in SLE, 672
Polysaccharides, kinins in peptidoglycan arthritis and, 1327
Porphyria, acute intermittent, acute muscle pain, fever, weakness
and, 586
Positron emission tomography in CNS vasculitis, 1189
Potassium, adjuvant arthritis, inflammatory cachexia and, 534
Prednisolone, oral, in inflammation and bone loss in polymyalgia
rheumatica, 2022
Prednisone
antiinflammatory drugs in polymyalgia rheumatica and, 1873
in arthropathy of fibroblastic rheumatism, 183
intravenous pulse cyclophosphamide, methylprednisolone and, in
JRA, 1852
oral, in Wegener's granulomatosis, 2099, 2187
in reproductive immunology, 209
Preeclampsia
eclampsia, catastrophic antiphospholipid syndrome and, 1534
reproductive immunology and, 209
Pregnancy
biologic agents in RA and, 397
JRA and, 971, 2235
loss, reproductive immunology and, 209
oral contraceptives, SLE and, 797
in relapsing polychondritis, 1245
Wegener's granulomatosis in, 1354
Premenopausal women, glucocorticoid-induced osteoporosis and, 1548
Pre-messenger RNA
cathepsin B, in rheumatoid synovial tissue, 1540
HLA-B27, bacteria and, 694
Prepubertal children with JRA, bone mineral density in, 1967
Primary angiitis of the CNS, 1189
Primary antiphospholipid syndrome
catastrophic antiphospholipid syndrome and, 1534
thrombosis in, 834
Primary juvenile fibromyalgia, 752
Primary Raynaud's phenomenon, l-arginine and cutaneous
vascular response in, 352
Primary Sjogren's syndrome
Fas in, 87, 1912
TAP2 gene in, 1685
Proα1(I) collagen mRNA, scleroderma lung fibroblasts, collagen
synthesis and, 1237
Procalcitonin, in autoimmune diseases, 1250
Procainamide, drug-induced lupus and, 1334, 1436
Procollagen
collagen in experimental OA and, 1046
type I, 461, 2022
Procollagenase, collagen degradation in cartilage and, 164
Progestagens, oral contraceptives, SLE and, 797
Proinflammatory cytokines
in JRA SF immune complexes, 2039
somatostatin in RA and, 2128
Th1/Th2 cytokine balance in, 2105
Prolactin, DRB and, in RA and SLE, 1383
Proliferating cell nuclear antigen mRNA, antisense treatment of
rheumatoid fibroblasts and, 1292
Proliferative lupus glomerulonephritis, C1q collagen-like
antibodies in, 1504
Promonocytic U937 cells, cytokines in JRA SF immune complexes and,
2039
Proprioception, knee joint, in OA, 1518, 2260
Prostaglandin D2, human synovial mast cells and, 469
Prostaglandin E2
pulse methylprednisolone and, in RA, 1400
recombinant human osteogenic protein 1, articular chondrocytes
and, 2157
Prostaglandins, NSAID and, 1940, 1944
Prosthetic surgery, bacterial arthritis and, 884
Protease, apoptosis in the rheumatic diseases and, 1917
Protein
acute-phase, 1096, 1327, 1940, 1944
adhesion molecules and, 991
anti-DNA Id human myeloma, intravenous gamma globulin and, 683
anti-proteinase 3 antibodies in human umbilical vein endothelial
cells and, 2030
apoptosis in autoimmune diseases and, 306
C, thromboembolic disease, antiphospholipid antibodies and, in
lupus, 1720
cartilage and, 1029
CD40 and CD40 ligand in autoimmune diseases and, 1735
chondrocytes and, 270, 562, 966, 1275, 1455, 2157
in collagen arthritis, 893, 1064, 1662
collagenase 1 gene and, 1772
complement regulatory, CD59, in synovial tissue in rats, 527
C-reactive, 723, 1680, 1940, 1944
eukaryotic ribosomal L7, 661
52-kd, in Ro/La immune response, 936
52β, congenital heart block and, 655
heat-shock, 277, 510, 1409
HLA-B27, bacteria and, 694
hnRNP C1 and C2 core, in SSc and psoriatic arthritis, 2172
in idiopathic inflammatory myopathy, 1257
in JRA, 332, 1803, 1967
kinase, 2178
link, 562, 1037
matrix, tenidap in antigen-induced arthritis and, 2147
monocyte chemoattractant 1, oncostatin M, human synovial
fibroblasts and, 2139
nuclear factor [gk]B, cyclooxygenase 2 and, 226
nuclear membrane, in chronic fatigue syndrome, 295
in OA, 562, 723, 1037
plasma, phosphate in, in SLE, 2178
plasma elastase in ANCA-related vasculitis and, 1680
in RA, 397, 510, 598, 919, 1096, 1219, 1292, 1512
recombinant fusion, in SLE, 1364, 1493
recombinant human osteogenic 1, 2157
in the rheumatic diseases, 1152, 1917
self antigens, epitopes and, 1374
Sm snRNP, in SLE, 672
T cells and, 69, 1157
tax, ribozyme-based gene cleavage, HTLV-I and, 2118
transcription activator Sp1 and, 1085
Proteinase
cathepsin L in RA and, 499
collagen degradation in cartilage and, 164
plasma elastase in ANCA-related vasculitis and, 1680
serine, in rheumatoid synovium, 1780
Proteinase 3-ANCA (PR3-ANCA), antiidiotype antibody and, 135
Proteinuria, cyclosporine in SLE and, 27
Proteoglycans
cartilage and, 164, 1037, 1670
OA and, 1046, 2075
recombinant human osteogenic protein 1, articular chondrocytes
and, 2157
synthesis of, 893, 1020
Proteolipid protein, CD40 and CD40 ligand in autoimmune diseases
and, 1735
Protons, P-31 MRS in polymyalgia rheumatica and, 1817
Proto-oncogenes, H-ras mutations, in arthritic synovium,
1636
Protozoa, in CNS vasculitis, 1189
Proximal tibia, periosteal new bone formation in canine neuropathic
OA and, 1756
Proximal tubules, renal CD40, CD40 ligand and, 124
P-selectin, adhesion molecules and, 991
Pseudovasculitis, scurvy and, 589
Psoriasis, autologous stem cell transplantation, hematologic
malignancy and, 1712
Psoriatic arthritis
hnRNP C1 and C2 core protein in, 2172
mortality in, 1868
Psychological factors
in fibromyalgia, 752, 1553, 1560, 1571
NSAID and, in RA and OA, 1940, 1944
Psychological stress, in fibromyalgia, 1928
Psychosocial factors, risk, outcome and, in SLE, 47
Psychosocial outcomes, in adults who had JRA, 2235
P-31 MRS, in polymyalgia rheumatica, 1817
Puberty, oral contraceptives, SLE and, 797
Pulmonary fibrosis, cytokines in SSc and, 743
Pulmonary hypertension, fibrosing alveolitis in SSc and, 1229
Pulse cyclophosphamide
intravenous, 797, 1852
and Wegener's granulomatosis, 2099, 2187
Pulse methylprednisolone
and osteonecrosis in rabbits, 2055
and RA, 1400, 1512
Pyridinoline
collagen crosslinks in fibromyalgia and, 1450
in inflammation and bone loss in polymyalgia rheumatica, 2022
in Paget's disease, 461
Pyrrolidine dithiocarbamate, IL-17, nitric oxide and, in OA
cartilage, 1050
Pyrophosphate, chondrocytes and, 966, 1275
Q
QKRAA, in RA, 341, 598
QRRAA, in RA, 341
Quality of life, fibromyalgia after spinal injury and, 446
Quality of Well-Being scale, in self-care education for knee OA,
1466
Questionnaires
in fibromyalgia, 1553, 1560, 1571
Health Assessment, 419, 1843, 1984, 2235
Health Status, 2235
McGill Pain, 1940, 1944
Quality of Well-Being, 1466
self-assessment, 752, 1955, 1984
R
Rabbit studies
anti-F(ab`)2 reactivity with nuclear antigens, 109
97-kd Golgi complex autoantigen in Sjogren's syndrome and,
1693
tenidap in antigen-induced arthritis, 2147
Racial factors
in SLE, 47, 804, 2199, 2207
in SSc, 441, 734
Radiography
in acute calcific tendinitis of the hip, 974
in AS in twins, 1746, 1823
chest, breast implants in connective tissue disease and, 437
in OA, 723, 728, 1444, 1518, 1756, 1760, 2260
in RA, 5, 341, 1829, 2241, 2248
in SSc, 1229, 2252
in Wegener's granulomatosis, 1992
Radiologic Vignette
accessory soleus muscle and chronic calf pain, 783
amyloid arthropathy, 1903
bone pain after transplantation, 1361
hip pain in an adolescent, 583
idiopathic transient osteoporosis of the hip, 1178
intraosseous lipoma, 978
longitudinal stress fracture of the tibia, 385
Range of motion
in juvenile arthritis, 1202
proprioception in knee OA and, 1518, 2260
RANTES, in SSc lung disease, 743
Rapamycin, human synovial mast cells and, 469
Rash, malar, transcriptional activator Sp1 and, 1085
Rat studies; See also Lewis rats
adhesion molecules, 991
CD59 in synovial tissue, 527
of fibromyalgia, 1928
mono-iodoacetate-induced experimental OA, 1670
mononuclear phagocytes in rheumatoid synovitis, 5
mycobacterial heat-shock protein 65 in adjuvant arthritis, 277
TNFα receptor gene in collagen arthritis, 1662
Raynaud's phenomenon
Health Assessment Questionnaire in SSc and, 1984
primary, l-arginine and cutaneous vascular response
in, 352
transcriptional activator Sp1 in, 1085
Reactive arthritis
chlamydial antigen in HLA-B27 transgenic mice and, 945
IL-10/IL-12 in, 1788
septic arthritis and, 592
Reactive polyarthritis, Ureaplasma urealyticum in, 2084
Recombinant erythropoietin, human, autoantibodies to, in SLE, 2212
Recombinant free human Ku, autoantibodies and, 1344
Recombinant fusion protein, in SLE, 1364, 1493
Recombinant growth-arrest-specific gene 6, chondrocytes and, 1455
Recombinant high mobility group 2 protein, in JRA, 1803
Recombinant human growth hormone, in JRA, 332
Recombinant human osteogenic protein 1, articular chondrocytes and,
2157
Recombinant human SS-A/Ro-SS-B/La protein, immune response and, 936
Recombinant human vimentin, in chronic fatigue syndrome, 295
Recombinant IFNγ, in RA, 62
Recombinant IL-1α, collagen and, 164, 893
Recombinant IL-4, in collagen arthritis, 249
Recombinant IL-10, in collagen arthritis, 249
Recombinant matrix metalloproteinase 13, in rheumatoid synovium,
1391
Refractory RA, biologic agents in, 397
Relapsing polychondritis, pregnancy in, 1245
Renal disease
drug-induced lupus and, 1334
in RA, ANCA in, 710
in SSc, 1984
Renal function, in hydroxychloroquine retinopathy, 1482
Renal glomeruli, C1q collagen-like antibodies in, in proliferative
lupus glomerulonephritis, 1504
Renal involvement
CD40, CD40 ligand and, 124
in Henoch-Schonlein purpura, 859
procalcitonin, infection and, in autoimmune diseases, 1250
in SLE, oral contraceptives and, 797
in SSc, 734, 1146
Renal osteopathy, aluminum-modified, 1724
Reproductive immunology, clinical rheumatology and, 209, 1910
Reproductive variables, RA and, 1955
Respiratory distress syndrome, adult, heterotopic ossification,
neuromuscular blockade and, 1619
Respiratory tract
lower, cytokines in SSc lung disease and, 743
in psoriatic arthritis, 1868
upper, infection, in Henoch-Schonlein purpura, 859
Reticulohistiocytosis, multicentric, spontaneous femoral neck
fracture in, 2266
Retinoic acid, cartilage collagenase and, 1065
Retinopathy, hydroxychloroquine, 1482
Retroviruses
endogenous synovial, in RA, 627
MFG, IL-1 receptor antagonist gene therapy in OA and, 1012
retrovirus-5 proviral DNA in Sjogren's syndrome, 2016
Revascularization, osteonecrosis in rabbits and, 2055
Rheumatic diseases
adhesion molecules and, 991
anti-p53 in, 980
apoptosis in, 1917
CR1, CD35 in SF in, 520
EBV and lymphoma in, 1152
eukaryotic ribosomal protein L7 in, 661
fibromyalgia and, 1553, 1560, 1571
guidelines for, 2
Medicare Part B claims in, 1594
in MRL/gld mice, 1054
standards of care for, 410, 413
systemic, hnRNP C1 and C2 core protein in, 2172
Rheumatism, fibroblastic, arthropathy of, 183
Rheumatoid arthritis
adhesion molecules and, 991
adjuvant arthritis, inflammatory cachexia and, 534
AIMS2 short form in, 1267
antinuclear antibodies in, 1601
apoptosis in, 306, 1073, 1917
autologous stem cell transplantation and, 1005, 1712
B cells in, 1409
biologic agents in, 397
blood transfusions and, 1955
cartilage in, 490, 1029
cathepsin L in, 499
CD4 cells in, 1106, 1186
CD8 cells in, 237
CD40 and CD40 ligand in, 1735
CD57 cells in, 237
CD70 in, 1186
chemotherapy in, 426
chronic, 499
collagenase 3 in, 1391, 1653
cost of, in managed care setting, 1475
CR1, CD35 in SF in, 520
cyclosporine in, 1721, 1843
cytokines in, 639, 1096
dehydroepiandrosterone in collagen arthritis and, 907
destructive joint disease and, 1420
drugs in, 391
early, 217, 791, 794, 842, 2241
EBV and lymphoma in, 1152
economics of, 1587
endogenous synovial retroviruses in, 627
eukaryotic ribosomal protein L7 in, 661
Fas ligand in, 1644
Fas-mediated apoptosis of synoviocytes in, 919
granulocyte colony-stimulating factor in, 1838
HLA-B27 autoantigens in AS and, 2047
HLA-DMA and DMB polymorphism in, 854
homocysteine metabolism in, 718
HOX4C gene on rheumatoid synovial fibroblasts and, 1628
human cartilage glycoprotein-39 in, 1115
interferon-β-1B in, 1370
IFNγ in, 62
large granular lymphocytes in, Felty's syndrome and, 624
macrophages/monocyte cell line in, 490
malignancy in, 1580
mast cells in, 479
Medicare Part B claims in, 1594
minocycline in, 419, 794, 842
mononuclear phagocytes and rheumatoid synovitis in, 5
MTX and, 193, 194, 195, 391, 984, 1308, 1721, 1829, 1843
murine anti-ICAM-1 monoclonal antibody in, 849
mycobacterial heat-shock protein 65 in, 510
Mycoplasma infection and, 1219
new-onset juvenile DM and, 1526
NSAID in, 1940, 1944
nuclear factor [gk]B and cyclooxygenase 2 in, 226
obesity and, 1955
outcome measures in, 419
paclitaxel in, 1073
pain in, 1912
pancytopenia in, 193, 194, 195
pathophysiology and treatment of, 5, 397, 595, 598
perinuclear ANCA in, 710
prolactin and DRB in, 1383
pulse methylprednisolone and, 1400
refractory, 397
ribozyme-based gene cleavage, HTLV-I and, 2118
seropositive, 794, 842
smoking and, 594, 1955
soluble Fas in, 80, 1126
soluble Fas ligand in, 1126
synovial fibroblasts in, 490, 1292, 2139
synovial membrane volume in, 1856
synovial tissue in, 217
T cell receptors in, 1387, 1798
T cells in, 510, 595, 598, 1210, 1316
tenidap in antigen-induced arthritis and, 2147
Th1/Th2 cytokine balance in, 2105
thrombospondin 1 in, 1780
TNF in, 1368
total lymphoid irradiation in, 426
transcription factor AP-1 in synovium in, 912
tuberculosis cutis colliquativa and immunosuppressive drugs in,
188
Rheumatoid factor
MTX, rheumatoid nodules and, in JRA, 175
NSAID and, 1940, 1944
in RA, 594, 794, 842, 1005, 1387
Rheumatoid-like nodules, in carcinoma polyarthritis and vasculitis,
779
Rheumatoid nodules, MTX and, in JRA, 175
Rheumatoid synovial fibroblasts
antisense treatment of, 1292
cartilage and, 1298
HOX4C gene on, 1628
Rheumatoid synovial membrane, mononuclear phagocytes, rheumatoid
synovitis and, 5
Rheumatoid synovial tissue
analysis of, 217
cathepsin B pre-messenger RNA in, 1540
Rheumatoid synoviocytes, nuclear factor [gk]B, cyclooxygenase 2 and,
226
Rheumatoid synovitis, in RA, 595, 648
Rheumatoid synovium
collagenase 3 in, 1391
mast cells in, 479
in RA, 5, 595
tenosynovial nodulosis in HTLV-I and, 578
thrombospondin 1 in, 1780
transcription factor AP-1 in, 912
Rheumatology and rheumatologists
challenges and opportunities for, 610
economic evaluation in, 1587
guidelines for rheumatic diseases and, 2, 1909
Medicare Part B claims and, 1594
pediatric rheumatology, 1182, 1202
proposed recertification requirements, 1733
references in rheumatology journals, 199
reproductive immunology and, 209
standards of care and, 410, 413
Rheumatology education
challenges and opportunities for, 610
specialty training for pediatric rheumatology, 2273
Ribosomal protein L7, eukaryotic, 661
Ribozyme-based gene cleavage, HTLV-I and, 2118
Ricin A chain, in RA, 397
Rickettsiae, in CNS vasculitis, 1189
RNA
growth factors, chondrocytes and, 270
helicase protein, autoantibodies to, in connective tissue disease,
1487
messenger, 19, 69, 80, 226, 249, 261, 284, 306, 562, 578, 598,
639, 655, 704, 912, 1037, 1046, 1096, 1157, 1237, 1292, 1455, 1628,
1749, 1772, 1917, 2030, 2039, 2065, 2118, 2128, 2147
pre-messenger, 694, 1540
synovial, endogenous retroviruses in RA and, 627
T cell receptors in Felty's syndrome and, 615
transcriptional activator Sp1 and, 1085
RNP
52-kd protein, immune response and, 936
self antigens, epitopes and, 1374
small nuclear, 295, 1493
Ro
antigens, reference sera for antinuclear antibodies and, 410, 413
complete congenital heart block in monozygotic twins and, 381
Ro/La (SS-A/SS-B), self antigens, epitopes and, 1374
S
S1 nuclease, anti-F(ab`)2 reactivity and, 109
Saline
anti-DNA Id, intravenous gamma globulin and, 683
Ku antigen and, 1344
Salivary gland, in Sjogren's syndrome, 87, 875, 987, 1917,
2016, 2271
Salmonella bacteria, HLA-B27 and, 694
Salmonella enteritidis, IL-10/IL-12 in reactive
arthritis and, 1788
Sarcoidosis, uveitis in, 358
Scalp, MTX, rheumatoid nodules and, in JRA, 175
Scars, Vasculitis Damage Index and, 371
Scleroderma
apoptosis and, 1917
childhood-onset, 1183
cytokines and MHC class II in, 540
esophageal dysfunction in, 2252
lung fibroblasts and collagen synthesis in, 1237
palpable tendon friction rub in, 1146
racial factors in, 734
registry, 1556
Scleromyositis, idiopathic inflammatory myopathy and, 1257
Scurvy, pseudovasculitis and, 589
Secondary CNS vasculitis, 1189
Secondary Sjogren's syndrome
human retrovirus-5 proviral DNA in, 2016
97-kd Golgi complex autoantigen in, 1693
Selectins, adhesion molecules and, 991
Self-administered questionnaires
RA and, 1955
SSc and, 1984
Self antigens, epitopes and, in systemic autoimmunity, 1374
Self-assessment, in primary juvenile fibromyalgia, 752
Self-care education, for knee OA, 1466
Sendai virus, gene transfer into articular cartilage and, 901
Sensorimotor polyneuropathy, small fiber neuropathy, vasculitis
and, 1173
Sensory input, periosteal new bone formation in canine neuropathic
OA and, 1756
Septic arthritis
reactive arthritis and, 592
Ureaplasma urealyticum in destructive reactive
polyarthritis and, 2084
Serine proteinase, in rheumatoid synovium, 1780
Serology
human herpesvirus 8 in autoimmune diseases and, 1906
in idiopathic inflammatory myopathy, 1257
in JRA in affected sibpairs, 1962
in RA, 1005, 1219
Seropositive RA, minocycline in, 794, 842
Serotonin, fibromyalgia and, 1928
Serum
antinuclear antibodies in, 1601, 1612
anti-RNA helicase antibodies in connective tissue disease and,
1487
autoantibodies in chronic fatigue syndrome and, 295
CD59 in synovial tissue in rats and, 527
chondrocytes and, 270, 1455
in collagen arthritis, 907, 1064, 1662
collagen crosslinks in fibromyalgia and, 1450
C1q collagen-like antibodies in, in proliferative lupus
glomerulonephritis, 1504
CR1, CD35 in SF in inflammatory joint diseases and, 520
cytokines and, in SSc, 540
eukaryotic ribosomal protein L7 and, 661
growth factors, chondrocytes and, 270
hepatitis C virus in type II cryoglobulinemia and, 2007
hnRNP C1 and C2 core protein in, in SSc and psoriatic arthritis,
2172
in idiopathic inflammatory myopathy, 1257
in JRA, 1803, 1967
Ku antigen and, 1344
97-kd Golgi complex autoantigen in Sjogren's syndrome and,
1693
NSAID and, 1940, 1944
OA of the knee and, 590, 723
in Paget's disease, 461
procalcitonin, infection and, in autoimmune diseases, 1250
in RA, 80, 1096, 1219, 1400, 1512, 1843
reference, for antinuclear antibodies, 410, 413
rheumatic diseases and, 1054, 1126
in SLE, 27, 103, 672, 1168, 1364, 1493, 1810, 2178, 2212, 2217
transcriptional activator Sp1 and, 1085
Sexual abuse, fibromyalgia and, 453
Shared epitopes, HLA-DRB1 genotype in early RA and, 2241
Shortness of breath, in MTX lung injury in RA, 1829
Sicca symptoms, human retrovirus-5 proviral DNA in Sjogren's
syndrome and, 2016
Sicca syndrome, lambda light chain disease presenting as, 587
Silicone implants
clinical experience with, 1545
collagen arthritis and, 1064
immune response and, 1730
Single-photon-emission computed tomography, in CNS vasculitis, 1189
6-keto-prostaglandin F1α,
β2-glycoprotein I, endothelial cells and, 551
6-thioguanine nucleotides, in azathioprine-induced pancytopenia, in
juvenile HLA-B27 spondylarthritis, 1896
60-kd SS-A/Ro, 52-kd protein, immune response and, 936
Sjogren's syndrome
antinuclear antibodies in, 1601
apoptosis and, 1917
B cell proliferation in, 318
CNS vasculitis and, 1189
cytokines in salivary gland in, 987
52-kd protein and immune response in, 936
human retrovirus-5 proviral DNA in, 2016
97-kd Golgi complex autoantigen in, 1693
nitric oxide in, 865
primary, 87
soluble Fas and soluble Fas ligand in, 1126
T cells in, 2271
TAP2 gene in, 1685
Skeletal involvement
collagen in experimental OA and, 1046
in Paget's disease, 461
Skin
in arthropathy of fibroblastic rheumatism, 183
biopsy, 1450, 1810, 2116
fibroblasts, 490, 578
hepatitis C virus in type II cryoglobulinemia and, 2007
hyperpigmentation, minocycline and, 1353
nodule, spontaneous femoral neck fracture in multicentric
reticulohistiocytosis and, 2266
reactions, after IFNγ in RA, 62
reproductive immunology and, 209
in SSc, 540, 1146, 1984
surgery of calcinosis cutis and, in SLE, 570
Skull, in Paget's disease, 461
Sleep disturbance, in fibromyalgia, 1553, 1560, 1571, 1928
Slow-acting antirheumatic drugs (SAARDs), autologous hemopoietic
stem cell transplantation, RA and, 1005
Sm
antigen, reference sera for antinuclear antibodies and, 410, 413
snRNP proteins, in SLE, 672
Small bowel motility, esophageal dysfunction in scleroderma and,
2252
Small fiber neuropathy, vasculitis and, 1173
Small nuclear RNP (snRNP)
chronic fatigue syndrome and, 295
in mixed connective tissue disease, 1493
self antigens, epitopes and, 1374
in SLE, 672, 1493
Smoking
fibrosing alveolitis in SSc and, 1229
knee OA and, 723, 728
RA and, 594, 1955, 2248
S-nitrosoproteins, in RA, 1512
Social factors, risk of RA and, 1955
Sociodemographic factors, in work disability in SLE, 2199
Socioeconomic factors
outcome in adults who had JRA and, 2235
risk of RA and, 1955
risk of SLE and, 47
Sodium, nitroprusside, l-arginine in Raynaud's
phenomenon and, 352
Soft tissue
infection, with Streptococcus pneumoniae, in SLE, 1716
rheumatism, antinuclear antibodies in, 1601
Soleus muscle, accessory, chronic calf pain and, 783
Soluble CR1, in SF in inflammatory joint diseases, 520
Soluble Fas
in RA, 80
in rheumatic diseases, 1126
Soluble Fas ligand, in rheumatic diseases, 1126
Soluble IL-1 receptor
biologic agents in RA and, 397
IL-17, nitric oxide and, in OA cartilage, 1050
Soluble oligonucleosomal complexes, in SF, 648
Somatostatin, in RA, 2128
Spectroscopy
cerebral proton, in SLE, 36
magnetic resonance, 36, 1817
Spinal calcinosis, in SSc, 1882
Spinal cord
in CNS vasculitis, 1189
compression, complicating fractured ossification of the posterior
longitudinal ligament, 2277
in fibromyalgia, 1928
injury, heterotopic ossification, neuromuscular blockade and, 1619
Spine
cartilage genes in OA and, 1760
cervical, injury, fibromyalgia after, 446
inflammation, bone loss and, in polymyalgia rheumatica, 2022
Spleen
congenital heart block, 52β and, 655
in drug-induced lupus, 1334
in RA, 5, 598
rheumatic diseases in MRL/gld mice and, 1054
Splenocytes, adjuvant arthritis, inflammatory cachexia and, 534
Splenomegaly, large granular lymphocyte leukemia in RA and, 624
Spliceosomes, hnRNP C1 and C2 core protein in SSc and psoriatic
arthritis and, 2172
Spondylarthritis, juvenile HLA-B27, azathioprine-induced
pancytopenia in, 1896
Spondylarthropathy
AS and, 1746, 1823, 2047
HLA-B27 in, 388
uveitis in, 358
Spontaneous abortion
in pregnancy in relapsing polychondritis, 1245
reproductive immunology and, 209
Spontaneous femoral neck fracture, in multicentric
reticulohistiocytosis, 2266
Spontaneous OA, in guinea pigs, 2075
Sports participation, bone mineral density in prepubertal children
with JRA and, 1967
35S-proteoglycan synthesis, recombinant human
osteogenic protein 1, articular chondrocytes and, 2157
Squamous cell carcinoma of the lung, polyarthritis, vasculitis and,
779
SS-A antibody, TAP2 gene in Sjogren's syndrome
and, 1685
SS-A/Ro autoantigen, 52-kd, 52β, congenital heart block and, 655
SS-A/Ro-SS-B/La complex, 52-kd protein, immune response and, 936
``Stabilizing'' autoantibodies, Ku antigen and, 1344
Standards of care, 410, 413
Staphylococcal enterotoxin B, apoptosis in autoimmune diseases and,
306
Stem cells, RA and, 1005, 1838
Steroid drugs; See Corticosteroid drugs
Stifle joint, tenidap in OA and, 284
Stillbirth, reproductive immunology and, 209
Stomach, watermelon, anti-RNA helicase antibodies in, 1487
Stress, spontaneous OA in guinea pigs and, 2075
Stress fractures, longitudinal, of the tibia, 385
Stroma, collagenase 3, rheumatoid synovium and, 1391
Stroke
heterotopic ossification, neuromuscular blockade and, 1619
reproductive immunology and, 209
Subchondral bone
erosion of, cathepsin L in RA and, 499
OA bone cells, cartilage metabolism and, 1282
spontaneous femoral neck fracture in multicentric
reticulohistiocytosis and, 2266
Subcutaneous fat necrosis, pancreatitis and, 1732, 2116
Subcutaneous tissue atrophy, steroid-induced, 294
Substance P, fibromyalgia and, 1928
Sulfasalazine
in AS, 1911
intravenous pulse cyclophosphamide and methylprednisolone in JRA
and, 1852
and HIV-associated reactive arthritis, 1911
35S-sulfate, recombinant human osteogenic protein 1,
articular chondrocytes and, 2157
Sulindac, hepatic injury and, 201
Superantigens, T cells and, 598, 615
Supernatants
CR1, CD35 in SF in inflammatory joint diseases and, 520
OA bone cells, cartilage metabolism and, 1282
oncostatin M, human synovial fibroblasts and, 2139
testosterone, anti-DNA antibodies and, in SLE, 1703
Th1/Th2 cytokine balance and, 2105
Surgery
in calcinosis cutis universalis in SLE, 570
in fibromyalgia, 1553, 1560, 1571
heterotopic ossification, neuromuscular blockade and, 1619
in OA, 284, 1012, 1050, 1475, 1756
RA and, 1475, 1955
prosthetic, bacterial arthritis and, 884
spontaneous femoral neck fracture in multicentric
reticulohistiocytosis and, 2266
in Wegener's granulomatosis, 1992
Survival
bacterial arthritis and, 884
in SSc, 734, 1146, 1984
in Wegener's granulomatosis, 2099, 2187
Swelling
distal extremity, with pitting edema, in polymyalgia rheumatica,
1551
human IL-1 receptor antagonist in murine collagen arthritis and,
893
joint, 5, 419, 527, 1327, 1843
NSAID and, in RA and OA, 1940, 1944
Symmetric polyarthritis, in fibroblastic rheumatism, 183
Sympathetic nervous system, fibromyalgia and, 1928
Synovectomy, IL-1 receptor antagonist gene therapy in OA and, 1012
Synovial biopsy
in amyloid arthropathy, 1903
synovial membrane volume in RA and OA and, 1856
Synovial cells
adhesion molecules and, 991
in destructive joint disease, 1420
human mast, 469
IL-1 receptor antagonist gene therapy in OA and, 1012
oncostatin M, human synovial fibroblasts and, 2139
paclitaxel, synoviocyte apoptosis and, 1073
in RA, 5, 80, 217, 397, 598, 627, 919, 1005, 1096, 1292, 1644,
2128
ribozyme-based gene cleavage, HTLV-I and, 2118
spontaneous femoral neck fracture in multicentric
reticulohistiocytosis and, 2266
tenidap in antigen-induced arthritis and, 2147
Synovial fibroblasts
human, oncostatin M and, 2139
IL-1 receptor antagonist gene therapy in OA and, 1012
in RA, 490, 1096, 1292, 1298
Synovial fluid (SF)
adhesion molecules and, 991
CR1, CD35 in, in inflammatory joint diseases, 520
IL-1 receptor antagonist gene therapy in OA and, 1012
IL-10/IL-12 in reactive arthritis and, 1788
immune complexes, in JRA, 2039
mononuclear cells, T cell cytokines in Lyme arthritis and, 69
nitric oxide, articular chondrocytes and, 261
oncostatin M, human synovial fibroblasts and, 2139
in RA, 5, 80, 510, 598, 627, 1005, 1096, 1186, 1219, 1400, 1409,
1512, 1644
soluble oligonucleosomal complexes in, 648
tenidap in OA and, 284
Synovial hyperplasia
HOX4C gene on rheumatoid synovial fibroblasts and, 1628
tenidap in antigen-induced arthritis and, 2147
Synovial inflammation
adenosine A1, monocytes, MTX and, 1308
in OA, 284, 1856
in RA, 1856
Synovial lining
adhesion molecules and, 991
paclitaxel, synoviocyte apoptosis and, 1073
in RA, 479, 1391, 1400
tenidap in antigen-induced arthritis and, 2147
Synovial lymphocytes, Fas ligand in RA and, 1644
Synovial membrane
in destructive joint disease, 1420
IL-10/IL-12 in reactive arthritis and, 1788
in OA, 1856
in RA, 5, 794, 842, 1400, 1856
T cell cytokines in Lyme arthritis and, 69
tenidap in antigen-induced arthritis and, 2147
Synovial peripheral blood, T cells in RA and, 598
Synovial retroviruses, endogenous, in RA, 627
Synovial surface, CD59 in synovial tissue in rats and, 527
Synovial tissue
CD59 in, in rats, 527
in destructive joint disease, 1420
fibroblast-macrophage interaction in cartilage degradation and,
490
H-ras oncogene point mutations in arthritic synovium
and, 1636
IL-4, IL-10 and, in collagen arthritis, 249
mononuclear phagocytes, rheumatoid synovitis and, 5
in RA, 217, 479, 598, 627, 912, 1096, 1219, 1391, 1409, 1540,
1628, 1644
spontaneous femoral neck fracture in multicentric
reticulohistiocytosis and, 2266
Synoviocytes
apoptosis and, 1073, 1917
collagenase 1 gene and, 1772
in RA, 226, 479, 595, 598, 919
ribozyme-based gene cleavage, HTLV-I and, 2118
Synovitis
adenosine A1, monocytes, MTX and, 1308
CD59 in synovial tissue in rats and, 527
intravenous pulse cyclophosphamide and methylprednisolone in JRA
and, 1852
in RA, 217, 595, 648
TNFα receptor gene in collagen arthritis and, 1662
Synovium
apoptosis in the rheumatic diseases and, 1917
in arthropathy of fibroblastic rheumatism, 183
CD59 in synovial tissue in rats and, 527
H-ras oncogene point mutations in, 1636
IL-1 receptor antagonist gene therapy in OA and, 1012
in RA, 5, 479, 598, 639, 912, 1005, 1096, 1292, 1780, 2128
spontaneous femoral neck fracture in multicentric
reticulohistiocytosis and, 2266
Th1/Th2 cytokine balance and, 2105
Synthetic peptides
human cartilage glycoprotein-39 in RA, 1115
IgG antibodies in SLE and, 1364
Syphilis, antiphospholipid antibodies in parvovirus B19 infection
and, 103
Systemic ANCA-associated vasculitis, procalcitonin and infection
in, 1250
Systemic autoimmune diseases
eukaryotic ribosomal protein L7 in, 661
Ku antigen in, 1344
procalcitonin and infection in, 1250
Systemic autoimmunity
apoptosis in the rheumatic diseases and, 1917
self antigens and epitopes in, 1374
Systemic JRA
intravenous pulse cyclophosphamide and methylprednisolone and,
1852
MTX and rheumatoid nodules in, 175
outcome of adults who had, 2235
Systemic Lupus Activity Measure (SLAM), in SLE, 27, 47, 57, 1250,
2092
Systemic lupus erythematosus (SLE)
acquired factor VIII inhibitor and intravenous immunoglobulin and,
775
anabolic steroid use in, 1899
anti-β2-glycoprotein I in, 1366
anti-CD2 in, 822
anti-DNA Id, intravenous gamma globulin and, 683
anti-(Fab`)2 reactivity in, 109
antinuclear antibodies in, 1601, 1612
anti-p53 in, 980
antiphospholipid antibodies in, 103
anti-RNA helicase antibodies in, 1487
apoptosis in, 306, 927, 1917
calcinosis cutis universalis in, 570
cancer in, 761
CD40 and CD40 ligand in, 1735
CNS vasculitis and, 1189
cognitive function in, 1542
cyclosporine and, 27
cytolytic activity in, 1130
disease activity in, 57
Disease Activity Index (SLEDAI) in, 809, 2217
disease flares in, 393, 2092, 2093
eukaryotic ribosomal protein L7 in, 661
fibromyalgia in, 1544
IgG antibodies in, 1364
IL-1 in, 389
IL-10 in, 1429
infection in, 1168, 1180, 1186, 1250
Medicare Part B claims in, 1594
MHC genes in, 1138
neuropsychiatric, 1542
nitric oxide in, 1810
non-Hodgkin's lymphoma in, 761
nucleosomes in, 2217
oral contraceptives and, 797, 804
polymorphism of TNFα in, in African-Americans, 2207
PR3-ANCA antiidiotype antibody in, 135
prolactin and DRB in, 1374
reproductive immunology and, 209
revised criteria for, 1725
risk factors and outcome in, 47
self antigens and epitopes in, 1374
SLAM in, 27, 47, 57
SLICC/ACR damage index in, 809
Sm snRNP protein in, 672
soluble Fas and soluble Fas ligand in, 1126
soluble oligonucleosomal complexes in SF and, 648
testerosterone and anti-DNA antibodies in, 1703
work disability in, 2199
Systemic Lupus International Collaborating Clinics (SLICC)/ACR
damage index, in SLE, 47, 809
Systemic lymphadenopathy, in MRL/gld mice, 1054
Systemic sclerosis (SSc)
antinuclear antibodies in, 1601
anti-RNA helicase antibodies in, 1487
cytokines and lung disease in, 743
eukaryotic ribosomal protein L7 in, 661
fibrosing alveolitis in, 1229
Health Assessment Questionnaire in, 1984
hnRNP C1 and C2 core protein in, 2172
incidence of, 441
palpable tendon friction rub in, 1146
soluble Fas and soluble Fas ligand in, 1126
Systemic vasculitis
in the CNS, 1189
myelodysplastic syndromes and, 179
Vasculitis Damage Index in, 371
Systemic Wegener's granulomatosis, steroids and cyclophosphamide
in, 2099, 2187
T
T cells
adhesion molecules and, 991
antiphospholipid antibody immunogenesis and, 196
apoptosis of, 306, 927
CD40 and CD40 ligand in autoimmune diseases and, 1735
cytokines and, 19, 69, 540, 865
cytotoxic, chlamydial antigen in HLA-B27 transgenic mice and, 945
in drug-induced lupus, 1334, 1436
HLA-B27 autoantigens in AS and, 2047
mycobacterial heat-shock protein 65 and, 277, 510
oxicams, leukocytes and, 143
in polyarthritis in chromosome 22q11.2 deletion syndrome, 430
in RA, 5, 237, 397, 595, 598, 1005, 1106, 1115, 1186, 1210, 1798
receptors for, 397, 598, 615, 991, 1316, 1387, 1798
in the rheumatic diseases, 1054, 1917
self antigens, epitopes and, 1374
in Sjogren's syndrome, 2271
in SLE, 822, 1493
tacrolimus and, 1157
Th1/Th2 cytokine balance in, 2105
Taiwanese studies, MHC genes in SLE, 1138
Takayasu arteritis, apoptosis in, 306
TAP2 gene, in Sjogren's syndrome, 1685
Tartrate-resistant acid phosphatase, in Paget's disease, 461
Taq I polymorphism, vitamin D receptor in knee OA and,
1444
tax/rex mRNA
ribozyme-based gene cleavage, HTLV-I and, 2118
in tenosynovial nodulosis in HTLV-I, 578
Taxol, synoviocyte apoptosis and, 1073
Taxoplasma gondii, in new-onset juvenile DM, 1526
Technetium bone scans, heterotopic ossification, neuromuscular
blockade and, 1619
Teeth, periodontal disease in RA and, 2248
Telopeptides, in Paget's disease, 461
Temporal arteritis, antiinflammatory drugs in polymyalgia
rheumatica and, 1873
Temporal artery biopsy, cytokines in giant cell arteritis and, 19
Tender points, fibromyalgia and, 446, 752, 1450
Tenderness
fibromyalgia and, 98, 446, 1928
in OA, 1940, 1944
in RA, 419, 1843, 1940, 1944
Tendinitis, acute calcific, of the hip, 974
Tendon friction rubs, in SSc, 1984
Tenidap
in chronic antigen-induced arthritis, 2147
in OA, 284
Tenosynovial nodulosis, in HTLV-I, 578
Testosterone, anti-DNA antibody in SLE and, 1703
Tetracycline, minocycline in RA and, 794, 842
Th cells, CD40 and CD40 ligand in autoimmune diseases and, 1735
Th0, histone-specific, dsDNA antibody in SLE and, 2162
Th1 cytokines, 69, 598, 1788, 2162
Th1/Th2 cytokine balance, in arthritis, 2105
Th2 cytokines, 69, 1788, 2162
Thermal regulation, fibromyalgia and, 1928
Thigh, tenosynovial nodulosis in HTLV-I and, 578
Thiopurine methyltransferase gene, in azathioprine-induced
pancytopenia in juvenile HLA-B27 pancytopenia, 1896
Thoracic involvement, in Wegener's granulomatosis, 1992
3,7-dimethyl-1-propargylxanthine, adenosine A1,
monocytes, MTX and, 1308
Thrombocytopenia
osteonecrosis in rabbits and, 2055
thrombosis in primary antiphospholipid syndrome and, 834
Thromboembolic disease, antiphospholipid antibodies and, in SLE,
1720
Thromboembolism, oral contraceptives, SLE and, 797
Thrombosis
anti-proteinase 3 antibodies in human umbilical vein endothelial
cells and, 2030
deep vein, reproductive immunology and, 209
phosphate in plasma proteins in SLE and, 2178
in primary antiphospholipid syndrome, 834
venous, 797, 1998
Thrombospondin 1, in rheumatoid synovium, 1780
Thrombus, osteonecrosis in rabbits and, 2055
Thy1.2, rheumatic diseases in MRL/gld mice and, 1054
Thymus
apoptosis in the rheumatic diseases and, 1917
T cells, collagen and, in RA, 1210
Tibia, longitudinal stress fracture of, 385
Tibial articular cartilage, spontaneous OA in guinea pigs and, 2075
Tibial plateau
medial, 499
in OA, 284, 1012
in RA, 499, 1653
Tissue
anti-proteinase 3 antibodies in human umbilical vein endothelial
cells and, 2030
apoptosis and, 1073, 1917
cytokines and, 19, 865, 987, 2105
damage, 479
endothelial activation in monosodium urate monohydrate crystal
inflammation and, 955
factor, thrombosis in primary antiphospholipid syndrome and, 834
fetal, congenital heart block, 52β and, 655
fibrous, 479
granulation, osteonecrosis in rabbits and, 2055
heterotopic ossification, neuromuscular blockade and, 1619
kidney, C1q collagen-like antibodies in, in proliferative lupus
glomerulonephritis, 1504
kinins in peptidoglycan arthritis and, 1327
lymphoid, 598, 991
in OA, 1012, 1856, 2075
peripheral, in fibromyalgia, 1928
in RA, 5, 595, 1005, 1391, 1856
repair and remodeling, growth factors, chondrocytes and, 270
in Sjogren's syndrome, 318, 2016
soft, Streptococcus pneumoniae infections, in SLE, 1716
subcutaneous atrophy of, steroid-induced, 294
synovial, 5, 217, 249, 479, 490, 527, 598, 627, 912, 1096, 1219,
1391, 1409, 1540, 1628, 1636, 1644
Tonsillectomy, fibromyalgia and, 1553, 1560, 1571
Total lymphoid irradiation, in RA, 426
Toxicity
in azathioprine-induced pancytopenia in juvenile HLA-B27
spondylarthritis, 1896
in hydroxychloroquine retinopathy, 1482
paclitaxel, synoviocyte apoptosis and, 1073
in RA, 62, 397, 794, 842, 1829
in Wegener's granulomatosis, 2099, 2187
Toxins, biologic agents in RA and, 397
Toxoplasmosis, uveitis in, 358
Trachea, cartilage matrix synthesis of, 1029
Traction, cervical, breast implants and, 2097
Transcription factors
AP-1, in RA synovium, 912
nuclear factor [gk]B and cyclooxygenase 2, 226
Transcriptional activator Sp1, 1085
Transforming growth factor β (TGFβ)
adhesion molecules and, 991
chondrocytes and, 270, 966, 1275
collagenase 3 in human arthritic cartilage and, 1653
mononuclear phagocytes, rheumatoid synovitis and, 5
in muscle tissue in inflammatory myopathy, 865
tenidap in antigen-induced arthritis and, 2147
Th1/Th2 cytokine balance and, 2105
Transfusions
in azathioprine-induced pancytopenia in juvenile HLA-B27
spondylarthritis, 1896
RA and, 1955
Transglutaminase, in articular chondrocytes and articular
cartilage, 966
Transient osteonecrosis of the hip, idiopathic, 1178
Transmembrane polypeptide chains, adhesion molecules and, 991
Transplantation
autologous hemopoietic stem cell, RA and, 1005
bone pain after, 1361
EBV, lymphoma and, in rheumatic diseases, 1152
Transverse myelitis, anabolic steroid use in SLE and, 1899
Trapezius region, collagen crosslinks in fibromyalgia and, 1450
Trauma
fibromyalgia and, 446, 453
head, heterotopic ossification, neuromuscular blockade and, 1619
meniscal, thrombospondin 1 in rheumatoid synovium and, 1780
in OA of the knee, C-reactive protein and, 723
cyclosporine in SLE and, 27
Traumatic brain injury, heterotopic ossification, neuromuscular
blockade and, 1619
Triphosphate pyrophosphohydrolase, nucleoside, aging, chondrocytes,
TGFβ and, 1275
Trunk, MTX, rheumatoid nodules and, in JRA, 175
Tryptase, mast cells and, 469, 479
Tuberculosis cutis colliquativa, immunosuppressive drugs in RA and,
188
Tumor necrosis factor
apoptosis in the rheumatic diseases and, 1917
CD40 and CD40 ligand in autoimmune diseases and, 1735
cytolytic activity in SLE and, 1130
in JRA SF immune complexes, 2039
in OA, 1940, 1944
in RA, 598, 1368, 1400, 1940, 1944
Tumor necrosis factor α (TNFα)
adhesion molecules and, 991
adjuvant arthritis, inflammatory cachexia and, 534
cartilage collagenase and, 2065
collagen arthritis and, 1064, 1662
in endothelial activation in monosodium urate monohydrate crystal
inflammation, 955
IL-4, IL-10 and, in collagen arthritis, 249
IL-10/IL-12 in reactive arthritis and, 1788
in Lyme arthritis, 69
MHC and, 540, 1138
in muscle tissue in inflammatory myopathy, 865
nitric oxide and, 875, 261
oxicams, leukocytes and, 143
in RA, 5, 217, 397, 595, 639, 1096
in SLE, 1130, 2207
spontaneous femoral neck fracture in multicentric
reticulohistiocytosis and, 2266
in SSc lung disease, 743
thrombosis in primary antiphospholipid syndrome and, 834
Tumor necrosis factor β (TNFβ)
cytolytic activity in SLE and, 1130
in RA, 397
Twin studies
AS, 1746, 1823
autologous hemopoietic stem cell transplantation, RA and, 1005
congenital complete heart block, 381
JRA in affected sibpairs and, 1962
2-methoxyestradiol, suppression of collagen arthritis by, 154
Tyrosine kinase receptor axl, chondrocytes and, 1455
Tyrosine phosphorylation, protein, in Fas-mediated apoptosis of RA
synoviocytes, 919
U
U snRNP, T cells, B cells and, in SLE and mixed connective tissue
disease, 1493
U937 macrophage/monocyte cell line, cartilage degradation and, in
RA, 490
Ulcers
periosteal new bone formation in canine neuropathic OA and, 1756
surgery of calcinosis cutis in SLE and, 570
in SSc, 1984
Umbilical vein endothelial cells, human anti-proteinase 3
antibodies in, 2030
Undifferentiated connective tissue disease
anti-RNA helicase antibodies in, 1487
breast implants in, 437
transcriptional activator Sp1 and, 1085
Unilateral knee OA, proprioception in, 1518
Upper respiratory tract infection in Henoch-Schonlein
purpura, 859
Ureaplasma urealyticum in destructive reactive
polyarthritis, 2084
Urine
collagen crosslinks in fibromyalgia and, 1450
in Paget's disease, 461
retention of, in anabolic steroid use in SLE, 1899
Uterus, reproductive immunology and, 209
Uveitis as a diagnostic marker, 358
V
V Leiden factor, protein C, thromboembolic disease,
antiphospholipid antibodies and, in SLE, 1720
Vβ peptides, biologic agents in RA and, 397
Vβ region in RA, 237, 598, 1316
V[gk] region, anti-F(ab`)2 reactivity and, 109
Vaccination, biologic agents in RA and, 397
Vacuoles, cytoplasmic, cathepsin L in RA and, 499
Vagina, cancer of the, in SLE, 761
Vascular cell adhesion molecule 1, 991, 1420
Vascular disease, inflammatory, CNS vasculitis and, 1189
Vascular ectasia, gastric antral, anti-RNA helicase antibodies in,
1487
Vascular endothelial cells, collagenase 3, rheumatoid synovium and,
1391
Vascular endothelial growth factor, in POEMS syndrome, 786
Vascular endothelium
hepatitis C virus in type II cryoglobulinemia and, 2007
nitric oxide in SLE and, 1810
Vascular injury, apoptosis in the rheumatic diseases and, 1917
Vascular involvement
cutaneous, l-arginine in Raynaud's phenomenon and, 352
oral contraceptives, SLE and, 797
Vasculitides
apoptosis in, 306
PR3-ANCA antiidiotype antibody in, 135
systemic, Vasculitis Damage Index in, 371
Vasculitic process, anti-proteinase 3 antibodies in human umbilical
vein endothelial cells and, 2030
Vasculitis
ANCA-related, 986, 1250, 1680
carcinoma, polyarthritis and, 779
in the CNS, 1189
Damage Index, in systemic vasculitides, 371
multiple myeloma and, 395
small fiber neuropathy and, 1173
systemic, 179, 371
Vasculopathy, of Behcet's disease, 1915
Vasodilatation
after IFNγ in RA, 62
l-arginine in Raynaud's phenomenon and, 352
nitric oxide in Sjogren's syndrome and, 875
Vasopressin, arginine, in fibromyalgia, 1928
Veins
in CNS vasculitis, 1189
deep, thrombosis of, reproductive immunology and, 209
Venereal diseases
reactive arthritis, septic arthritis and, 592
Ureaplasma urealyticum in destructive reactive
polyarthritis and, 2084
Venous thromboembolism, oral contraceptives, SLE and, 797
Venous thrombosis, anticardiolipin IgG subclasses and, 1998
Venules, cytokines in muscle tissue in inflammatory myopathy and,
865
Vernal conjunctivitis, Th1/Th2 cytokine balance and, 2105
Versican, proteoglycan, link protein and, in OA cartilage, 1037
Vertebral fractures, antiinflammatory drugs in polymyalgia
rheumatica and, 1873
Villous formation, synovial membrane volume in RA and OA and, 1856
Villous hypertrophy, paclitaxel, synoviocyte apoptosis and, 1073
Vimentin in chronic fatigue syndrome, 295
Viral infections
CD40 and CD40 ligand in autoimmune diseases and, 1735
mononuclear phagocytes, rheumatoid synovitis and, 5
Viruses
adeno-, in collagen arthritis, 1662
antiphospholipid antibodies in parvovirus B19 infection, 103
cancer in SLE and, 761
in CNS vasculitis, 1189
coxsackie B, 1526
Epstein-Barr, 109, 1085, 1152
entero-, 1526
hepatitis C, in type II cryoglobulinemia, 2007
herpes simplex, 1526
retro-, 627, 1012, 2016
self antigens, epitopes and, 1374
Sendai, gene transfer into articular cartilage and, 901
tenosynovial nodulosis in HTLV-I, 578
Visceral involvement, palpable tendon friction rub in SSc and, 1146
Vision, azathioprine in Behcet's syndrome and, 769
Visual abnormalities, cytokines in giant cell arteritis and, 19
Visual analog scale
in juvenile idiopathic inflammatory myopathy, 1976
nociception in fibromyalgia and, 98
in OA, 1466, 1940, 1944
in RA, 1940, 1944
in SSc, 1984
Vitamin D
bone mineral density in JRA and, 1967
receptor, knee OA and, 1444
Vitronectin, phosphate in, in SLE, 2178
Vogt-Koyanagi-Harada syndrome, uveitis in, 358
Vulva, cancer, in SLE, 761
W
Walking, self-care education for knee OA and, 1466
Watermelon stomach, anti-RNA helicase antibodies in, 1487
Weakness in acute intermittent porphyria, 586
Wegener's granulomatosis
anti-proteinase 3 antibodies in human umbilical vein endothelial
cells and, 2030
apoptosis in, 306
chronic meningitis in, 573
mediastinal mass and hilar adenopathy in, 1982
microscopic polyangiitis, polyarteritis nodosa and, 1183
in pregnancy, 1354
steroids and cyclophosphamide in, 2099, 2187
Vasculitis Damage Index in, 371
Weight
adjuvant arthritis, inflammatory cachexia and, 534
in knee OA, 723, 728
Weight-bearing, knee OA in the elderly and, 728
Western blotting, reference sera for antinuclear antibodies and,
410, 413
White blood cell counts
cyclosporine in SLE and, 27
NSAIDs and, in RA and OA, 1940, 1944
Work disability
in fibromyalgia, 1553, 1560, 1571
in adults who had JRA, 2235
in SLE, 2199
Wrist
HLA-DRB1 genotype in early RA and, 2241
tenosynovial nodulosis in HTLV-I and, 578
X
Xeroradiography, periosteal new bone formation in canine
neuropathic OA and, 1756
Y
Yersinia bacteria, HLA-B27 and, 694
Yersinia enterocolitica, IL-10/IL-12 in reactive
arthritis and, 1788
Yunus and Masi criteria, in primary juvenile fibromyalgia, 752
Z
Zygosity, AS in twins and, 1746,
1823
